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Summary 
Molecular Similarity and Xenobiotic Metabolism Samuel Edward Adams 
MetaPrint2D, a new software tool implementing a data-mining approach for predicting sites 
of xenobiotic metabolism has been developed.  The algorithm is based on a statistical 
analysis of the occurrences of atom centred circular fingerprints in both substrates and 
metabolites.  This approach has undergone extensive evaluation and been shown to be of 
comparable accuracy to current best-in-class tools, but is able to make much faster 
predictions, for the first time enabling chemists to explore the effects of structural 
modifications on a compound’s metabolism in a highly responsive and interactive manner. 
MetaPrint2D is able to assign a confidence score to the predictions it generates, based on 
the availability of relevant data and the degree to which a compound is modelled by the 
algorithm. 
In the course of the evaluation of MetaPrint2D a novel metric for assessing the performance 
of site of metabolism predictions has been introduced.  This overcomes the bias introduced 
by molecule size and the number of sites of metabolism inherent to the most commonly 
reported metrics used to evaluate site of metabolism predictions. 
This data mining approach to site of metabolism prediction has been augmented by a set of 
reaction type definitions to produce MetaPrint2D-React, enabling prediction of the types of 
transformations a compound is likely to undergo and the metabolites that are formed.  This 
approach has been evaluated against both historical data and metabolic schemes reported 
in a number of recently published studies.  Results suggest that the ability of this method to 
predict metabolic transformations is highly dependent on the relevance of the training set 
data to the query compounds. 
MetaPrint2D has been released as an open source software library, and both MetaPrint2D 
and MetaPrint2D-React are available for chemists to use through the Unilever Centre for 
Molecular Science Informatics’ website.  
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1. Introduction 
This thesis is concerned with the in silico prediction of xenobiotic metabolism – the 
metabolism of compounds such as drugs and environmental chemicals which would not 
normally be produced by an organism or form part of a normal diet.  The first two chapters 
provide an introduction to the thesis.  This chapter introduces current in silico molecular 
similarity and virtual screening techniques, which form the basis of the modelling 
approaches used later in this work.  Chapter two discusses the importance of understanding 
and predicting xenobiotic metabolism, and reviews current work in this field.  Chapters 
three and four report the development and evaluation of MetaPrint2D – a tool for the 
prediction of sites of phase I metabolism.  Chapter five extends these predictions beyond 
the identification of sites of metabolism, to prediction of types of transformation and the 
likely metabolites formed.  Finally, the performance of these predictions is assessed in a 
retrospective analysis of recently published metabolic schemes, reported in chapter six. 
The search for substances with the potential to cure sickness and disease has been ongoing 
since prehistoric times.  For thousands of years both organic and inorganic materials such as 
plants, herbal preparations, animal products, metals and clays have been administered to 
sick humans and animals (1).  With the development and application of scientific 
methodology, mainly since the late 19th century, medication has become far safer and more 
effective than in earlier times.  Ever increasing demand for better medicinal drugs has led to 
the formation of a $600 billion dollar global pharmaceutical industry (2) whose future is 
dependent on the continual discovery of safe and effective medicines. 
Over the past twenty years the pharmaceutical industry has been revolutionized through 
the introduction of high-throughput screening (HTS) and combinatorial chemistry 
techniques.  Despite these changes, and the far higher speeds of synthesis and screening 
that they have made possible, the rate of introduction of new drugs to the market place 
does not seem to be showing any corresponding increase (3).  Indeed, the rate of attrition of 
compounds entering the development process shows no improvement from that of the 
1970s and 80s (4), currently estimated by the Pharmaceutical Research and Manufacturers 
of America (PhRMA) to stand at around 90% (5).  The length of time it takes to successfully 
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develop a new drug is also increasing.  Various estimates place the average from 8½ (6,7) to 
over 14 years (8) – up to 75% longer than during the 1960s (9).  Due, in part,  to the 
lengthening of the development process, there has been a spiralling in the costs associated 
with the development of a novel drug; the average investment required to bring a new drug 
to market is now thought to stand at between US$800 million (10) and US$1.7 billion (11). 
In an attempt to combat the growing costs and timescales involved in drug discovery 
pharmaceutical research is increasingly turning to computational techniques.  It is hoped 
that decision support tools can help to accelerate selection of the most suitable candidate 
compounds, and elimination of the least suitable.  Computational tools are also needed in 
order to manage and exploit the increasingly large amounts of data that are now being 
acquired, particularly from the use of high-throughput methods taking advantage of 
robotics to perform in vitro screens of large compound libraries. 
An additional factor is the use of virtual screening techniques in the safety assessment of 
chemical substances required under recently introduced legislation such as the European 
Union’s Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) 
regulation (12).  The potential costs of this testing, combined with the public opposition to, 
and legal restrictions upon, animal testing, have made computational prediction of a 
number of key biological properties of molecules, such as toxicity and metabolism, an 
attractive alternative. 
This chapter provides a brief overview of the modern drug discovery process, and describes 
the roles played by computational methods.  The different approaches to computational 
modelling are described, with particular focus on molecular similarity and Quantitative 
Structure Activity Relationship (QSAR) techniques.  Finally, some of the recent 
developments and current challenges in virtual screening are reviewed. 
1.1 The drug discovery process 
The road from the initial decision to discover and develop a new drug to its finally reaching 
the market place is a long one.  The process can be broadly broken down into three phases, 
shown in Figure 1; the central phase, lead discovery and development, is perhaps the most 
challenging, involving as it does an exploration of the ‘sea of chemical space’ in search of an 
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‘island of activity’, followed by the detailed exploration of this island in order to identify a 
candidate drug compound (13) – a process known as lead identification and optimisation.  
 
Figure 1: An outline of the drug development process 
The first steps in the process of the development of a new drug are target identification and 
validation (14).  Once a decision has been made as to the clinical needs of the new drug, the 
discovery process commences with a thorough investigation of the mechanism of the 
disease.  Differences between the functioning of the body in both the diseased and healthy 
states are explored.  With the rapid advances in understanding of genetics over the past 
decade, due in part to programmes such as the Human Genome Project, increasingly the 
genetic basis of a disease is investigated.  The aim in all of this is to pinpoint a mechanism 
(perhaps involving an enzyme, transport system or receptor) that is the cause of the disease, 
so that drugs can be designed to target it, whilst minimizing their effects on the rest of the 
body.  Once a target has been identified it is then validated, to confirm its function and 
effects, and ensure that it is essential to the disease process and is safe to target.  At the 
same time assays to determine whether a molecule binds to the target, and the effect this 
has on the target, may be developed.  Throughout this process bioinformatics and other 
computational tools are widely used, however these are beyond the scope of this review. 
The Human Genome Project has reported that there are in the region of 20000–25000 
protein coding genes within in the human genome (15).  Through alternative splicing, 
whereby one gene can code for a number of related proteins, the human proteome is larger 
still, but in spite of this large number of potential drug targets, to date only 500 or so 
proteins have been targeted by pharmaceuticals (3). 
Target 
Identification 
Target 
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Lead 
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Lead 
Optimization 
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DRUG 
Target Discovery Lead Discovery 
and Development 
Evaluation 
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Once a target has been successfully identified and validated the search for one or more lead 
compounds begins.  Lead compounds are molecules that exhibit some of the desired 
pharmacological activity against the target, and form the base from which a drug is 
developed.  Traditionally the search for lead compounds started with collections of natural 
products (14); wide ranges of natural materials such as plants, roots, bark and marine 
organisms were collected, with as great a biodiversity as possible, and as many chemical 
compounds extracted as possible.  These compounds were then screened against the 
identified targeted, searching for any that showed some level of activity.  More recently 
pharmaceutical companies have developed in-house screening libraries, typically containing 
a million or more compounds (16).  These may be purchased from external suppliers, 
produced through combinatorial chemistry programmes or synthesised within the company. 
Although lead compounds show some useful pharmaceutical activity against the drug 
target, they themselves are not usually suitable for therapeutic use.  Once their molecular 
structure has been confirmed, lead compounds undergo cycles of structural modification, or 
‘optimization’, in order to improve their potency and other properties such as solubility and 
membrane permeability. 
Knowledge of the 3-dimensional structure of a drug target enables an alternative approach, 
whereby molecules are designed to best complement the target’s binding site – so called 
‘rational’ drug design.  These two approaches are often employed in parallel.  Screening can 
be guided by knowledge of the receptor, and the results of screening can then form the 
basis for the application of rational techniques to the optimization of the molecule’s 
structure. 
Once a candidate compound has been developed, but before it can be tested in humans, it 
undergoes a series of pre-clinical tests, in order to determine its safety profile (14).  This 
testing is carried out through a mixture of in vitro (test-tube) and in vivo (animal) studies.  
The candidate’s pharmacodynamic (what the drug does to the body) and pharmacokinetic 
(what the body does to the drug) profiles are investigated, with the primary aim being to 
ensure that the candidate compound is safe to test in humans, and determine at what 
dosage initial testing should take place. 
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A long series of clinical trials in human volunteers are then carried out to ensure the safety 
of the candidate drug, and to determine the optimum protocol for its administration.  
Phase  I clinical trials are performed on a small group of normally healthy volunteers, with 
the primary purpose being to ensure the safety of the drug, since this is the first time that 
the drug will have been tested on a human body.  Volunteers are initially administered very 
low doses of the drug, and closely monitored for any adverse effects.  As the trial proceeds, 
the doses are increased towards expected therapeutic levels, and further information 
evaluating the properties of the drug may be obtained. 
Once the drug has been demonstrated to be safe in humans, a larger trial is held to 
determine its safety and effectiveness within its target population.  Phase II trials typically 
involve several hundred patients, one group of whom are administered the new drug, and 
another group given either the standard treatment or a placebo.  The aim of the Phase II 
trial is to determine the most effective administration regime, varying factors such as 
dosage, frequency of administration and length of treatment.  In order to eliminate any bias, 
it is common practice to perform a so-called ‘double blind’ trial, where neither the patients 
nor clinicians know who is receiving the new treatment, and who is receiving the old 
treatment or placebo.  Phase III trials are then performed in a larger and more diverse group 
of patients, in order to confirm the drug’s effectiveness and detect any less common side-
effects, and to compare the effectiveness of the NCE (New Chemical Entity) to currently 
available therapeutics. 
 Throughout this process there is a high rate of attrition of candidate compounds.  Five years 
ago the acting commissioner of the US Food and Drug Administration (FDA) reported 
estimates that just 8% of candidate drugs entering Phase I trials will go on to receive FDA 
approval, and that only one half of the drug candidates reaching Phase III trials show the 
necessary safety and effectiveness for approval (11).  A more recent study examining cancer 
trials found that only 25-50% of the new treatments reaching Phase III randomized clinical 
trials proved successful (17). 
Once released, monitoring of a drug’s efficacy and side effects continues.  Rare adverse 
reactions may only become apparent once a large population is using the drug, as was the 
case in the recent widely publicised discovery of an association between an increased risk of 
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heart attacks amongst patients taking the painkiller Vioxx (18,19) and other cyclooxygenase-
2 (COX2) inhibitors; a discovery that led to the withdrawal of a number of high-value 
products and left Merck defending itself against over 30,000 lawsuits (20) at an estimated 
cost of US$4.85 billion (21), due to allegations that it was aware of the risks, but failed to 
alert users to the possible dangers. 
1.2 The role of computational methods 
Computational methods, often referred to as in silico methods or virtual screening methods, 
are increasingly being seen as an attractive technique that can be used to complement both 
traditional and high-throughput screening (HTS) and optimisation strategies (22).  As 
computers have increased in power and decreased in price it has become feasible to carry 
out computational screening of ever larger databases, using algorithms of increasing 
sophistication.  It is fairly trivial to screen, in silico, compound libraries that (while nowhere 
close to being fully representative of all potential drug-like molecules) are several orders of 
magnitude larger than even the biggest HTS experiments can handle (23).  In order to 
identify a novel lead molecule with an activity of 1μM, a pharmaceutical company will 
typically have to screen in the order of ten thousand compounds (24), and anything that can 
be done to reduce this number can significantly increase productivity. 
High-throughput screening experiments typically have high rates of false negative and false 
positive results (25)  – active molecules that are missed, or inactive molecules that appear to 
be active.  False positive results cause less of a problem since they are identified during the 
more reliable secondary or follow-up screens.  False negative results, on the other hand, are 
more serious, since they cause potentially useful hits to be missed. 
Virtual screening programmes can be used to help overcome this problem (26).  In silico 
screens may be run in parallel to HTS programmes, and the hits from both combined to be 
used for secondary screening, or alternatively compounds thought to be inactive but similar 
to active compounds can be added to the HTS hits (27) for further testing. 
Not all protein targets are amenable to high-throughput screening.  In such cases, possibly 
resulting from the high cost of an assay, smaller scale iterative screening may be carried out 
(28).  Rather than screening an entire compound collection in one go, a much smaller initial 
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screen is performed, and its results used to construct a model which is in turn used to select 
compounds for the next round of screening.  This can be repeated until a sufficient number 
of active compounds have been identified. 
Besides virtually screening compounds against a single target, predictions of activity can be 
made against a large panel of targets in order to identify likely off-target hits, the 
occurrence of which can lead to toxic side effects, or to suggest novel uses for a compound 
(29).  In silico models are also used to predict physicochemical properties such as solubility 
(30), logP, the octanol/water partition coefficient (31), and pKa (32), and there is growing 
use of computational models to make predictions of more complex behaviour of molecules, 
such as prediction of the metabolic fate of drug molecules (33), of skin penetration (34) and 
the identification of toxicophores (35,36,37,38) – structural features of molecules indicating 
likely toxicity. 
It has already been mentioned that there is a high rate of attrition of candidate compounds 
over the course of the drug development process.  Figure 2 shows that around two thirds of 
the failures of drugs reaching clinical development are due to pharmacokinetic problems, 
animal toxicity and adverse effects in man (39).  Historically these issues are often not 
discovered until late in the development process, by which time significant resources and 
expense have been incurred.  It is hoped that in silico tools will enable much earlier 
identification of potential problems, and reduce the number of lead compound with 
liabilities that are not discovered until after significant investment has been made in the 
compound’s development, hence reducing overall drug development costs. 
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Figure 2: The reasons for the failure of 198 NCEs after reaching clinical development 
(39).  Pharmacokinetic problems, animal toxicity and adverse effects in man together 
account for almost two thirds of the failures. 
1.3 Virtual screening methods 
Virtual screening efforts can be broadly divided into two complementary groups of 
approaches – target- and ligand- based methods.  Target-based virtual screening methods 
generally involve modelling the interactions between the receptor or enzyme active site 
under investigation and each of the candidate molecules under consideration.  This requires 
a model of the 3-dimensional structure of this target.  Ligand-based methods, on the other 
hand, do not require a model of the target structure; instead they draw on information 
about molecules with known properties and activities.  In ligand-based virtual screening 
predictions are made on the basis of similarity to known molecules, or on the basis of 
models constructed around patterns identified in series of compounds.  While both 
approaches have their stories of success and failure, it is ligand similarity based approaches 
that are the most widely applied, due both to their orders of magnitude greater speed and 
the far greater availability of suitable data. 
Alternatively, de novo design techniques, such as SPROUT (40) can be used to design 
molecules meeting the constraints imposed by the receptor model in situ. 
39%
30%
11%
10%
5% 5%
Causes of Drug Failures
Pharmacokinetics
Lack of efficacy
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Adverse effects in man
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1.3.1 Ligand-based virtual screening methods 
The concept behind ligand-based virtual screening can be summarised by the ‘similar 
property principle’ (41): similar molecules are likely to exhibit similar biological activities and 
properties.  Whilst this is a straightforward enough concept, actually deciding how similarity 
should be measured is a complex matter, and highly dependent on the properties that are 
under investigation (42). 
There are two classes of ligand based virtual screening – molecular similarity searching, 
which usually has as its aim the identification of potentially active molecules from large 
databases, and Quantitative Structural Activity/Property Relationships (QSAR/QSPR), which 
are mainly used in the lead optimisation phase of drug discovery and development, as they 
are more suited to the detailed analysis of compounds that belong to fairly congeneric 
chemical series.  Both approaches rely on the representation of a molecule through some 
form of descriptors. 
Molecular descriptors 
There are many possible representations of a molecule; chemists variously consider a 
molecule to consist of a collection of atoms and bonds, regions of high and low electron 
density, or an ensemble of wave-functions, depending on the task at hand.  Similarly, there 
are many ways in which molecules can be represented in a computer.  Computers often 
store molecules as ‘coloured-graphs’ – lists of atoms (nodes) and the bonds (edges) 
between them, or as a list of atoms together with their coordinates.  These representations 
are not very well suited to mathematical analysis.  In order to make comparisons between 
molecules, descriptors are employed to capture the various properties and features that are 
thought to be important for modelling molecular interactions, and represent them in a 
manner that can be understood and manipulated by a computer.  Without any clear answer 
as to how to construct a descriptor that best represents a molecule, an enormous number 
of different descriptors have been investigated. 
Todeschini & Consonni’s Handbook of Molecular Descriptors (43) contains definitions for 
over 1800 different descriptors, many of which have a number of different 
implementations.  Many software packages, such as Mold2 (44), MOE (45) and SYBYL® (46), 
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each provide methods for calculating hundreds of descriptors.  Despite this huge apparent 
variety, most descriptors can be assigned to one of three common categories: 
 macroscopic physicochemical properties (most often calculated, but sometimes 
measured) such as the octanol/water partition coefficient (logP) and molecular 
weight 
 substructural fingerprints and feature counts 
 shapes and surface properties such as distributions of electrostatic potential 
These classifications broadly correspond to the various levels of molecular representation 
from which the descriptors can be calculated: so-called ‘1D’ descriptors depend only on the 
formula of the molecule; ‘2D’ descriptors depend on the molecule’s connection table – the 
atoms and the bonds between them; ‘3D’ descriptors depend on the stereochemistry and 
geometry of the molecule.  There are also ‘4D’ descriptors (47) which take into account the 
wide variety of 3D conformations a molecule can take, and higher dimensionalities 
accounting for flexibility in protein structures and the induced fit of ligands have also been 
suggested (48,49). 
Examples of the different representations of molecules (1D, 2D, 3D, 4D), and a selection of 
the descriptors calculable from each are shown in Figure 3. 
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Representation Descriptors 
1D (Formula) 
C10H12N2O 
Molecular weight 
Heavy atom count 
Atom counts: carbon, nitrogen, sulphur... 
Experimental properties (logP, affinities) 
2D (Connection Table) 
 
Hydrogen bond donor/acceptors 
Number of rotatable bonds 
Graph invariants 
Atom additive QSPR (logP, molar refractivity) 
Substructural fingerprints 
3D (Coordinates/Surface) 
 
Shape 
Solvent accessible surface area 
HOMO and LUMO energies 
Polar volume 
Dipole moment 
Pharmacophore fingerprint 
4D (Ensemble of Conformations) 
 
As 3D descriptors, but sampled for different ligand 
conformations 
Figure 3: 1D, 2D, 3D and 4D representations of molecular structure, illustrated with 
Serotonin, and examples of the descriptors calculable from each representation. 
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Molecular properties 
Molecular properties such as logP and molecular weight are probably the descriptors to 
have been most widely utilised to express similarity between molecules, and these are still 
commonly used (50) today.  Lipinski’s Rule of Five (51), for example, uses four whole 
molecule properties (molecular weight, logP, and counts of the numbers of hydrogen-bond 
donors and acceptors) as an indicator of a compound’s aqueous solubility, and hence oral 
bio-availability.  Lipinski’s Rule states that poor absorption or permeation are likely when a 
compound violates more than one for the following constraints: 
 There are more than 5 hydrogen-bond donors. 
 The molecular weight is over 500. 
 The logP is over 5. 
 There are more than 10 hydrogen-bond acceptors. 
This rule of thumb is used throughout the pharmaceutical industry to aid with the selection 
of compounds for inclusion in screening libraries (although properties required for screening 
are sometimes at odds to those required for oral bioavailability). 
Molecular weight, atom counts and numbers of hydrogen-bond donors/acceptors and 
rotatable bonds are obvious examples of descriptors for which precise values can be 
obtained.  Values of many more complex descriptors can often be approximated using 
simple representations of a molecule.  Properties such as logP and molar refractivity (MR) 
can be reliably estimated through atom contribution models, such as XLOGP (52), where 
each atom is assumed to make an independent contribution to the total logP value, the size 
of which depends on its local topological environment.  An example of such a calculation is 
given in Figure 4.  Surface and volume properties, such as van der Waals areas, which 
require a 3-dimensional model for a rigorous treatment, can be approximated using 
analogous methods.  Alongside these fairly simple calculations, the results of more complex 
calculations of molecular properties, such as dipole moments, HOMO and LUMO energies, 
heats of formation and ionisation potentials derived from quantum mechanical calculations 
are also often used as descriptors. 
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Atomic Grouping 
1 x C3 (2° heteroatom) 
1 x C10 (2° aromatic) 
1 x C13 (aromatic heteroatom) 
4 x C18 (aromatic) 
2 x C19 (aromatic bridgehead) 
1 x C21 (4° aromatic) 
1 x N1 (1° amine)  
1 x N10 (aromatic) 
1 x O2 (alcohol) 
8 x H1 (hydrocarbon)  
1 x H2 (alcohol) 
3 x H3 (amine) 
Contribution 
-0.2035 
-0.0516 
-0.5443 
0.1581 
0.2955 
0.1360 
-0.3239 
-0.2893 
-1.0190 
0.1230 
-0.2677 
0.2142 
LogP 0.287 
Figure 4: Illustration of logP calculation using an atomic contribution model (31). 
Substructural descriptors 
The descriptors most widely used in molecular similarity searching are substructural 
descriptors.  These consist of sets of atoms and/or bonds describing regions of a molecule.  
Substructural descriptors originally used dictionaries of predefined structural fragments, 
such as Symyx® MACCS keys (53), to identify the features contained in a molecule.  This has 
the drawback that fragments not considered important by the designers of the dictionary 
are ignored, when in fact they could prove vital to a particular interaction.  This makes the 
techniques highly dependent on the quality and appropriateness of the particular dictionary 
that they employ. 
Various techniques for automatically identifying fragments have been used to overcome this 
limitation.  Initially these tended to produce fairly small, simple fragments (e.g. augmented 
atoms, formed from a central atom and its immediate neighbours) (54), but as computer 
power has increased so have the fragment sizes and complexities that can reasonably be 
handled. 
Descriptors of this type include Daylight’s fingerprints (55) which consist of an exhaustive list 
of all the paths of atoms and bonds that can be traced through the molecular graph, 
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generally up to a maximum length of seven atoms, and Tripos’ UNITY fingerprints (56) which 
combines paths  calculated in a similar fashion to those of Daylight’s fingerprints with added 
counts of certain chemical elements and of additional features such as ring systems. 
Molecular fingerprints encode the presence or absence of each substructural feature with a 
1 or 0 at a position in a binary bit-string.  In the case of key-based systems each feature can 
be assigned to a specific position in the fingerprint, but this is not possible when the feature 
set is dynamically generated.  Instead, a hashing function is applied to each feature to 
determine which position in the bit-string to set.  This has the disadvantage of reducing the 
interpretability of the generated fingerprints; many different features may hash to the same 
fingerprint position, so it is no longer possible to identify the specific features present from 
the fingerprint’s bit-string. 
Atom-centred hierarchical fragments of molecules, illustrated in Figure 5 below, form a 
further class of substructural descriptor.  Hierarchically ordered spherical environment 
(HOSE) and hierarchically ordered ring description (HORD) codes (57) were originally 
proposed in 1978 for use in the prediction of 13C NMR chemical shifts and indexing files of 
molecular structures.  A more modern description of hierarchical fragment-type descriptors 
are the Signature Molecular Descriptors of Faulon (58,59).  
 
 
C(C(C C) C(N)) 
Figure 5: Illustration of the hierarchical structure of fragments and circular atom 
environments.  This specific example is of the generation of a Signature (58,59) -like 
atom environment fragment description.  The region of the molecule on which the 
fragment is centred is shown, along with the tree structure of the fragment and the 
descriptor generated. 
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Most recently, circular atom environments have been introduced, with the aim of encoding 
the electronic environment surrounding each atom in a molecule, rather than the exact 
connectivity of a substructural fragment.  Their use was proposed by Xing et al. (32,60) for 
the prediction of physicochemical properties such as pKa and logP through partial-least-
squares regression models based on contributions from the occurrences of SYBYL® (46) 
atom types at successive topological distances from a central atom, as illustrated in Figure 6 
below.  This descriptor, combined with a Naive Bayesian classifier and Information Gain 
based feature selection, forms the basis of Bender et al.’s MOLPRINT-2D molecular similarity 
searching technique (61,62). 
 A similar concept has been used by SciTegic in the development of their Extended 
Connectivity and Functional Class Fingerprints (ECFP/FCFP) (63,64), where each atom is 
assigned a numeric description representing its class, and this classification is augmented 
with the classes of atoms’ neighbours using a series of iterations in a procedure similar to 
that of the Morgan algorithm (65).  R-Group descriptors (66) are generated through the 
same Morgan-like approach, but are based upon the values of a number of atomic 
properties including atomic weight, hydrophobicity, molar refractivity and polar surface 
area, rather than the elemental or pharmacophoric descriptions (pharmacophores are 
described on page 18) used by SciTegic. 
 
 
(  C.ar  ;  C.ar [x2], C.sp2  ;  C.ar [x2] , O.sp2 , O.sp3  ) 
Figure 6: Illustration of the calculation of a circular atom environment fingerprint, 
using SYBYL® atom types.  To the left is a molecule with the fingerprinted region 
identified, and to the right is the fingerprinted region, showing the SYBYL® atom types.  
The fingerprint consists of the count of each atom type at each hierarchical depth 
from the central atom.  In this representation layers in the fingerprint are separated 
by semicolons.  ‘C.ar’ represents an aromatic carbon atom, and ‘X.sp2’/’X.sp3’ 
represent atoms of the specified element and hybridization. 
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A number of descriptors representing longer range features than are usually captured by 
substructure fragments have also been proposed.  Carhart et al. introduced atom pairs (67) 
in 1985.  These consist of a pharmacophore-based representation of each pair of atoms in 
the molecule, along with the length of the shortest path between them.  A similar concept, 
named REX, was developed by Judson (68), where the length of every path was included, 
not just the shortest.  Melville and Hirst (69) have reported the use of partial charges, molar 
refractivity, logP and logS in the calculation of topological autocorrelation descriptors, which 
capture the distribution of these physicochemical properties through pair-wise 
combinations of atoms, and the shortest path between them.  Young et al. (70) proposed 
the use of augmented atom pairs – a combination of atom pair and environment 
approaches, where each end of an atom pair is described in terms of its chemical 
environment, and a range-based, rather than exact, measure of the distance between the 
atoms is used in model generation.  Nigsch and Mitchell (71) introduced Molecular 
Orthogonal Sparse Bigrams, which have the potential to described correlation between 
different regions of a molecule through the pairing of selected atoms’ circular fingerprint 
descriptors, but do not capture the distance between the features. 
Fingerprints may be constructed from the combination of several types of feature.  As 
mentioned above, Tripos’ UNITY (56) fingerprints are the result of the concatenation of a 
hashed path fingerprint and a fingerprint representing the counts of certain chemical 
elements and features such as ring systems.  Other fingerprints have combined 
substructural descriptors with non-structural properties, for instance having bits indicating 
whether the molecule has a logP value within a particular range. 
Certain types of descriptors are better suited to particular applications.  Originally the major 
use of descriptors was in database searching and chemical registration (72), where 
fingerprints based on a descriptor are used to quickly identify and rank similar molecules, or 
refine queries by reducing the number of molecules for which it is necessary to carry out 
computationally much more expensive graph matching against the query compound.  Only 
certain types of descriptor, such as path fingerprints and certain structural keys can be used 
to refine database searches.  Hierarchical fragments and circular atom environments are not 
suitable for this task, but have shown better performance than path-based descriptors when 
used to predict biological activities (73,74).  
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Example calculations of a number of common classes of substructural descriptor are 
illustrated in Figure 7. 
Molecule 
 
 
Structural Keys 
   
  
 
1 0 1 0 0 1 
 
Paths 
 
 
Hashing 
 
404,251,677,79,145,469,833,10,350,775,720,448,968,805,367,408,401... 
To fingerprint 
 
00000000010000001000010011000000000000111100000000010000100... 
 
Fragments 
  
 
  
  
 
Circular Fingerprints 
(N;3C)(N;3C;2C)(N;3C;2C;2C)(C;2C,N)(C;3C)(C;3C;2C,2O)(C;3C;2C,2O;2C) 
The circular fingerprints correspond to the fragments above.  In this notation each 
layer of the fingerprint contains the counts of each type of atom in that layer, and 
layers are separated by a semicolon. (C;3C;2C,2O) means the central atom is a 
carbon atom, the first neighbours are 3 carbon atoms and the second neighbours 
are two carbon atoms and two oxygen atoms: 
 
central atom 1st neighbours 2nd neighbours 
   
 
Figure 7: Example calculation of structural keys and path, fragment and circular atom 
environment substructural fingerprints. 
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Pharmacophores 
Pharmacophores are descriptions of the spatial arrangement of molecular features that are 
believed to be necessary for biological activity (75) (similar to the ‘lock and key’ hypothesis).  
Generally there are six feature types from which pharmacophore models are built – 
hydrogen-bond donors, hydrogen-bond acceptors, basic groups, acidic groups, aromatic 
groups and hydrophobic groups.  Pharmacophoric features can be identified through the 
use of simple rules, such as ‘primary and secondary amines, and hydroxyl groups are 
hydrogen-bond donors’ (75).  Pharmacophores can be constructed from the features 
common to a number of molecules that are known to bind to a target, or through manual 
inspection of likely modes of binding. 
 
Figure 8: An example pharmacophore model superimposed on the template structure 
from which it was generated.  The yellow spheres represent aromatic regions, the blue 
sphere a hydrogen–bond acceptor and the red sphere a hydrogen–bond donor and 
cation. 
Pharmacophore fingerprints are an extension of the pharmacophore approach to the 
generation of 3D fingerprints.  The fingerprints are based on combinations of all the 
potential pharmacophore points identified in the molecule, together with the distances 
between them (76).  Two to four point pharmacophores are constructed from the potential 
pharmacophore points, and the pharmacophore types together with the distances between 
the points are hashed into a position in the fingerprint bit string. 
As well as pharmacophore fingerprints based on 3-dimensional geometric fingerprints, 
topological pharmacophores, similar to the atom-pair descriptors mentioned on page 16, 
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can be constructed.  Schneider et al. (77) suggested that pharmacophore models generated 
using topological distances rather than geometric ones, a technique they named Chemically 
Advanced Template Search (CATS), could overcome one of the main limitations of screening 
with substructure-based descriptors – the tendency models have to ‘learn’ the core 
scaffolds that they have been trained on.  Unfortunately models constructed with this 
approach have been found to perform poorly (74). 
Shape and surface descriptors 
Whilst a large number of descriptors rely on the comparison of the structural framework of 
molecules it is well known that molecules with different core scaffolds can interact with the 
same biological site in similar ways.  This is because molecules interact via their electronic 
properties, with the point atoms and rigid bonds picture that chemists typically employ 
being merely a convenient representation of the structure.  Substructure based descriptors 
have been found to exhibit a tendency to ‘learn’ these core scaffolds, restricting their use 
for scaffold-hopping between chemotypes.  3D descriptors aim to surmount this short-
coming by describing the shape and surface properties of molecules independently of their 
connection tables. 
As has already been mentioned, approximations to various surfaces can be calculated quite 
simply; however more precise surfaces can be calculated from a 3D representation of the 
molecule.  Commonly observed surface descriptors include the solvent accessible surface 
area of the molecule, the van der Waals surface area, and the proportions of these areas 
that are acidic, basic, hydrophobic, polar, or hydrogen-bond accepting (45).  
Molecular shapes have been described in terms of assemblies of standard geometrical 
objects, or using mathematical functions.  Morris et al. (78) have proposed the use of 
spherical harmonics to describe the shapes of molecules, which presents a straightforward 
method of comparison through use of the spherical harmonic expansion coefficients; and 
Ballester and Richards (79) have proposed representing molecular shapes through the 
moments of the distribution of atom’s distances from key points in the molecule. 
Other common molecular shape and surface related approaches include molecular 
interaction field (80) based descriptors, where molecules are first aligned and then various 
probes, measuring steric and electrostatic interactions, are moved over the surfaces of the 
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molecules, or through regularly spaced grids containing the molecules.  Most commonly 
force field based methods, such as GRID (81) and CoMFA (82) (Comparative Molecular Field 
Analysis) are used to score these interactions, though Quantum Similarity (83) approaches 
making use of electron probability density functions are also found, however the latter can 
be very time consuming to calculate. 
Typically, once interaction fields have been determined for a number of known active 
molecules (training set) they are overlaid and common regions detected.  In CoMFA 
searches this is carried out through partial least squares (PLS) regression between the 
interaction energy at each grid point and the molecules’ activity.  These conserved features 
are assumed to be responsible for the interactions involved in binding to the target.  Test-
set molecules are examined to see whether they possess the same features.  These types of 
techniques are particularly suited to data sets consisting of relatively rigid structures, since 
these make it much easier to generate good alignments. 
 
Figure 9: Example of a CoMFA model constructed from a set of steroid molecules, 
overlaid on the most active molecule from the training set.  The green and yellow 
regions indicate areas that are favourable or unfavourable with respect to steric 
effects, and the red and blue regions indicate where positive and negative charges are 
favourable.  
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Cheeseright et al. (84) have developed an alternative analysis of field approaches, based 
around the idea of electrostatic, steric and hydrophobic field extrema.  They propose that 
previous efforts in modelling what is ‘seen’ during molecular interactions have failed due to 
inadequate definition of charge distribution, and the large quantity of data required to 
describe surface properties.  To resolve this they have developed an improved molecular 
mechanics charge model – the eXtended Electron Distribution (XED) force field, which 
moves away from the conventional atom centred charge monopole towards a more 
distributed model.  To surmount the second hurdle they have proposed using a 
pharmacophore point like model, working only with points at the local extrema of the fields, 
as opposed to trying to process the whole surface or grid, though these models are not 
restricted to the three or four points generally used in pharmacophore models. 
Cheeseright et al. (84) have shown that ‘molecular field overlays’ generated using this 
approach can identify experimentally observed conformations of the ligands without 
requiring knowledge of the active site.  This was achieved by generating a number of 
conformations of each of two or three active site substrates, and detecting consistent 
molecular field overlays between the different molecules.  A consistent molecular field 
overlay is a set of field extrema which are conserved between two or more ligands; all 
combinations of molecular field extrema generated from the different conformations of 
each pair of ligands (each conformation of a ligand produces a different molecular field) is 
examined to determine the best matches.  When a consistent molecular field overlay can be 
found for the set of known ligands, it is assumed that this reflects the required features for 
binding to the active site. 
The main problem with many 3D techniques is their high dependence on the conformation 
and alignment of the molecules.  In order to make analysis as fast as possible, 
conformations are usually generated using a rule based system, such as CORINA (85) or 
CONCORD (86).  Coordinates may subsequently be optimised using a force field calculation, 
but there is no guarantee that the biologically active conformation is close to that found 
through optimisation in a vacuum.  When molecules have a high degree of flexibility or are 
substantially different it can be very difficult to generate an alignment (87). 
22 
In order to increase the speed and improve the accuracy of these methods, attempts have 
been made to remove the need to align molecules before performing grid and field based 
analysis.  GRid-INdependent Descriptors (GRIND) (88) select a small, representative subset 
of the tens or hundreds of thousands of grid points generated in a typical analysis of a drug-
sized molecule, based on the strength of interaction and distance from other representative 
points.  These representative points are encoded on the basis of their pair-wise distances 
and energies, giving a representation independent of the molecule’s alignment in space. 
Bender et al. proposed the MOLPRINT-3D (89) technique, where the results from GRID 
probes are assembled into surface patches a few Ångströms in diameter, and the 
distribution of scores at increasing distances from the centre of the patch binned and 
recorded, in a manner analogous to the generation of 2D atom environments.  These 
descriptors were found to perform at a mid range level when compared to a variety of 
standard substructural techniques, though they did detect actives with a wider variety of 
chemotypes. 
Unfortunately such methods take far longer to calculate, so are currently less feasible for 
use in large scale screening as 2D fingerprinting techniques. 
Other descriptors 
Many other descriptors have been tried, and only a few of them will briefly be mentioned 
here.  Many topological and other graph based indices have been proposed, examples of 
which are described in Todeschini & Consonni’s Handbook of Molecular Descriptors (43).  A 
range of molecular spectra (90) – X-ray, electron diffraction, infra-red and NMR (91) have 
also been used, with mixed reports of success (92,93).   
Rather than generating fingerprints on the basis of the occurrence of structural features in a 
molecule, they can be constructed based on the binding affinities when screened against a 
panel of uncorrelated reference targets.  Use of these fingerprints is based on the 
hypothesis that compounds binding to the reference proteins in a similar manner are likely 
to bind in a target protein in a similar manner too.  Both in vitro (using experimentally 
determining binding affinities) (94) and in silico (based on docking experiments) (27,95) 
affinity fingerprints have been investigated.  Compounds are screened against the reference 
panel, and their activity profiles, representing the response of each target to the compound, 
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generated.  For novel targets, a subset of the profiled compounds is screened, and then 
models constructed using the compounds’ activity profiles. 
Molecular similarity searching 
Molecular similarity searching has developed out of tools originally created to enable the 
searching of databases of chemical structures.  Initially these relied on the matching of a 
single query structure against the database contents, with presence of the query structure 
in a database molecule resulted in the entry being flagged for retrieval (96).  This was 
subsequently developed into searches for molecules containing a number of substructural 
fragments.  As searches became more complex it became desirable for them to return 
results matching some but not all of the substructural features specified, and these results 
needed ranking depending on how many of the substructural features they contained.  This 
led on to search systems where an entire query molecule could be entered, and all the 
nearest-neighbour matches identified through a similarity measure based on substructures 
common to the query compound and the database molecules. 
In order to perform a basic similarity search, a query molecule – such as a known binder to 
the target under investigation – is specified, and substructural fingerprints generated.  This 
fingerprint is compared with the fingerprint of each of the compounds in the database, and 
the similarity determined using some metric, the best known of which is the Tanimoto (97) 
coefficient (also known as Jaccard’s “coefficient of community” (98,99)), which scores 
similarity as the ratio of the number of features the two molecules have in common to the 
total number of distinct features found between them.  There are a wide variety of such 
similarity metrics available (96) and since their scores are generally highly correlated (100) 
the results are quite insensitive to the choice of metric. 
𝑡 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑐𝑜𝑚𝑚𝑜𝑛 𝑡𝑜 𝑏𝑜𝑡𝑕 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑓𝑜𝑢𝑛𝑑 𝑖𝑛 𝑒𝑖𝑡𝑕𝑒𝑟 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒
 
Figure 10: Calculation of the Tanimoto coefficient. 
Various modifications to the basic bit-string approach can also be made, such as setting 
multiple bit positions to represent different numbers of occurrences of a feature, rather 
than simply recording its presence or absence (101,102).  Binary fingerprints have also been 
extended to produce feature count vectors, known as Molecular Holograms (103).  A study 
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by Fetchner et al. (104) found that models constructed using holographic fingerprints rarely 
yielded significantly higher enrichment factors than models constructed using their binary 
equivalents.  It is however interesting to note that the lists of individual molecules returned 
by the holographic and binary fingerprints did differ considerably, so there could be 
advantages found in amalgamating lists of actives produced through both methods, in order 
to increase the molecular diversity of the compounds retrieved. 
The use of bit-string based similarity can cause a number of problems; in particular there 
can be a bias towards larger molecules, which will tend to have more bits set, and there is 
quite a large ‘twilight zone’ (105) in which it can be difficult to know whether the similarity 
score calculated indicates that the molecules are really similar, or not.  This can be 
overcome by deciding up front how many molecules the search should return, and picking 
enough of the top scoring results to fit this. 
Tanimoto coefficient based similarity searches are still used, but there is also a wide range 
of machine learning and regression techniques that are often applied.  Recent similarity 
techniques such as MOLPRINT-2D and SciTegic’s fingerprints make use of machine learning 
techniques such as Naïve Bayesian classifiers to compare molecules.  These offer a number 
of advantages over the older similarity metrics, most noticeably the ability to train models 
on a large number of both active and inactive molecules, selecting the relevant descriptors 
from each, and also producing a more meaningful output than similarity coefficients 
generally do – the relative likelihood of the molecule under investigation being active or 
inactive, given that it contains the features that it does, rather than a more abstract 
‘similarity score’. 
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Figure 11: Outline of molecular similarity techniques.  Molecules are represented to 
computers in a numerical or binary form.  Models are constructed from these 
descriptors using similarity metrics or machine learning methods. 
Toolkits such as the Weka Machine Learning Workbench (106), RapidMiner (formerly YALE) 
(107) and the R Project for Statistical Computing (108) provide straightforward access to 
large numbers of machine learning and statistical methods. 
By no means all similarity searching is carried out using substructural features – any 
descriptors can be used.  Many machine learning methods can take real-valued descriptors 
as inputs, but if not, these can either be binned, to form binary bit-strings, or vectors of 
values can be used along with distance measures such as the Euclidian distance (length of 
the line whose ends are at the points represented by the two vectors of descriptors). 
QSAR/QSPR modelling 
Once a lead series has been identified, interest often moves away from basic molecular 
similarity measures to the construction of more quantitative models of  the activity and 
properties of molecules in that chemical series.  The original QSAR and QSPR models were 
pioneered by Hansch (109,110) and by Free and Wilson (111) in the 1960s, using linear-
regression models based on a small number of molecular property-type descriptors with 
clear physicochemical meaning (112) to predict activities and properties for specific 
chemical series. 
Similar techniques are still employed today, particularly for the prediction of 
physicochemical and pharmacokinetic properties such as solubility, with a continuing stream 
of new publications in the area; one study reports the identification of over 18,800 QSAR 
and QSPR models (113).  Modern models tend to use a much greater range of descriptors, 
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often including far less clearly interpretable descriptors than the earlier models did.  In 
tandem, newer statistical techniques such as partial least squares and principal component 
analysis regression, or machine learning methods such as neural networks and support 
vector machines, are being employed.  These methods have the advantage that they can 
better model the non-linear relationships that are often found to occur between descriptors 
and activities or properties, but this can come at the cost of a loss of interpretability. 
When generating models from a large number of descriptors, particularly when the quantity 
of training data is relatively small, the selection of relevant descriptors and features is 
essential (114) if over-fitting of the model to the training data is to be avoided.  This 
selection process can also enable the model to run faster, and produce models that do not 
contain more complexity than is necessary, making them more clearly understandable 
(115). 
Descriptors that are relevant in one circumstance may be useless in another – one study 
reported finding that logP (one of the most widely used descriptors in QSAR modelling) was 
no more useful than random numbers when predicting the biological activity of certain 
chemical series (13).  The cost of calculating descriptors may also be borne in mind – often a 
complex descriptor may be strongly correlated to a much simpler one (112,116), leaving the 
time spent calculating advanced descriptors wasted.   
Descriptor and feature selection can be an integral component to a machine learning 
method, as is the case with Random Forests, or can be applied as a filter prior to the 
model’s generation, as with the Naïve Bayesian classifier/Information Gain (117) filter 
employed by MOLPRINT-2D. 
1.3.2 Target-based virtual screening methods 
Docking 
The most commonly used form of target-based virtual screening is docking, which is the 
subject of many reviews, examples being those by Kitchen et al. (118) and Mohan et al. 
(119).  Docking experiments investigate how a candidate ligand could potentially bind to the 
active site of an enzyme or receptor.  The possible conformations and orientations of a small 
molecule are sampled, and each is placed into the binding pocket of a biological target.  The 
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fit for each docking pose is measured using a scoring function typically based on the 
interactions between the ligand and its target.  The highest scoring poses are taken to have 
the strongest interactions between the ligand and receptor, and postulated to be the 
biologically relevant fit. 
Attempts have been made to correlate docking scores to experimentally determined 
binding affinities, though this has proven to be challenging (120), likely due to the complex 
nature underlying the thermodynamics associated with the weak non-covalent interactions 
involved in protein-ligand binding, particularly entropic and solvent effects.  Errors are also 
likely to be, at least in part, due to deficiencies in the receptor model.  As will be discussed 
later, there is no guarantee that the 3-dimensional structure used for docking is in the 
biologically relevant conformation.  This is compounded by the little or no flexibility 
afforded to the protein structure, unlike the ligand, due to the high computational cost that 
would be involved. 
A range of docking programs such as GOLD (121), FlexX (122,123) and Glide (124,125) are 
regularly used in drug discovery processes.  These are most successful when consensus 
methods, combining the results of a number of different scoring functions for each pose, are 
used.  This has been found to reduce the occurrence of false-positives (126), though 
obviously at a cost of increasing the computational effort required, which reduce the 
technique’s through-put. 
Receptor-based pharmacophores 
Pharmacophores, which were discussed in more detail on page 18, are arrangements of 
generalised molecular features representing the main interactions required for the binding 
of a ligand to a protein.  Pharmacophore models are usually constructed from known 
ligands, however Meagher and Carlson have reported (127) the development of 
pharmacophore models through analysis of the flexibility found in a collection of un-
liganded protein structures.  This technique was found to be able to discriminate between 
known inhibitors of HIV protease and drug-like non-inhibitors, and offers the promise of 
providing more flexible models than traditional pharmacophore techniques where only a 
single structure is considered. 
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Structures 
As has already been mentioned, in order to carry out target-based virtual screening a 3-
dimensional model of the target’s structure is required.  The most common sources of these 
are X-ray crystallographic models, followed by NMR and homology modelling and 
simulation.  Some of the greatest challenges associated with target-based virtual screening 
arise from to the quality and the limitations of the structural data available.  For many 
potential targets no structural data is available – this is particularly true of membrane 
proteins which are notoriously difficult to crystallise, though structures are starting to 
appear as new crystallization techniques are developed (128), such as the recently 
published  human G protein-coupled receptor (GPCR) structures (129,130,131).  Even in 
cases where ‘good quality’ crystallographic data is available, mistakes are often made; 
PDBREPORT (132) estimates that as many as 15% of deposited structures contain errors.  
Some of the problems associated with the use of crystallographic data are due to users not 
appreciating that X-ray crystallographic structures are “one crystallographer’s subjective 
interpretation of an electron density map” (133), rather than the direct output of X-ray 
crystallographic experiments.  The inherently static nature of a crystal makes it difficult to 
appreciate the dynamic nature of structures under native conditions, which can be 
particularly important when a ligand is bound through an ‘induced-fit’ mechanism, and the 
crystallisation process can also lead to instances where the crystal structure does not 
accurately reflect the conformation of a protein when in solution. 
1.4 Current challenges and developments 
In spite of the huge growth of virtual screening over the past decade, the high rate of 
attrition in drug development has continued.  Recently there has been a growing feeling 
among practitioners that in silico screening is not performing as well as was expected 
(134,135).  It is increasingly apparent that the reported performance of models, generally 
from cross-validation or hold-out data at the time of construction, are not being achieved 
when the models are applied to novel data (136). 
1.4.1 Activity cliffs 
In part these problems are caused by deficiencies in the modelling techniques.  There is a 
growing appreciation of the appearance of ‘activity cliffs’ (136) in QSAR data.  QSAR models 
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are based on the ‘similar property principle’ and exhibit ‘neighbourhood behaviour’ (13) – 
the assumption that activity landscapes can be compared to gently rolling hills,  where small 
changes in molecular structure lead to a small change in activity (137).  For many series of 
compounds this holds true, however instances of the ‘similarity paradox’ (138) where a 
seemingly small structural modification leads to a large change in biological activity are also 
common.  Examples of this are shown below.  Figure 12 shows how successive lengthening 
of the alkyl chain in a series on morphine analogues moves the compound’s activity from 
potent agonist to potent antagonist and then back to a potent agonist (139). 
 
Substituent (R) Activity 
methyl potent agonist 
ethyl inactive 
propyl potent antagonist 
butyl inactive 
pentyl potent agonist 
hexyl potent agonist 
 
Figure 12: The activities of Morphine (R=methyl) and a series of analogues.  Small 
changes to the structure of the compound can dramatically alter its activity. 
The presence of activity cliffs can often be rationalised if the binding mode of the ligand is 
known; it could be, for example, that the addition of a methyl group leads to an 
unfavourable steric interaction.  If an appropriate descriptor is used to represent the 
molecule then this behaviour may be captured in the model, otherwise an activity cliff 
appears.  The occurrence of activity cliffs can also be receptor dependent – ligands that 
appear very similar in some circumstances can behave quite differently in others.  Figure 13  
shows how a small structural change can lead to small changes in activity against some 
targets, but an order of magnitude increase in binding to another. 
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Ligand 
Activity (Ki / μM) 
Thermolysin NEP 24.11 ACE 
 
1.8 0.0019 0.14 
 
2.3 0.0023 10 
Figure 13: Example of molecules simultaneously illustrating both the ‘similar property 
principle’ (when binding to thermolysin or NEP 24.11) and the ‘similarity paradox’ 
(when binding to ACE) (140,141). 
1.4.2 Simple models 
There have recently been a number of reports of relatively simple models being found to 
perform as well as much more sophisticated ‘state of the art’ methods.  In one comparison 
of virtual screening tools (116) predictions based on 'dumb' atom count descriptors, 
consisting of the total number of atoms in a structure, the number of heavy atoms and the 
numbers of each of ten commonly occurring elements (boron, bromine, carbon, chlorine, 
fluorine, iodine, nitrogen, oxygen, phosphorus and sulphur), were compared with a number 
of much more sophisticated methods.  On average the best performing method in the study 
(MOLPRINT-2D) achieved enrichment factors that, although 70% higher than the ‘dumb’ 
atom counts, were much lower than the often reported 10× or higher enrichment relative to 
random compound selection.  For two of the eleven datasets described in the study the 
atom counts achieved higher enrichment factors than UNITY fingerprints, and as was noted 
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by the authors, generally found hits with a wide variety of scaffolds, avoiding the biases 
commonly associated with many substructural descriptors. 
Gillett et al. (142) have reported the use of simple descriptors to detect compounds from 
the World Drug Index in a much larger collection of molecules.  They found that even single 
descriptor models using features such as the number of hydrogen-bond donors in a 
structure gave enrichment factors of up to 4.6× higher than random selection. 
Another recent study (143) evaluated a number of logP prediction methods using two small 
public datasets (223 and 43 molecules) and two larger in-house datasets (882 molecules 
from Nycomed and 95809 molecules from Pfizer). Thirty methods of predicting logP were 
evaluated using the public datasets, and 18 against the in-house datasets.  Included in the 
comparison were two ‘dumb’ models: an Arithmetic Average Model (AAM), which assigned 
all molecules the same logP (the mean of the dataset), and a very simple QSPR, based only 
on the number of carbon atoms (NC) and the number of hetero-atoms (neither carbon nor 
hydrogen atoms – NHET) in the molecule: 
𝐿𝑜𝑔𝑃 = 1.46 + 0.11 × 𝑁𝐶 − 0.11 × 𝑁𝐻𝐸𝑇 
When evaluated against both of the in-house datasets no more than half of the tested 
methods performed better (assessed by RMSE in predictions) than the Arithmetic Average 
Model, and the simple NC+NHET QSAR was among the best performing of all the methods.  
Against the public datasets the majority of prediction methods performed better than the 
AAM and NC+NHET models.  The authors suggest that this could to be due to the paucity of 
publicly available data making it likely that many of the tools would have included data from 
the public datasets in their development. 
It has also been shown that simplistic 3D models can perform on a par with more 
sophisticated ones.  Manchester and Czermioski (144) compared CoMFA with a significantly 
less sophisticated alternative they termed Simple Atom Mapping Following Alignment 
(SAMFA).  Like CoMFA, the SAMFA method is dependent on an alignment of structures, but 
rather than comparing steric and electrostatic field values at points on a regular grid 
containing each structure, SAMFA compares the occurrence of particular elements and 
pharmacophoric atom features at each point occupied by an atom in any of the aligned 
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structures.  In a comparison of the two techniques’ performance over nine data sets the 
authors found that the SAMFA method performed “as good, or slightly better” than COMFA.  
They surmised that the number of simplifications and approximations inherent in QSAR 
modelling techniques overshadowed any problems due to the simplifications made in the 
SAMFA method, and felt that the model’s atom-centred basis made it straightforward to 
interpret. 
1.4.3 2D versus 3D 
Despite 2D based virtual screening methods generally containing no information on the 
shape or stereochemistry of a molecule, they have widely been found to perform as well as, 
or better than, either descriptor- or docking- based 3D methods (145,146,147,148).  
Combined with their generally much higher throughput, this has led to 2D models being 
used much more regularly than 3D approaches.  Although there is considerably more 
information lost in the generation of 2D models, the construction of 3D models introduces 
more noise into the data.  While it is well known that stereochemistry is important to 
molecular recognition (149), a method of including stereochemistry in 2D descriptors is yet 
to find widespread acceptance. 
As previously discussed, ligand and protein flexibility are often only partially considered, or 
completely ignored, by docking programs.  If they are fully included then this can result in 
too many degrees of freedom in the system for the problem to be computationally tractable 
with current resources and techniques.  Ligand flexibility is also often ignored in 3D 
modelling.  The ligand conformations used in 3D model generation and docking are often 
taken to be the coordinates of an idealised energy minimum structure, while it is known 
that binding often occurs in higher energy conformations.  Feher and Williams (150) have 
reported that despite docking tools usually allowing for ligand flexibility, their generated 
poses and scores are highly sensitive to the ligands’ input conformations.  In an investigation 
into the effects of input geometry of ligands on docking calculations, Feher and Williams 
found that none of the sources of coordinates evaluated (X-ray crystal structures, force field 
minimized CORINA (85) generated structures and conformational searches) consistently 
produced better results than the alternative sources. 
33 
A further complication arising with docking approaches is that a docking program relies on 
two distinct components: a method for generating ligand (and possibly protein) 
conformations and a scoring function that evaluates the binding of each ligand 
conformation to the target.  Scoring functions are generally intended to reflect binding 
pose, providing a relative ordering of ligand/protein complex conformations.  Unfortunately 
current scoring functions are not considered to be very reliable in predicting binding affinity 
(151); one recent investigation of docking (152) reported that “comparative studies indicate 
that none of the docking programmes truly outperforms the others”.  This is likely to be at 
least in part due to scoring functions being based mainly on the strength of interactions 
between the ligand and protein, while the free energy of binding depends on many other 
factors, such as the hydrophobic effect, destabilisation of the unbound protein or ligand or 
changes to proteins’ normal modes (heat capacity), and hence entropy, on binding. 
Specific biomolecular systems can be investigated through atomistic simulations, but this is 
not tractable in a high-throughput manner due to the computational resources required.  
There are also a number of challenges associated with such simulations; bespoke force field 
parameterization is often necessary for uncommon ligands, and there are difficulties 
associated with modelling protein quaternary structures, cooperative binding and lipid 
bilayers that have not yet been fully solved. 
1.4.4 Local versus global models 
Early QSAR/QSPRs were local models, describing changes in activity, or the variation of a 
property, within a single chemical series – a collection of structurally related compounds.  
Modern in silico models tend to be global, able to make predictions for any compound.  The 
predictions of these models are, however, only reliable within the regions of chemical space 
in which the model was trained (the applicable domain).  Some of the dissatisfaction with 
current in silico models arises from attempts to extrapolate beyond these limits, which 
generally results in poor predictions (135).  A number of studies have shown that 
compromises between local and global approaches, such as the construction of sub-models 
or the application of local corrections, can lead to improvements over a single global model. 
While predicting molecules’ pKa, Xing et al. (60) constructed separate models for subsets of 
chemical space; acids were subdivided into four broad categories: aromatic acids, aromatic 
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alcohols, aliphatic alcohols and aliphatic acids, and bases were similarly separated into 
different classes of molecule.  The combination of these simple sub-models gave much more 
accurate predictions than their previously published global models for the pKa of all acids 
and all bases (32).  Similarly, when modelling solubility, Bergström et al. (145) found that by 
generating sub-models for acids, bases and ampholytes (molecules containing both acidic 
and basic groups) more accurate predictions were possible than when using a single global 
model. 
Rather than pre-selecting which sub-models to generate, local models can be generated on-
the-fly, based only on the subset of the training data most relevant to a query compound 
(153,154).  Based on the assumption that similar compounds will be subject to similar errors 
in prediction, local model corrections can also be applied, adjusting the value of predictions 
made from global models according to the mean error in prediction of the k-nearest 
neighbouring molecules from the training data (155) or from data acquired after the model 
is constructed (156,157).  It has been reported that this type of approach can be much more 
accurate than use of a single global model.  However, there are conflicting reports as to the 
circumstances under which it is appropriate to apply this technique: 
“[Local regression] can also lead to larger prediction errors when compared to 
ordinary global regression.  This is especially true when the training data is 
sparse.” (153) 
 “[Locally weighted linear regression] appears to be especially well-suited for 
the development of highly predictive models for the sparse or unevenly 
distributed data sets.” (154) 
Similar results can be achieved through the use of certain machine learning techniques, such 
as decision trees, which inherently divide the model space in a (hopefully) optimal manner. 
QSARs, and other in silico models, have tended to be static, generated and evaluated by an 
expert, and then left unchanged for long periods.  Rodgers et al. have shown that the 
performance of these models can exhibit time dependent behaviour (158).  They reported 
the results of constructing and evaluating models for Human Plasma Protein Binding on a 
monthly basis over a two year period, with a portion of the new data collected each month 
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held back from model generation and used for testing.  The accuracy of predictions of 
earlier test data were found to be stable as the models were updated.  However, the 
updated models were better at predicting both new and future test data.  This suggests that 
over time the focus of current research can shift away from the compounds with which 
models were constructed, and into new regions of chemical space.  By ensuring that models 
are updated regularly to reflect this, the accuracy of predictions can be maintained. 
1.4.5 Consensus methods and data fusion 
Consensus methods, basing predictions on the combined output of many different 
approaches, have been found to perform well in a wide variety of fields.  There are many 
reports on the ‘wisdom of crowds’ – the average of many independent estimates made by 
humans being more accurate than those of individuals, even those of specialists (159), and 
the same is often true of computational models.  The recently announced winning entry of 
the Netflix Prize for the machine learning algorithm that best predicts subscribers’ ratings of 
movies makes its predictions through the combination of a number of diverse approaches 
(160). 
Increasing computer power has made combining the results of multiple models ever more 
feasible.  A recent review of data fusion methods by Willet (161) did not find them to be any 
more effective than the best individual predictor in most studies, but their results were 
comparable to the best individual functions, and were robust to changes, while the best 
predictor varied from experiment to experiment. 
The logP study (143) discussed above included a consensus model based on the mean value 
of the predictions made by the other models.  This was more accurate (predicted logP 
values had a lower RMSE) than any of the tools individually for three of the four datasets 
used in the study, and was close to the best performing model in the fourth. 
In virtual screening experiments it is often not only the accuracy of the results that is 
important, but also the diversity of the structures identified.  The output of screening 
approaches with little correlation, such as affinity and structural fingerprints (162), are often 
complementary to each other – many of the hits returned by each method are missed by 
the other (27).  Combining the results of different similarity searching methods leads to the 
inclusion of more hits than are identified by any one method alone (163).  Similarly, it has 
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been found that in docking experiments use of consensus scoring functions substantially 
improves tools’ performance in most cases (164,165). 
1.4.6 Model interpretability and inverse QSAR 
Ideally, models and the factors contributing to each prediction are easily interpreted by a 
chemist, enabling them to appreciate how alterations to the molecule’s structure will affect 
the model’s predictions.  Linear models tend to provide this interpretability, however non-
linear models and machine learning methods are often found to offer the highest 
predictivity, but at the expense of losing interpretability.  Non-linear models are often 
considered to be ‘black boxes’, giving little or no indication of the basis for a prediction. 
This is not true of all machine learning and non-linear techniques, for example Bayesian 
classifiers can be interrogated to determine the contribution of each feature to a prediction.  
When using other machine learning techniques, such as Random Forests, it may be possible 
to extract the importance of each variable within a model, but not assess its contribution to 
an individual prediction. 
Carlsson et al. (166) have recently proposed a novel method of assessing the importance of 
each input variable of a model to an individual prediction.  They proposed the generation of 
a locally linear approximation to non-linear or black-box models by either analytical or 
numerical calculation of the partial derivative with respect to each variable about the point 
at which a prediction is made.  Assuming that the function is sufficiently smooth, the 
gradient of each variable reflects its importance to that particular prediction, and enables 
rational exploration of chemical space in the local neighbourhood about a molecule, by 
indicating how the predicted property will vary with minor changes to that variable. 
1.4.7 Data quality 
One of the major issues that virtual screening research has faced, especially in academia, is 
access to and quality of data.  Much chemical data is commercially sensitive, so never gets 
published.  Many of the available datasets are fairly small, and published as supporting 
information to papers (e.g. Briem and Lessel (27), Jacobsson et al. (167) and Fontaine et al. 
(168)).  As a result many virtual screening studies report building and evaluating their 
models on far smaller data sets than the libraries to which they intend the models to be 
applied. 
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A number of databases abstracting details of active ligands from the literature are available.  
The Symyx® Molecular Drug Data Report (MDDR) (169) and the World of Molecular 
Bioactivity (WOMBAT) (170) database are commercial offerings that have been available for 
some years, and recently the EBI has acquired a similar resource, the StARlite database, and 
made it freely available rebranded as ChEMBL (171).  While useful resources, these 
databases do have limitations; they often contain a relatively small number of molecules 
tested against the majority of reported targets, and being aggregated from literature 
generally report only active compounds. 
A further problem with data aggregated from a number of sources is that results are not 
necessarily comparable between experiments.  Where quantitative results are available, 
some measures, such as IC50 values, depend on the experimental conditions, and even 
measurements of a property as apparently straightforward as solubility can vary wildly 
(172). 
Due to the relative rarity of activity, it is assumed in many analyses that any compound not 
reported to be active is inactive, but it could be that this compound has just not been 
tested, and also problems can arise if promiscuous binders are not identified. 
The NIH Molecular Libraries Initiative (173) is now making publically available the results of 
high-throughput screening (HTS) programmes through the PubChem Bioassay service (174), 
providing data on both activity and inactivity.  So far there have been few reports of models 
constructed using this data, possibly because, as with all HTS data, this brings with it issues 
regarding quality and noise. 
Due to the large imbalance in much of this data, with many more inactive (or presumed 
inactive) compounds than active ones, very high prediction accuracies can be achieved 
simply by ignoring the presence of active compounds altogether (175) – if only one in a 
thousand molecules is active, a model can correctly classify 99.9% of compounds simply by 
predicting that all of them are inactive!  This can be a particular problem when models are 
being generated and evaluated in an automated manner. 
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Many screening libraries and other datasets contain series of close analogues designed to 
bind to a particular target, which can also skew the results of evaluations of virtual 
screening techniques. 
Some datasets contain inherent biases.  In the α1A agonist dataset published by Jorisson and 
Gilson (176) active molecules are considerably larger than the inactive compounds*, 
meaning that any model including a measure of size as a descriptor can easily discriminate 
between actives and inactives.  Inherent anomalies such as this are not discoverable 
through cross-validation, but only become clear when the model generated is applied to 
alternative data and not found to perform as expected. 
The relative scarcity of data means that many supposedly independent models have in fact 
been trained using much of the same data.  As with the case of the logP models discussed 
earlier, not knowing exactly which data was used to develop a model can make reliable 
evaluation of its performance difficult. 
1.4.8 Applications of virtual screening 
Molecular similarity, QSARs and other virtual screening methods are widely used in the 
prediction of activities and properties of compounds (such as logP and solubility) but 
additionally these approaches are increasingly being applied to other more complex 
problems. 
Originally virtual screening experiments were conducted with the aim of testing as many 
compounds as possible against a single target.  Multi-target models are now being 
generated which enable compounds to be evaluated against a large panel of potential 
targets at once (e.g. BioPrint from Cerep (177)).  It is hoped that this will lead to early 
identification of off-target effects and potential drug-interactions, and may help to better 
understand the mode of action of multi-target drugs. 
A further application of multi-target predictions is the identification of novel therapeutic 
uses of existing drugs.  While some additional trials are necessary, extending the use of an 
existing drug to a novel therapeutic area is much less expensive than developing a new drug 
                                                     
* The mean length of the shortest path between the most distant atoms in each inactive compound 
is 9.3 bonds, but for the actives it is 16 bonds – an increase of 71%. 
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from scratch – the compound will already have been developed into a therapeutically useful 
form, and have undergone extensive safety testing. 
A recent study has reported the in silico screening of 3,665 approved small-molecule drugs 
and other pharmaceutical compounds (29) against a large panel of targets, using molecular 
similarity techniques.  This predicted a number of previously unknown targets for many of 
the compounds.  The authors tested 30 of the predicted drug-target interactions, and 23 of 
these were confirmed (29). 
In a similar manner, several groups have used virtual screening approaches to investigate 
traditional Chinese medicines (TCMs) (178,179,180).  The constituent compounds from TCM 
ingredients such as ginger and ginseng have been screened against models constructed for 
panels of drug targets, generating ‘bio-prints’ of the compounds’ likely activity.  These bio-
prints have been related to the TCM’s therapeutic use in order to elucidate possible modes 
of action, and potentially identify new lead compounds for pharmaceutical development.  
Evidence has been found supporting a number of the modes of action of TCM ingredients 
predicted using this approach (179). 
QSAR models often perform well within a series of closely related compounds, however it is 
often desirable to identify molecules with a novel scaffold (core structure) but offering 
similar properties to a query compound.  This may be due to a desire to avoid a liability 
identified with a particular scaffold such as toxicity or promiscuous binding, or to avoid 
regions of chemical space infringing on a competitor’s patents.  A number of studies e.g. 
(181) have investigated the scaffold hopping potential of different tools, particularly 3D 
methods. 
There have been a number of advances in automated model generation (182,112).  This can 
offer the potential to explore many combinations of descriptors and modelling techniques in 
order to identify the optimal combination.  While the risks of models over-fitting their 
training data are believed (at least for the users of such models) to be fairly well 
understood, the huge numbers of descriptors and machine learning and regression 
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techniques available to an automated system increases the likelihood of discovering chance 
correlations*. 
Virtual screening tools are also being applied to the improvement of screening library 
collections, with the aim of generating more drug-like hit and lead compounds, reducing the 
effort required to move from lead to candidate (183).  In silico models are increasingly being 
used to identify potential ADMET (Absorption, Distribution, Metabolism, Excretion, and 
Toxicity) liabilities as early in the discovery process as possible, in order to reduce the 
number of hugely expensive late-stage failures.   
The prediction of xenobiotic metabolism, which is of great importance to the 
pharmacokinetics, efficacy and toxicity of New Chemical Entities, forms the basis for the 
remainder of this thesis.  The next chapter provides an introduction to xenobiotic 
metabolism, and current approaches to its prediction.  The development and evaluation of 
MetaPrint2D, a new tool for predicting sites of xenobiotic metabolism, is then discussed, 
and the extension of MetaPrint2D to prediction of types of metabolic transformation and 
the likely metabolites formed described in subsequent chapters. 
 
                                                     
* Assuming that there is a 0.1% probability of a model exhibiting chance correlation, only 693 
independent models must be generated for there to be a better than 50% likelihood that one will 
show chance correlation (0.999693 = 0.4999). 
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2. Prediction of xenobiotic metabolism 
The remainder of this thesis describes work investigating prediction of the metabolism of 
xenobiotic compounds.  The Substrate/Product Occurrence Ratio Calculator (SPORCalc) 
method for predicting sites of xenobiotic metabolism has been re-designed with a number 
of enhancements, thoroughly evaluated, and its performance increased to the point where 
it can be used in an interactive or high-throughput manner.  The new software 
(MetaPrint2D) is available as a freely distributable library and includes a number of example 
applications, enabling more wide-spread use of the method. 
This chapter provides an introduction to xenobiotic metabolism and its effects, and to the 
current computational approaches used for its prediction.  The following two chapters 
describe the development and evaluation of MetaPrint2D, and Chapter 5 describes 
MetaPrint2D-React: an extension of MetaPrint2D extending it from site of metabolism 
prediction, to prediction of the metabolic transformations and metabolites formed.  Both 
MetaPrint2D and MetaPrint2D-React have been extensively evaluated, and this is described 
in their respective chapters.  Finally a retrospective analysis of recently published metabolic 
pathways is reported in Chapter 6. 
2.1 Introduction 
2.1.1 Xenobiotic metabolism 
Xenobiotics are compounds that are introduced into an organism, but which would not 
normally be produced by the organism or form part of a normal diet.  These can include, for 
example, drugs and food additives together with environmental chemicals, such as 
agrichemicals and personal and household products, to which the organism has been 
exposed.  These compounds must often be removed from the organism to prevent their 
producing any adverse effects, and this is achieved through their metabolism. 
Xenobiotic metabolism is generally considered to occur in two phases (184,185).  Phase I 
transformations act to ‘functionalise’ the xenobiotic in order to prepare it for phase II 
reactions, where the compound is conjugated to groups that will aid in its clearance from 
the organism.  Phase I transformations may add new functional groups to the compound, 
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increase the polarity of existing groups, or unmask existing but protected ones; reactions 
such as hydroxylation and hydrolysis are common.  Phase II transformations conjugate 
functional groups of the parent compound or its phase I metabolites to highly polar 
endogenous molecules such as glucuronic acid, sulphate and glutathione, which increase 
the hydrophilicity of the compound, facilitating its excretion.  An example of a metabolic 
pathway showing both phase I and phase II transformations is shown in Figure 14, below. 
 
Figure 14: One metabolic pathway of the sedative Clorazepate, from the 2008.1 
release of the Symyx® Metabolite database.  In the first two steps the compound is 
undergoing phase I transformations, resulting in the introduction of a hydroxyl group.  
The metabolite formed then undergoes a phase II transformation, conjugating to a 
glucuronic acid molecule.  The highly polar product formed will be rapidly excreted. 
Understanding how xenobiotics are metabolised is of great interest both within the 
pharmaceutical industry and the wider chemical community.  Metabolic transformations 
may reduce the bioactivity of a compound – deactivating the therapeutic properties of a 
drug, or detoxifying an environmental compound.  Alternatively they may increase a 
compound’s bioactivity, which can be exploited through the development of prodrugs, but 
this can also lead to the formation and build up of toxic metabolites.  These effects can only 
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be predicted if the biotransformations that a molecule will undergo can be understood or 
anticipated.  Additionally, prediction of likely biotransformations can help to guide 
experimental design when trying to identify a compound’s metabolites.  
Over the past decade pharmacokinetic problems, including metabolic liabilities, have been 
recognised as a major cause of failures in the development of new pharmaceuticals, 
particularly in the later stages of the drug development process where failures are most 
expensive.  It is now recognised that potential ADME and Toxicology problems should be 
addressed as early in the development cycle as possible (186,187) – ideally when selecting 
and optimising lead compounds.  At these early stages in the drug discovery process it is 
often not practical or economical to exhaustively experimentally determine the ADME 
profile of candidate compounds, so computational models are used instead, enabling the 
results of high-throughput screening programmes to be prioritized, and even the selection 
and elimination of compounds pre-synthesis. 
2.2 Effects of metabolism 
2.2.1 Toxicity, bioavailability and clearance 
In order for a drug to exhibit its desired pharmaceutical effect it must be present at a 
concentration within the drug’s therapeutic window.  At too low a concentration the drug 
will not have its desired effect, but conversely at too high a concentration the drug will likely 
exhibit adverse side-effects.  It is important that pharmaceutical compounds are removed 
from the body after their administration, in order to prevent their accumulation to toxic 
levels.  At the same time they require a certain degree of metabolic stability, in order to 
persist long enough to be able to achieve their therapeutic effect.  This is particularly true of 
orally administered compounds which have to survive the harsh conditions of the digestive 
system and first-pass metabolism in the liver, before they are able to enter the 
bloodstream. 
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Figure 15: In order to be effective (black line) a drug’s concentration must remain 
within its therapeutic window (yellow region).  The drug’s concentration rises on 
dosing, and then drops as the compound is metabolised and excreted.  If the 
compound is metabolised too slowly (red line) then repeated dosing causes its 
concentration to rise to toxic levels (red region).  On the other hand, if the compound 
is metabolised too quickly (blue line) then its concentration will fall below that 
required for the drug to be effective (below the yellow region).  Figure adapted from 
(188). 
Understanding a drug’s metabolism can enable adjustment of the compound’s 
pharmacokinetic profile through the blocking of major sites of metabolism, or addition of 
functional groups facile to metabolism.  Where a molecule has very poor bioavailability, 
caused by its rapid metabolism and clearance, this can be resolved through the 
identification of the major route of metabolic degradation, and subsequent modification of 
the compound in order to block this pathway.  A successful example of this is illustrated in 
Figure 16. 
C
o
n
ce
n
tr
at
io
n
Time
Theraputic Window
Toxic
Failure
45 
  
Figure 16: Identification of the major site of metabolism of the 5-HT2A antagonist 3-(4-
fluoropiperidin-3-yl)-2-phenyl-1H-indole (compound on left, major site of metabolism 
is highlighted), and its subsequent blocking with a fluorine atom (compound on right) 
reduced the rates of first pass metabolism and clearance, leading to the bioavailability 
in rats increasing from 18% to 80%, and the half-life from 1.4 to 12 hours (189). 
Knowledge of a drug’s metabolism is also necessary in order to determine safe dosage levels 
and warn of drug-drug interactions.  Consideration must be given to the possibility that a 
drug, which on its own is perfectly safe to take, may inhibit or induce the metabolism of 
other drugs if taken in combination.  Induction of a drug’s metabolism will lead to increased 
rates of clearance, lowering its concentration, possibly below effective levels.  Inhibition, on 
the other hand, can result in the accumulation of the drug to toxic concentrations.  The 
antihistamine Terfenadine was withdrawn for this reason (190).  
Terfenadine is metabolised in the gut wall, so usually has a very low systemic concentration.  
It was found that when Terfenadine’s rate of metabolism is decreased, through competition 
with or inhibition by other drugs, the increased concentration of Terfenadine in the blood 
stream led to a risk of cardiac arrhythmia.  Investigation of Terfenadine’s metabolites found 
that one of them – Fexofenadine (structures shown below in Figure 17) – was in fact the 
major active compound, while not exhibiting the adverse effects.  Fexofenadine is now 
prescribed in place of Terfenadine, as a safe alternative (191). 
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Figure 17: The antihistamine Terfenadine (left) has been withdrawn from sale due to 
safety considerations.  Fexofenadine (right), one of Terfenadine’s metabolites (the 
product of oxidation of a methyl group to carboxylic acid) was found to be the active 
compound and is now prescribed in place of Terfenadine. 
2.2.2 Toxic metabolites 
The most serious effect of xenobiotic metabolism is the formation of toxic metabolites.  The 
most frequent reason for the withdrawal from market of an approved drug is drug-induced 
liver injury (192) and this is often found to be due to a metabolite, rather than the 
xenobiotic compound itself (193).  If potential metabolites can be predicted, then these 
predictions can be linked with computer systems for the prediction of toxicity, of which a 
number are commercially available such as Derek (36) and TOPKAT (37,194), enabling in 
silico screens for such liabilities to be carried out (195,196). 
There are various biological pathways through which metabolites can generate adverse drug 
reactions.  Metabolites may exhibit pharmacological activity, which can be towards the 
same target as the parent drug, increasing the effects to those that would occur if the drug 
was administered at much higher concentrations, or may be off-target, affecting other 
systems in unintended ways.  A further possibility is the formation of reactive metabolites 
which bind to other proteins and enzymes, or damage DNA.  One mechanism through which 
this occurs is via the formation of reactive oxygen species, such as peroxides, oxides and 
oxygen radicals.  Despite the body’s mechanisms to deal with such toxins, these can lead to 
serious cell damage. 
Not all toxicity is due to compounds’ reactivity and activity. ‘Non-specific’ toxicology is the 
result of a general disruption of cell membranes and biochemical processes by a xenobiotic 
(197).  As drug development extends into new areas of medication, particularly the use of 
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biological agents as pharmaceuticals, there is the possibility of other types of toxicity.  
Monoclonal antibody therapies carry a risk of over-stimulating the immune system, with 
serious consequences, as was recently the case in the widely reported adverse reactions 
during the ‘first-in-man’ trials of TeGenero’s rheumatoid arthritis and leukaemia drug 
TBN1412 (198). 
2.2.3 Prodrugs 
The traditional approach to overcoming barriers to a drug’s bioavailability has been to 
search for analogues of the drug – i.e. an alternative compound that delivers similar activity, 
but providing different pharmacokinetic properties.  An alternative approach is the use of a 
prodrug (199,200), where chemical modification of a drug molecule, or the attachment of 
an extra moiety, renders the molecule inactive but allows it to overcome the barrier to 
bioavailability – conceptually similar to the use of a protecting group during an organic 
synthesis.  Once the prodrug is absorbed, the moiety is removed by the organism’s 
metabolic pathways, restoring the drug molecule to its active form.  Recently there has been 
a growing trend in the development of prodrugs; approximately 15% of the new drugs 
approved in 2001 and 2002 were prodrugs, and they are now thought to comprise from 5-
7% of the total drugs approved worldwide (201). 
 
Figure 18: Illustration of the concept of prodrugs; in situations where a drug molecule 
cannot pass some barrier to bioavailability (a) there are two possible solutions; an 
analogue (b) may be found – that is an alternative compound exhibiting the required 
activity, but with different properties, or a prodrug (c) may be developed. 
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The prodrug approach can be used to overcome a number of barriers to bioavalability.  The 
well known influenza drug Tamiflu (Oseltamivir ethylester) is in fact an ester prodrug of the 
active compound Oseltamivir carboxylate (see Figure 19).  The modified compound is orally 
bioavailable and overcomes the poor intestinal mucosal permeability of the active drug 
(202).  
 
Figure 19: Oseltamivir carboxylate (left) an antiviral, and (right) its prodrug Tamiflu 
(Oseltamivir ethylester), which was designed to improve intestinal mucosal 
permeability.  
The same prodrug approach can be undertaken for many other purposes (203), including 
improving solubility, aiding in the targeting of an active compound to a particular organ in 
the body and controlling drugs’ rates of release. 
2.2.4 CYP450 mediated drug-drug interactions 
A common cause of adverse drug reactions has been found to be the modulation of one 
drug’s metabolism by another.  Inhibition of a drug’s metabolic pathway by a co-
administered pharmaceutical may lead to the drug accumulating to toxic levels, as in the 
case of Terfenadine, mentioned previously.  Similar problems can arise when grapefruit 
juice or, to a lesser extent, red wine are consumed in combination with certain 
pharmaceuticals, since these contain flavonoids and other compounds which inhibit 
cytochrome P450 3A4 (204).  Competition between drugs metabolised by the same enzyme 
can also reduce their rates of clearance.  Alternatively, one xenobiotic can increase the rate 
of clearance of another, by induction of the enzymes in its metabolic pathway.  This can lead 
to the drug’s concentration falling below therapeutic levels, as can occur during co-
administration of oral contraceptives with St John’s Wort (188). 
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2.2.5 Metabolite elucidation 
Studies into the metabolic fate of drug compounds are performed at several stages in the 
drug development process.  During lead optimization, knowledge of the propensity of a drug 
candidate to undergo metabolic transformation can help identify candidate molecules with 
undesirable ADME characteristics and thus guide the selection of which compounds to 
commit substantial resources for further development (205).  As development of the drug 
candidate proceeds any metabolites are investigated for signs of toxicity, alongside the 
parent compound. 
A range of experimental techniques are employed for the investigation of a compound’s 
metabolites, but structural elucidation without additional data on the metabolites likely to 
be formed is challenging.  In silico systems can suggest metabolites unexpected or 
overlooked by human experts (206).  Liver microsomal preparations, plasma and excreta 
from in vivo studies and extracts obtained from necropsy can all be examined for the 
presence of metabolites.  Covalent protein binding assays are carried out to test for 
potential liver toxicity.  High resolution liquid chromatography-mass spectrometry (LC-MS) is 
used to determine accurate masses of ions, which can be used to calculate the elemental 
composition of compounds.  LC-MS reveals which fragment of a compound has undergone 
metabolism, but there can be several atoms within that fragment at which the metabolic 
transformation could be centred, and tools for predicting sites of metabolism can help 
resolve this ambiguity. 
A further challenge is the identification of which components of complex biological mixtures 
are in fact metabolites of the compound under investigation.  Labelling of the parent 
compound with radioisotopes such as tritium can facilitate this.  However, radiolabelling 
experiments require the time-consuming and expensive synthesis of a labelled compound, 
and when this is not possible, prediction of potential metabolites is necessary. 
Of particular difficulty is the experimental detection of reactive metabolites.  Stable drug 
metabolites can be isolated, purified and identified using standard experimental techniques; 
however reactive metabolites are generally too short-lived for the same to apply.  This is an 
area where in silico predictions of the structure of metabolites can be particularly useful. 
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2.3 Mechanisms of metabolism 
Orally delivered drugs are first subjected to metabolism in the gastrointestinal tract.  From 
here the parent compound and any metabolites formed are absorbed through the mucous 
membrane of the small intestine or through the wall of the stomach, and carried to the liver 
where they encounter further metabolic enzymes.  Finally the remaining drug and its 
metabolites enter systemic circulation.  Metabolism occurring before the drug has first 
entered systemic circulation is termed ‘first-pass metabolism’, and in some instances can 
reduce the bioavailability of a drug to such a degree that alternative routes of 
administration are required.  As a protein, insulin, administered to Type I diabetics, is 
catabolised in the gastrointestinal tract so must be administered through subcutaneous 
injections in order to reach circulation without degradation.  The corticosteroid 
beclometasone dipropionate, until recently administered to asthmatics, does not enter the 
blood stream in detectable levels when taken orally due to its high rate of clearance through 
first-pass metabolism (207), so is instead administered as a nasal spray (Beconase) or 
through an inhaler (Becotide). 
 
Figure 20: First pass metabolism: drugs encounter metabolising enzymes in the 
gastrointestinal tract and the liver, before entering systemic circulation.  This can 
considerably decrease the bioavailability of the drug. 
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There are a wide variety of pathways and mechanisms through which xenobiotic 
compounds are metabolised (184).  Many compounds can be metabolised through a 
number of competing pathways, leading to the generation of a variety of metabolites, in 
differing concentrations.  The degree of formation of each metabolite depends on a number 
of factors, such as the availability of enzymes and cofactors, and competition with other 
xenobiotics.  This means that the metabolic profile of a drug varies with both environment 
and genetics.  A drug’s metabolism can differ between species, between individuals of the 
same species but different gender and age, and even within one individual at different 
instances in time. 
The pathways through which Phase I metabolism occurs are generally divided into those 
involving cytochromes P450 (CYP450), and those which do not.  Cytochromes P450 are a 
large family of enzymes, involved in the majority of drug metabolisms.  A study carried out 
by Pfizer examining the top 200 drugs prescribed in the United States in 2002 found that 
cytochromes P450 where involved in two-thirds of the metabolic clearance pathways (208).  
The human genome project has identified 57 CYP450 genes (209), which give rise to a 
variety of different CYP450 enzymes, known as isoforms.  Each isoform can bind to a 
number of substrates.  Some are very promiscuous, metabolising a wide variety of 
molecules. 
Cytochromes P450 can catalyse a range of reactions, some examples of which are illustrated 
in Figure 21, below.  The most common cytochrome P450 catalysed transformation is 
monooxygenase hydroxylation, inserting a single oxygen atom into an R-H bond, producing 
R-OH (210).  This can be the final product of the transformation, or may lead to a 
dealkylation, as in the case of the oxidative deamination reaction shown below.  
Cytochromes P450 can also oxidise hetroatoms, such as nitrogen, and form epoxides of 
alkenes (209). 
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C-Hydroxylation 
 
 
Oxidative deamination 
 
 
Heteroatom oxidation 
 
 
Epoxidation and oxidative migration 
Figure 21: Commonly observed CYP450 mediated metabolic transformations. 
The active site of cytochromes P450 contains a heme group (Figure 22).  The catalytic cycle 
of CYP450 metabolism involves the binding of an oxygen molecule to the iron atom at the 
centre of the heme group.  Reduction of the oxygen molecule, with the release of water, 
and a single electron transfer lead to the formation of an oxygen radical.  This radical can 
react with the enzyme’s substrate in a number of ways, leading to a variety of potential 
products.  An overview of the catalytic cycle and more detailed mechanisms for a number of 
transformations are shown in Figure 23 and Figure 24. 
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Figure 22: The heme group at the catalytic site of cytochrome P450 2C8; PDB ID: 2VN0 
(211). 
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Epoxidation 
 
Heteroatom release (e.g. oxidative deamination) 
 
 
 
Figure 23: Mechanisms of some cytochrome P450 catalysed transformations (212). 
55 
 
Figure 24: The basic catalytic cycle of CYP450 oxidation (209).  First (top right), the 
substrate (RH in the figure above) binds close to the heme group in the CYP450 active 
site, displacing water.  Oxygen binds to the heme group, and is activated by a single 
electron-transfer, resulting in the generation of a highly reactive Fe(V) oxo species.  
This reacts with the substrate, inserting an oxygen atom into the R-H bond, leading to 
the addition of a hydroxyl group. 
The regioselectivity of CYP450 catalysed transformations – the atom or atoms where the 
reaction occurs – is determined by a number of factors: the energy required to remove a 
hydrogen atom from the substrate (hydrogen abstraction energy) and the stability of the 
resulting carbon radical, and also the structure and shape of the binding pocket of the 
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specific CYP450 variant catalysing the transformation.  Each CYP450 isoform has a different 
sized and shaped binding pocket, which exhibits a different binding motif, favouring affinity 
to substrates displaying particular structural features. 
While cytochromes P450 catalyse many metabolic transformations, a number of other 
enzymes are also involved in phase I metabolism (213).  A number of enzymes facilitate 
oxidation reactions; Flavin-Containing Monooxygenase (FMO), Monoamine Oxidase (MAO) 
and Aldehyde Oxidase are among those commonly found.  Although less common than 
oxidations, reductions often occur in metabolic pathways, and are catalysed by a number of 
enzymes including the cytochromes P450.  Epoxide Hydrolases, Esterases and Amidases 
catalyse the hydrolysis of epoxides, esters and amides, respectively. 
Phase II transformations are also catalysed by a number of different enzymes.  Common 
phase II conjugates are glucuronic acid, glutathione and sulphate, though conjugation to 
many other molecules, including macromolecules such as proteins, DNA and RNA is also 
possible. 
2.4 Predicting xenobiotic metabolism 
Due to the interest in understanding the metabolism of xenobiotics, a considerable amount 
of effort has been put into the development of predictive tools.  There are a number of 
different goals when predicting xenobiotic metabolism: identifying sites of metabolism, 
predicting the metabolites formed, predicting rates of metabolism and metabolite 
formation, and predicting the cytochrome P450 specificity of substrates.  As might be 
expected, with a range of aims, a number of diverse approaches have been developed, with 
different techniques better suited to certain types of prediction. 
The enzymes involved in xenobiotic metabolism are fairly nonspecific towards their 
substrates.  If this were not the case then a vast array of different metabolic enzymes would 
be needed by an organism.  The upshot of this is that enzyme specificity has less effect on 
the enzyme activity than is the case in many other receptor mediated systems, so ligand-
based tools are often found to perform well.  Since cytochrome P450 mediated oxidation is 
the most common route for xenobiotic metabolism many tools consider only this system. 
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2.4.1 Site of metabolism prediction 
The atoms of a xenobiotic at which metabolic transformations are centred are termed its 
‘sites of metabolism’.  Identification of the likely sites of metabolism of a drug enables 
medicinal chemists to design modifications to the drug’s molecular structure in order to 
prevent its metabolism at that site.  Blocking the major sites of metabolism of a drug can 
reduce the rate of first-pass metabolism, allowing it to enter systemic circulation at high 
enough concentrations to exhibit a therapeutic effect and can reduce the clearance rate of 
the drug, extending the time required between doses. 
As trans-membrane proteins, it is difficult to produce crystal structures of mammalian 
cytochromes P450.  Indeed it is only in the last decade that X-ray structures for CYP450s 
from humans and other mammals have been published (214,215,216).  Prior to this, 
mammalian CYP450 structures could only be approximated through homology modelling 
based on crystal structures of soluble bacterial CYP450s e.g. (217). 
Quantum mechanical methods/reactivity calculations 
The mechanism of many cytochrome P450 catalysed biotransformations include a hydrogen 
abstraction step, where the heme-bound oxygen radical of the CYP450 active site removes a 
hydrogen atom from the substrate, creating a carbon radical.  It is believed that this is the 
rate determining step of the transformation (218), and that the likely sites of metabolism 
can be predicted from the ease with which hydrogen abstraction can take place at each 
atom of the substrate.  
Calculations using the AM1 semi-empirical quantum mechanical method have been 
performed on a number of radicals formed by hydrogen abstraction, and their parent drug 
compounds (219,220).  In most cases the calculated radical stabilities showed good 
agreement with experimental bond dissociation energies.  However, such quantum 
mechanical calculations are time-consuming, even if only a single energy minimized 
conformation of the drug molecule and each of the hydrogen abstracted radicals is 
considered. 
Olsen et al. (221) have investigated the hydrogen abstraction energies of 24 substrates in a 
model CYP450 system using state of the art Density Functional Theory (DFT) calculations.  
They have also used this approach to study specific classes of transformations in detail: 
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aromatic oxidations (222) and sulphoxide, sulphur and nitrogen oxidation and dealkylation 
(223), and the structure of the CYP450 heme complex (224).  These calculations can require 
days or weeks of CPU time for molecules the size of a typical drug, making them unsuitable 
as a tool for regular screening.  However, these results have been used to establish a 
hierarchy of methods, from visual inspection of functional groups through semi-empirical 
calculations to DFT, which can be selected depending on the accuracy required and the 
complexity of the molecule under consideration.  A rule-based method, derived from the 
high-level DFT calculations, estimates activation energies at different sites in a molecule 
relatively well (225), but with currently only eleven rules, this approach is not able to 
provide any discrimination between similar sites. 
In a recent comparison of site of metabolism prediction tools (218) Afzelius et al. explored 
the possibility that the CYP450 catalysed biotransformations proceed via an alternative 
mechanism.  It has been proposed that a single electron could be transferred from the 
substrate to the heme of the CYP450, creating a positively charged radical that reacts with 
either the heme/iron/oxygen complex or a neighbouring water molecule.  According to this 
mechanism metabolism will be centred on the location of the spin ‘hole’ on the radical 
substrate, and the spin distribution can be estimated through quantum mechanical 
calculation. 
Pharmacophores 
Some cytochrome P450 families have been found to exhibit a pharmacophore that 
determines the orientation of the substrate in the active site (226).  Through alignment of 
substrate molecules with this pharmacophore it can be predicted which atoms will be 
positioned near the heme group in the active site, and hence undergo metabolic 
transformation.  
Docking methods 
Various docking methods have been used to predict sites of CYP450 mediated oxidation.  
Afzelius et al. (218) made predictions using the Dock (227) and Glide (124) programmes 
(techniques they termed MetaDock and MetaGlide, respectively).  Vasanthanathan et al. 
(228) have predicted sites of metabolism for cytochrome P450 1A2 ligands using GOLD 
(121). 
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These methods have all taken a common approach.  The docking algorithms generate an 
ensemble of docked poses with varying substrate conformations and orientations.  These 
poses are filtered, identifying any in which atoms are sufficiently close to the heme reactive 
centre for metabolism to be possible.  The atoms are then scored on the basis of their 
distance from the catalytic site, and the energy of the binding pose or other scoring function 
of the docking algorithm. 
Although only a small number of CYP450 isoforms have had their structures solved by X-ray 
crystallography, structures for some additional isoforms can be obtained through homology 
modelling, due to their degree of sequence similarity to solved structures, and these can be 
used for docking purposes (229). 
QSAR 
In an attempt to make faster predictions, a number of QSARs for metabolism prediction 
have been developed.  Because even semi-empirical calculations take a considerable length 
of time, Singh et al. (230) have used the results of AM1 calculations on 50 known CYP450-
3A4 substrates to generate a PLS QSAR model for the hydrogen abstraction energy.  This 
enables fast estimates of the hydrogen abstraction energy, based on the local chemical 
environment of the hydrogen atom.  They also added a sterically accessible solvent surface 
area requirement for substrate binding to the active site.  While this model showed some 
predictivity, they found that it was “unable to predict the major site of metabolism in an 
appreciable number of cases”, and showed some systematic errors, notably the calculated 
dehydrogenation energy always suggesting that the piperidine ring carbons adjacent to 
nitrogen of N-methylpiperidines is the likely site of metabolism while CYP3A4 has almost 
always been observed to oxidise the methyl groups (231). 
Besides predicting sites of metabolism, QSARs have also been developed to predict other 
aspects, such as rates of clearance (232). 
Enzyme/substrate interactions 
With the availability of structures of cytochromes P450, various techniques of predicting 
metabolism by examination of enzyme/substrate interactions have been developed.  Both 
Molecular Interaction Field (MIF) (80) and Receptor Interaction Surface (RIS) methods have 
been investigated.  In the MIF approach, a probe is positioned at regular intervals in a box 
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surrounding the active site and its interactions with the protein are calculated.  In the RIS 
approach, rather than being positioned at grid points throughout the space containing the 
receptor, the probe is placed at regular points across the receptor’s surface. 
MetaSite 
MetaSite bases its predictions on Molecular Interaction Field analysis.  MIFs (80) are pre-
calculated for the enzyme active site using the GRID force field and four types of probe – 
hydrophobic, hydrogen-bond acceptor, hydrogen-bond donor and charged.  The distance of 
each probe position from the catalytic site – the oxygen bound to the heme group – is 
calculated, and the distribution stored (233).  Each atom in a potential substrate molecule is 
assigned to one or more of the probe classes and an ensemble of conformers are generated 
and minimized.  The distance distribution of probe types is calculated around each atom, 
and the complementarity between the active site and each atom determined.  This provides 
a score for the fit of the substrate into the active site, with that atom at the catalytic site. 
A reactivity score can optionally be used to weight the results of the interaction calculations.  
This is based on ab initio calculations of the hydrogen abstraction energy, but rather than 
computing this for each substrate compound, abstraction energies for small fragments, 
common to many drug-like molecules, have been pre-computed, and reactivity scores are 
generated by matching the most relevant fragment.  Zhou et al. (234) reported that the 
inclusion of the reactivity weighting increased the accuracy of the predictions considerably: 
from an average of 30% to 60% that the highest ranked atom was a site of metabolism, and 
from 40% to 70% that one or more of the three highest ranked atoms was a site of 
metabolism. 
Data mining 
Boyer and Zamora (33) proposed a method of data-mining to the prediction of sites of 
xenobiotic metabolism.  The Symyx® Metabolite database (at the time, the MDL Metabolite 
database) is widely used by chemists investigating whether a substructure is involved in any 
sorts of metabolic transformation.  Boyer and Zamora generated small atom-centred 
fragments including the neighbouring 3-4 atoms and ring systems, and searched for 
transformations involving these fragments within the Metabolite database.  Counting the 
number of occurrences of these transformations within the Metabolite database, along with 
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the total number of occurrences of the substrate fragment within the database, allows the 
calculation of an occurrence ratio, giving a probabilistic score for the likelihood of the 
transformation taking place.  Boyer et al. (235) automated this process through the 
generation of fragments centred on each atom in a compound under consideration using 
circular atom environment fingerprints (60). 
2.4.2 Metabolite prediction 
A number of tools for the purpose of predicting the metabolites formed, rather than just the 
sites of metabolism of molecules, have been published.  A number of these are now 
described; all follow a fairly similar approach, describing potential transformations using 
rules, and searching a molecule for sites where each rule matches. 
META 
META (236,237,238) has two dictionaries of transformations – one of CYP450 
transformations and a second of spontaneous transformations.  Each transformation 
consists of a target fragment and a product fragment.  A prediction is made by identifying 
any occurrences of the target fragments in an input molecule, and substituting them with 
the corresponding product fragment.  An example CYP450 fragment pair would be “replace 
occurrences of ‘N-CH2’ with ‘N-CH-OH’” – meaning hydroxylate aliphatic carbons α to a 
nitrogen atom.  Each CYP450 product is then processed with the spontaneous reaction 
transformations, until no further target fragment matches are found.  In cases where 
tautomers are formed, a quantum mechanical calculation is performed to identify which is 
the most stable tautomeric form. 
Experts have assigned each transform a priority value, according to the prevalence of the 
observed metabolites.  This is based on a combination of data from “any mammalian 
source”, so the model represents an ”average mammal” (237).  If the rules were not 
prioritized then a combinatorial explosion of metabolites could be generated.  As the 
number of transformation rules increased, accurately deciding on this prioritization was 
found to be challenging, and a genetic algorithm was utilised to optimise the priorities. 
As of 2002, META contained over 750 transformation rules, developed from 
pharmacological data on around 150 xenobiotics.  This included 43 transformation rules for 
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CYP450 aliphatic hydroxylation, 28 transformations modelling dealkylation of aliphatic and 
aromatic ethers and 30 dehalogenations (237). 
Meteor 
Meteor (239,240), developed by Lhasa ltd., operates on a similar principle to META.  
Meteor’s prediction engine contains two sets of rules.  In order to predict a compound’s 
metabolites, Meteor first applies a set of biotransformation rules, encoded by human 
experts, describing possible transformations, and the features of a molecule required to 
make that transformation permissible.  Meteor allows the expression of sophisticated 
biotransformation rules, or ‘biophores’, such as “a single or double bond in a five- or six- 
membered ring, but not fused to another ring”, rather than simply encoding functional 
groups. 
Where many competing transformations could apply to a molecule, a system of reasoning 
rules (such as “benzylic oxidation is more likely than ring oxidation”) is applied in order to 
determine the most likely transformations.  The reasoning rules were developed through 
computational analysis of experimental data, in order to determine priority of the different 
biotransformation rules.  As of 2002, Meteor contained 217 biotransformations, together 
with 841 reasoning rules (240) and by 2005 the knowledgebase had grown to more than 300 
biotransformations and over 1000 reasoning rules (241). 
Once potential metabolites have been identified, Meteor assigns likelihoods to each, using 
rules associated with each biotransformation, depending on the logP value of the substrate 
molecule.  In order for a biotransformation to take place a substrate must have a logP value 
that allows it to enter and leave lipid membranes, and enough hydrophobic regions to 
facilitate enzyme binding. 
Sygma 
Another rule-based tool for the prediction of metabolites is Sygma (242) (Systematic 
Generation of potential Metabolites), developed and used in-house at Organon (now 
Schering-Plough).  Sygma’s rule-base was developed through the refinement of an initial set 
of very broad rules, such as ‘oxidation of primary alcohol’ and ‘O-glucuronidation’.  These 
rules were refined through a series of iterations, in each step of which more general rules 
were split on the basis of their performance; for example the general rule for the oxidation 
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of primary alcohols was divided into two separate rules for aliphatic and aromatic primary 
alcohols.  Rather than the small number of likelihood classes employed by Meteor, Sygma 
assigns more finely grained likelihoods to its predictions.  Associated with each rule is an 
empirical probability score calculated from the performance of that rule against a set of 
6187 known metabolic reactions in humans. 
MetaDrug 
A further rule-based tool for predicting metabolism is GeneCo’s MetaDrug (243).  Rules 
describing 65 metabolic pathways were developed.  QSAR models were constructed (for the 
23 reactions with sufficient data) through kernel-partial least squares (K-PLS) analysis of 317 
molecules randomly extracted from the MetaDrug database (244), and these are utilised to 
filter and prioritize the generated metabolites. 
Microbial catabolism 
A rule-based approach, very similar to that of Meteor, has been applied by Hou et al. (245) 
to the prediction of the biodegradation of chemicals in the environment by microbes.  Over 
1000 curated biotransformations from almost 200 metabolic pathways recorded in the 
University of Minnesota Biocatalysis/Biodegradation Database (UM-BBD) (246,247) have 
been used for the construction of a set of biotransformation rules.  These rules, compiled by 
biotransformation experts analysing the UM-BBD, each consist of a SMARTS pattern 
matching a functional group, and the biotransformation which that group undergoes (e.g. 
aldehyde to carboxylic acid). 
With around 200 rules, there are many possible transformations that could be applied to 
most molecules, leading to a combinatorial explosion in the number of predicted products.  
This leads to a high rate of false positives – predicted transformations that are not observed 
in nature.  In order to overcome this, each of the rules is assigned to a likelihood group (very 
likely, likely, neutral, unlikely, very unlikely).  A system of relative reasoning rules was also 
developed through analysis of all pair-wise occurrences of rule hits within the training data, 
and whether compounds triggered one or both of the rules (248).  Together these are used 
to prioritize and filter rule hits. 
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2.5 Conclusion 
In this chapter we have reviewed the importance of understanding the metabolism of 
xenobiotic compounds.  Metabolic transformations affect a drug’s efficacy and toxicology, 
so it is vital that any metabolic liabilities are identified.  If metabolic transformations can be 
anticipated then modifications can be made to overcome any liabilities, and the body’s 
metabolic systems can even be exploited, with the development of prodrugs. 
A wide variety of methods have been employed for the prediction of xenobiotic 
metabolism, though many focus only on cytochrome P450 catalysed transformations, 
ignoring other mechanisms.  Of the methods described, only a small number are publically 
available and straightforward for a chemist to use.  Some are in-house tools, only accessible 
to workers in the company that developed to tool.  Others, particularly the docking and 
quantum mechanical approaches, require complex calculations to be performed, and 
analysis of the results is complex, and these are typically only useable by experts.  Of the 
tools that are generally available, most are commercial offerings. 
The remainder of this thesis describes the development and evaluation of MetaPrint2D, a 
new tool for predicting sites of xenobiotic metabolism, and its extension to the prediction of 
types of transformation and metabolites likely to be formed. 
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3. Development of MetaPrint2D: a tool for 
predicting sites of xenobiotic metabolism 
This chapter describes the development of MetaPrint2D – a tool for predicting sites of 
xenobiotic metabolism, based on the previously published Substrate/Product Occurrence 
Ratio Calculator (SPORCalc) (33,235).  The initial goal of this work was to perform a more 
extensive evaluation of the SPORCalc program than had previously been carried out, and to 
remove the non-free dependencies (OEChem (249) and CORINA (85)), making the tool more 
readily distributable. 
As work progressed, it became apparent that being based on fingerprint similarity 
techniques, which generally offer very high performance, the SPORCalc method had the 
potential to form the basis of a site of metabolism prediction tool that was fast enough for a 
chemist to work with it in an interactive manner.  Unfortunately limitations in the SPORCalc 
software’s architecture meant that this performance could not be realised, so the decision 
was taken to develop a new tool – MetaPrint2D.  Additionally, a number of modifications to 
the method have been developed that could potentially improve accuracy, and the effects 
of these have been investigated. 
In this chapter the SPORCalc approach to metabolic site prediction is reviewed, and the 
available data on metabolic transformations from the Symyx® Metabolite (250) database 
examined.  The development of MetaPrint2D and the software distribution available are 
then described. 
The next chapter presents the method and results of the evaluation of MetaPrint2D, and 
Chapter 5 describes the extension of MetaPrint2D to the prediction of types of 
transformation and metabolites formed.  
3.1 Substrate/Product Occurrence Ratio Calculator 
As was briefly discussed in the previous chapter, the Substrate/Product Occurrence Ratio 
Calculator (SPORCalc) is a data-mining tool, designed to exploit the biotransformation data 
recorded in the Symyx® Metabolite database, in order to generate structure-metabolism 
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relationships.  SPORCalc introduced the use of knowledge-based statistical modelling to site 
of metabolism prediction.  An overview of the SPORCalc procedure is given in Figure 25. 
 
Figure 25: Overview of the SPORCalc procedure for site of metabolism prediction. 
SPORCalc contains two databases of atom fingerprints: one listing the fingerprints of all the 
substrate atoms found in transformations contained in the Symyx® Metabolite database 
(the Metabolite database is described in more detail on page 75), and a second listing the 
fingerprints of only those atoms occurring at a reaction centre (site of metabolism).  In order 
to investigate the sites of metabolism of a novel compound, SPORCalc generates 
fingerprints describing each of the atoms, and performs a similarity search against these two 
databases.  This enables calculation of occurrence ratios – the ratio between the number of 
reaction centre atoms in the Symyx® Metabolite database that occupy a similar chemical 
environment to each atom in the query structure, and the total number of occurrences of 
atoms in a similar chemical environment in the entire database. 
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While the SPORCalc program was envisaged as a data mining tool, its output is effectively a 
prediction of the likely sites of metabolism of a molecule, since the calculated occurrence 
ratio is equivalent to the calculation of a conditional probability: 
𝑃 𝑆 𝐸 =
𝑃 𝑆 ∩ 𝐸 
𝑃 𝐸 
 
=
𝑁 𝑆 ∩ 𝐸 𝑁𝑡𝑜𝑡 
𝑁 𝐸 𝑁𝑡𝑜𝑡 
 
=
𝑁 𝑆 ∩ 𝐸 
𝑁 𝐸 
 
= SPORCalc 𝑂𝑐𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒 𝑅𝑎𝑡𝑖𝑜 
where: 
𝑃(𝑆|𝐸) is the conditional probability that an atom is a site of metabolism, 
given the environment it occupies. 
𝑃 𝑆 ∩ 𝐸  is the probability that an atom is a site of metabolism and occupies 
the specified environment. 
𝑃 𝐸  is the probability that an atom occupies the specified environment. 
𝑁(… ) is the count of the number of atoms meeting the specified condition. 
𝑁𝑡𝑜𝑡  is the total number of atoms in the database. 
Once calculated, the occurrence ratios are normalised, so that the highest scoring atom 
always has a score of one.  This normalized occurrence ratio indicates the relative likelihood 
of each atomic site in a molecule being a centre of metabolism, while making no prediction 
as to the absolute likelihood of the molecule undergoing metabolic transformation. 
Apart from the normalization step, this is a similar calculation to that performed by a Naïve 
Bayesian classifier.  The major difference is that a Bayesian classification would consider 
both the likelihood that an atom is at a site of metabolism, given its environment, and the 
likelihood that it is not.  A Bayesian classifier would usually report the likelihood ratio (LR): 
𝐿𝑅 =  
𝑃(𝑆|𝐸)
𝑃(! 𝑆|𝐸)
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Where a likelihood ratio greater than 1.0 would indicate that, given its environment, it is 
more likely that the atom is at a site of metabolism than it is not, and a likelihood ratio of 
less than 1.0 would indicate the opposite. 
SPORCalc represents the chemical environments occupied by atoms using circular atom 
environments fingerprints (described on page 15, in Chapter 1) with Tripos’ SYBYL® (46) 
atom types (251).  Fingerprints of depth six – the central atom, and topological neighbours 
up to five bonds distant – are generated.  Each layer of the fingerprint contains 33 bins, one 
for each SYBYL® atom type.  Each bin holds a count of the number of occurrences of the 
respective atom type in that layer.  This leads to fingerprints with a total of 198 bins. 
 
 
Layer C.3 C.2 C.ar N.3 N.2 N.am O.3 O.2 O.co2  
0 0 0 1 0 0 0 0 0 0  
1 0 1 2 0 0 0 0 0 0  
2 0 0 2 0 0 0 1 1 0  
           
 
Figure 26: Illustration of the region of a structure forming an atom environment 
fingerprint (first three levels highlighted), and the contents of a subset of fingerprint’s 
bins. 
The SPORCalc package* consists of two separate programs: the database builder, which 
constructs the fingerprint databases with which SPORCalc performs its calculations, and the 
calculator which accepts a query molecule, input through a web interface, and generates a 
web page displaying the predicted sites of metabolism of the molecule. 
                                                     
* We gratefully acknowledge Lars Carlsson and AstraZeneca for sharing with us the latest version of 
SPORCalc. 
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3.1.1 SPORCalc databases 
A SPORCalc model requires two databases of atom fingerprints; one containing the 
fingerprints of all the reaction centre atoms in the training data, and a second containing 
the fingerprints of all the atoms in the training data.  The fingerprints are stored in text files, 
as a space separated list of integers – with one value for the occupancy of each of the 198 
bins making up the six-level fingerprint.  The reaction centre fingerprints are stored in a 
single file.  Due to their greater number, the substrate fingerprints are split into separate 
files, one for each type of central atom. 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 1 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 …   
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0  0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 … 
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 … 
0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 1 0 … 
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 … 
0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  2 0 0 0 0 0 0 0 1 0 … 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0  … 
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0  0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 … 
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 … 
0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 1  0 … 
Figure 27: A section of a SPORCalc reaction centre fingerprint file. 
3.1.2 Site of metabolism calculator 
The site of metabolism calculator is written mostly in Python, with a C++ program used to 
carry out the computationally expensive fingerprint similarity searching.  The Python code is 
designed to run as CGI scripts on a web server.  C++ was used in place of Python for the 
fingerprint searching since being a compiled rather than an interpreted language it is often 
much faster. 
The workflow of the SPORCalc calculator is shown in Figure 28, below.  The calculator takes 
an input molecule, using the SMILES (252) representation, and runs the CORINA (85) 
program to generate a PDB file containing a 3D structure of the molecule.  This step acts to 
check that a valid SMILES has been specified.  The calculator then uses the OEChem (249) 
library to load the SMILES, remove any hydrogen atoms, since they are not used in the 
calculation, and generate the tree-structure of the fingerprints.  The molecule, with 
hydrogen atoms removed, is written to an MDL molfile, and OpenBabel (253) is used to 
convert this to a MOL2 file, from which the atom type assignments are read.  CORINA is run 
again to generate a PDB file of the structure without hydrogen atoms, which is used to 
display the results.  The fingerprints, the selected database and parameters for the 
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calculation are passed to the calculator C++ program.  This generates normalized occurrence 
ratios for the atoms, by iterating through the database files, reading each line in turn and 
comparing it to each atom’s fingerprint.  If the distance between the fingerprints is small 
enough, then the occurrence of the environment is counted towards the atom’s reaction 
centre or overall occurrence counts, depending on the database file that is being read at the 
time.  Once the normalized occurrence ratio calculations are complete, their results are 
used to generate a RASMOL script that colours and labels the atoms in the results display. 
 
Figure 28: Overview of the SPORCalc calculator’s workflow. 
3.1.3 Database builder 
Generation of a SPORCalc database requires several hours’ computation, so the databases 
are pre-built, ready for use by the calculator.  The SPORCalc database builder is also a 
python script which depends on the OEChem library.  The database builder takes as its input 
a directory containing a collection of MDL rxnfiles, numbered sequentially 1,2,3,...  The 
script reads each file in turn, identifies the reaction centres, and generates fingerprints for 
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each of the atoms in the same manner as the calculator program.  The fingerprints are 
written to the reaction centre and substrate data files, as appropriate.  An overview of the 
database builder’s workflow is shown in Figure 29. 
 
Figure 29: Overview of the SPORCalc database builder’s workflow. 
Reaction centre identification and classification 
Reaction centres are identified through the comparison of the substrate and metabolite 
structures, detecting added and eliminated atoms and bonds, and changes to bond order.  
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* MCS = Maximum Common Substructure
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SPORCalc  
SPORCalc uses a process of up to four stages to identify the correct mappings between the 
atoms and bonds of the substrate and metabolite structures.  In each of the first three 
stages of searching, putative mappings generated by maximum common substructure (MCS) 
searches carried out using the OEChem toolkit (249) are compared with the annotated 
mappings from the Symyx® Metabolite database.  If none of the mappings is found to match 
the database’s annotations then the search is repeated with increasingly strict matching 
criteria.  If none of the search configurations generates an MCS mapping in agreement with 
the annotations from the Metabolite database then mappings from an MCS generated using 
the intermediate strictness are utilised. 
Step Matching criteria 
1 
Atoms: atomic number 
Bonds: order (single and double can interchange) 
2 
Atoms: atomic number, charge, aromaticity 
Bonds: order, aromaticity 
3 
Atoms: atomic number, charge, hydrogen count, mass, ring membership, chirality 
Bonds: order, aromaticity, ring membership, chirality 
Table 1: The SPORCalc database builder’s MCS matching criteria. 
Once the MCS has been determined, the database builder identifies and classifies the 
reaction centres in the structure.  SPORCalc classifies reaction centre atoms as being 
involved in one or more of phase I addition (defined as the addition of a single oxygen atom 
– i.e. hydroxylation, oxidation or epoxidation), phase II addition (addition of any group other 
than a single oxygen atom), elimination, bond order change, bond broken and bond created.  
In addition, any atoms flagged as both addition and elimination reactions are also flagged as 
substitutions.  Being concerned primarily with phase I transformations, by default SPORCalc 
discarded labelling other than phase I addition and/or elimination. 
Examples of each of the classes of transformation are shown below.  Added, eliminated and 
changed portions of the structures are highlighted, as are the assigned reaction centres. 
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Addition (Phase I) 
 
(MDLNUMBER*: RMTB00049209) 
Elimination 
 
(MDLNUMBER:  RMTB00000003) 
Bond order change 
 
(MDLNUMBER: RMTB0000400) 
                                                     
* The MDLNUMBER is the record identifier from the Symyx® Metabolite database. 
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Bond made 
 
(MDLNUMBER: RMTB00021409) 
Bond broken 
 
(MDLNUMBER: RMTB00000403) 
3.2 Development of MetaPrint2D 
Early investigations of SPORCalc found that the software’s architecture would make it 
difficult to perform the large-scale evaluation that was envisioned.  The processing time of 
several minutes per compound made any evaluation quite time-consuming to perform, and 
being accessible only through a website made the process difficult to automate.  In addition, 
since the OEChem library was integral to much of SPORCalc’s processing, it would be 
difficult to substitute and evaluate alternative software approaches – one of the goals of 
this work. 
Given this, it was decided to develop MetaPrint2D, a completely new piece of software, 
based on the SPORCalc approach to site of metabolism prediction.  MetaPrint2D has been 
designed in an extensible manner, enabling it to be integrated with other software, and its 
use automated.  This has enabled the introduction of a number of optimizations and other 
improvements to be evaluated. 
Since SPORCalc had already undergone several evaluations, and was being used both within 
AstraZeneca and through a website run by the Unilever Centre for Molecular Science 
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Informatics, it was considered to be important to, so far as possible, maintain compatibility 
and ensure that a fair comparison was possible between the tools.  To this end, the initial 
development of MetaPrint2D aimed to replicate SPORCalc’s results as closely as possible.  It 
was decided that, by default, MetaPrint2D should use the same training data as SPORCalc 
(the Symyx® Metabolite database) and the same type of models. 
3.3 The Symyx® Metabolite database 
3.3.1 Overview of the Symyx® Metabolite database 
The Symyx® (formerly MDL) Metabolite database (250), provides information on the 
metabolic fate of xenobiotics, abstracted from primary literature, conference proceedings 
and New Drug Applications.  The 2008.1 release of the database contained 87446 
transformations, with around 5000 new transformations being added each year.  
Transformations are annotated with a variety of information including references to the 
literature reporting the transformation, details of the species and systems in which the 
transformation has been detected and classification of the types of reaction the 
transformation involves.  Each individual transformation does not necessarily record all of 
these details; indeed different transformations report varying subsets of this information. 
Database Version 2005.1 2006.1 2007.1 2008.1 
Transformations 72599 78009 82671 87446 
Single step 58757 62147 65732 69402 
Product not reported 811 831 834 882 
Newly added  5410 4662 4775 
Table 2: Overview of the contents of the Symyx® Metabolite database 
A transformation in the Symyx® Metabolite database consists of a single reactant 
(substrate) molecule, and a single product (metabolite).  One substrate compound may 
undergo a number of competing metabolic transformations, leading to a variety of different 
products.  Each of these is recorded in a separate record in the database.  
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Database version 2005.1 2006.1 2007.1 2008.1 
Molecules 45486 47855 50515 53247 
as substrate 22654 23934 25272 26588 
as product 37677 39569 41786 44136 
Schemes 11280 11923 12502 13052 
Table 3: Contents of the 2005.1-2008.1 Symyx® Metabolite database releases. 
Transformations are collated into metabolic schemes, with each scheme containing the 
collection of pathways originating from a distinct parent compound.  The database contains 
one record for each single step transformation (e.g. P→1A; 1A→2D; P→1J – in Figure 30 
below) and an additional record for the overall transformation achieved in each multi-step 
pathway (in addition to the records for the individual transformations such as P→1A and 
1A→2A, there will be records for overall transformations like P→2A). 
 
Figure 30: Screenshot of a metabolic scheme from the Symyx® Metabolite database in 
the ISIS/Base Metabolite Browser.  The parent compound is designated ‘P’, and the 1st 
and 2nd generation metabolites 1X and 2X, respectively.  The database contains a 
record for each transformation (designated by a reaction arrow), and an additional 
record for the overall transformation from the parent compound to each non-first 
generation product. 
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3.3.2 Consistency of the Symyx® Metabolite database 
As will be discussed in more detail later in the chapter, this work required the simultaneous 
use of several different releases of the Metabolite database.  This made it important that a 
method was identified to track molecules and transformations between database releases, 
and to ensure that the data was consistent between the different versions of the database.  
Examination of the records in different releases of the Metabolite database shows that the 
transformation indexes and scheme identifiers change between database versions; however 
there is a hidden field – MDLNUMBER, which contains a unique identification reference for 
each molecule and transformation.  This identifier should remain the same with every 
release of the Metabolite database (254).  
In order to check that the data was consistent between releases of the Metabolite database 
and the MDLNUMBER identifier preserved, as expected, InChI™ (255,256) (IUPAC 
International Chemical Identifier) canonical identifiers were generated for each molecule – 
substrate and product – for every transformation in each Metabolite database release that 
was being used.  The InChIs were recorded along with the MDLNUMBERs of the molecules 
and of the transformation.  This information was used to check whether the MDLNUMBERs 
are preserved, and whether or not they too are canonical. 
During the InChI generation process one problem was encountered: the Symyx® Metabolite 
database contains a number of entries with generic R-groups representing parts of the 
structure (e.g. covalently bound proteins or DNA), but the InChI algorithm and software do 
not currently support the concept of ‘wildcard’ atoms – the connection table of molecules 
must be completely specified, and all atoms assigned a valid chemical element.  To 
overcome this limitation, any R-groups encountered were substituted with iodine atoms, 
selected because iodine has the same valence, but is relatively rare within the Metabolite 
database (a search of the 2008.1 database found only 140 iodine containing molecules), so 
unlikely to cause a clash.  This substitution was only carried out to facilitate the generation 
of InChI canonical identifiers for the molecules, and was not applied to any other analyses. 
Consistency of molecule and reaction identifiers 
The molecule’s MDLNUMBERs were found to be consistent between the 2006.1 and 
subsequent releases of the Metabolite database – the identifier always described the same 
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structure (the corresponding InChI is consistent).  Between 2005.1 and 2006.1, however, the 
structure of a small number of molecules was changed.  Examination of the altered 
molecules suggests that the changes are the result of a remediation process – fixing 
incorrect structures and stereochemistry: 
  
  
    
  
  
Figure 31: Examples of structures changed between 2005.1 and 2006.1 database 
releases (left: 2005.1; right: 2006.1 and later).  In a few instances alterations are made 
to elements and connectivity, but in the majority of cases the only changes are the 
addition or correction of stereochemistry. 
Other than these changes through remediation, the transformations’ MDLNUMBERs are 
also consistent (always describe a transformation between molecules having the same 
79 
InChIs) between database versions.  With respect to molecule MDLNUMBERs the 
transformation identifiers are consistent throughout the remediation process too. 
Canonicity of molecule identifiers 
An analysis was also carried out to determine whether the MDLNUMBER is a canonical 
identifier of molecules – i.e. whether all occurrences of molecules with the same structure 
are assigned the same MDLNUMBER.  In order to perform this analysis the MDLNUMBERs 
associated with each InChI were determined, and any InChI having more than one 
MDLNUMBER associated was identified. 
Initially it did appear that some molecules were assigned multiple MDLNUMBERs, but on 
further investigation it was found that in the majority of cases this could be explained by the 
recording of relative versus absolute stereochemistry.  Many transformations have been 
reported by a number of sources, some of which have specified the absolute 
stereochemistry of the molecules, and others the relative stereochemistry.  The metabolite 
database records these separately.  When the input structures’ chiral flag (indicating 
whether the structure represented a specific enantiomer) was taken into consideration this 
apparent duplication of molecules was eliminated. 
The remainder of problem cases were due to ‘indeterminate metabolites’.  In a number of 
metabolic schemes the presence of intermediate metabolites whose structure are unknown 
is reported.  The Symyx® Metabolite database represents these cases as empty structures, 
so while the molecules’ structures are in fact different (but unknown), identical (empty) 
InChIs were generated by this analysis. 
Canonicity of reaction identifiers 
The canonicity of reaction identifiers was also investigated.  Each reaction was described in 
terms of the InChI of its substrate and metabolite compounds, and these were mapped 
against the MDLNUMBER of the transformation.  Analysis of this data found that while the 
reaction identifiers were consistent across the database releases investigated, they were 
not canonical.  Some transformations from the same substrate to metabolite molecules are 
recorded multiple times in the Symyx® Metabolite database.  This is due to reaction 
schemes centred on different parent compounds converging on a common intermediate 
metabolite, and from that point on following identical reaction pathways. 
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3.3.3 Data formats 
The RDfile format 
The entire Symyx® Metabolite database can be exported as an RDfile.  The RDfile format is 
one of a family of related formats, known as CTfile (chemical table file) formats (257,258), 
developed at MDL Information Systems.  The first CTfile format is the molfile, which is used 
to specify the structure of a single molecule, and consists of a Header block and a Ctab block 
– providing a connection-table description of the molecule.  Related to molfiles are rxnfiles, 
which specify reactions and consist of a RXN Header block, together with a number of 
embedded molfiles – one for each reactant and product molecule.  The structures of one or 
more molecules, together with associated data and properties for each molecule, can be 
stored in an SDfile (structure-data file), which is again made up of a number of embedded 
molfiles, but also includes name-value data entries for each molecule.  Similarly, RDfiles 
provide the option to store one or more reactions, together with associated data and 
annotations, in a single file.  
$RDFILE 1 Header line 
$DATM 7/22/2008 15:12:35 Timestamp 
$RFMT $RIREG 1 Reaction record indicator, internal ID = 1 
$RXN 
... 
Embedded rxnfile, containing reactant and 
product molecules 
$DTYPE RXN:RXNREGNO Field title (RXN:RXNREGNO) 
$DATUM 1 Field value (1) 
$DTYPE RXN:VARIATION(1):RXNREF(1):PATH Field title 
$DATUM MTB1-A Field value 
$DTYPE RXN:VARIATION(1):RXNREF(1):STEP Field title 
$DATUM 1 Step Field value 
...  
$RFMT $RIREG 2 
... 
Next reaction record indicator 
Figure 32: Left, a portion of an RDfile export from the 2008.1 release of the Symyx® 
Metabolite database; and right, a description of the contents of each line or section of 
the file. 
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Data fields in the Metabolite database form a hierarchical tree structure, with each node in 
the tree containing child data fields, a value, or a list of values, as illustrated in Figure 33.  
The RDfile format, however, flattens this tree structure and stores reaction data as pairs 
consisting of a field name and the associated data.  
Tree Structure Corresponding Field Names 
 
 
RXN:RXNREGNO 
 
 
RXN:VARIATION(1):RXNREF(1):PATH 
RXN:VARIATION(1):RXNREF(1):STEP 
 
RXN:VARIATION(1):LITREF(1):AUTHOR 
RXN:VARIATION(1):LITREF(2):AUTHOR 
RXN:REACTANT_LINK(1):... 
RXN:PRODUCT_LINK(2):... 
Figure 33: A section of the tree structure holding the reaction data in the Symyx® 
Metabolite database, and the corresponding data field names from an RDfile export of 
the database. 
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Rxnfile format 
The structure of an rxnfile is shown in Figure 34.  The file contains a short header block 
which identifies the file as an rxnfile, allows the reaction to be named, and a short comment 
(up to 80 characters long) to be included.  The header can also contain the initials of the 
user who created the file, the identity and version of the software used to generated the 
file, the date and time the files was created, and an internal registry number for the 
reaction.  Following the header, an rxnfile has a line indicating the number of reactant and 
product molecules contained in the file, followed by those molecules embedded using the 
molfile format.  The molecules are ordered as reactants followed by products. 
$RXN Header line 
 Reaction name (blank in Metabolite) 
  ISIS  072220081512 Information on user/software 
 Line for comments 
  1  1 
The numbers of reactant and product 
molecules 
$MOL Molecule delimiter 
... Embedded molfile 
$MOL Molecule delimiter 
... Embedded molfile 
Figure 34: Overview of the format of an rxnfile. 
Molfile format 
The molfile format is similar to that of the rxnfile.  Molfiles contain a header allowing the 
molecule to be named and a comment added.  As with rxnfiles information regarding the 
user who created the file, the software used and an internal registry number can be 
included, but in addition it can be specified whether the file contains 2D or 3D coordinates, 
together with scaling factors and if used with a modelling program, a steric energy value.  
Following the header is the connection table (Ctab) block.  This starts with a counts line, 
specifying the number of atom, bond and property records in the block and a chiral flag.  
The counts line is followed by one line for each atom in the molecule, specifying the atom’s 
coordinates, element type, charge, isotope number and various other properties.  The atom 
records are followed by bond records, again with one line for each bond in the molecule, 
indicating the atoms making up the bond and the order of the bond, along with some 
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annotations.  The final section of the Ctab block contains a list of additional properties, 
including information on the isotopic composition, atomic charges and radical centres.  In 
earlier versions of the molfile format the number of properties lines was included in the 
Ctab block’s counts line, however the properties block is now terminated by a line reading 
‘M  END’.  This structure is illustrated in Figure 35, below. 
 Molecule name (blank in Metabolite) 
  -ISIS-  07220815122D Information line 
 Line for comments 
15 14  0  0  0  0  0  0  0  0999 V2000 
Counts line; first two figures are 
number of atoms and number of bonds 
in molecule 
  -8.5869  -2.2723  0.0000 C  0  0  3  0  0  0  0  0  0  1  0  0 Atoms block 
...  
  1  2  1  0  0  0  2 Bonds block 
...  
M  CHG 1 3 Properties block 
...  
M  END Molecule terminator 
Figure 35: The structure of a molfile. 
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3.3.4 Data fields in the Symyx® Metabolite database 
SPORCalc databases were generated from a list of rxnfiles.  This approach lost much of the 
information contained in the Symyx® Metabolite database, since the rxnfile format does not 
allow the inclusion of any additional data fields.  In the development of MetaPrint2D it was 
felt that although they are a more complex format, it was better to work with RDfiles, since 
they provide access to the full content of the Metabolite database. 
RXN:RXNREGNO Internal ID; reactions indexed from 1 
RXN:SCHEMEID Reaction scheme ID (e.g.: MTB1) 
RXN:VARIATION(1):RXNREF(1):PATH Reaction path ID (e.g.: MTB1-A) 
RXN:VARIATION(1):RXNREF(1):STEP Reaction step (e.g.: 1 Step;  2 of 5;  3 Steps) 
RXN:VARIATION(1):LITREF(1):ANIMAL(1):SPECIES 
RXN:VARIATION(1):LITREF(1):ANIMAL(2):SPECIES 
RXN:VARIATION(1):LITREF(2):ANIMAL(1):SPECIES 
Species/systems in which transformation 
has been observed to occur 
(e.g.: in vitro (Rabbit Liver Homogenate)) 
RXN:VARIATION(1):RXNCLASS(1):RXNCLASS 
RXN:VARIATION(1):RXNCLASS(2):RXNCLASS 
Annotated reaction types  
(e.g.: Deacetylation) 
RXN:VARIATION(1):MDLNUMBER Unique reaction ID (e.g.: RMTB00000005) 
RXN:REACTANT_LINK(1):MOL(1):MDLNUMBER 
Unique molecule ID for reactant 
(e.g.: MMTB00000001) 
RXN:PRODUCT_LINK(1):MOL(1):MDLNUMBER 
Unique molecule ID for product 
(e.g.: MMTB00002974) 
Figure 36: Selected fields from the Symyx® Metabolite database, relevant to the 
development of MetaPrint2D, with field names, descriptions and example entries. 
3.4 MetaPrint2D’s implementation 
There are two primary factors affecting the accuracy of SPORCalc and MetaPrint2D – the 
quality and breadth of the data in the Symyx® Metabolite database, and the correctness of 
the identification of sites of metabolism in the training data.  The former is something over 
which users of the database have no control (other than reporting any problems identified 
to the database’s publishers, to be fixed in subsequent releases), the latter, however, is 
open to investigation. 
Among other uses, OEChem was required by SPORCalc in order to carry out the maximum 
common substructure searches performed for the identification of reaction centres.  Since 
the goals of this work included the removal of commercial dependencies, such as OEChem, 
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from the software, and the implementation of dependable algorithms to improve the 
reliability of predictions, this area has been investigated.  Analysis of the method through 
which SPORCalc identified sites of metabolism suggested a number of alternative 
approaches. 
MetaPrint2D was written using the Java programming language.  Java is widely used in the 
chemical computing community, and offers the advantage of being easily portable between 
computers running different operating systems, while not suffering from the performance 
problems of purely interpreted languages. 
3.4.1 Reaction centre identification 
Over the course of the development of MetaPrint2D a number of approaches to the 
identification of sites of metabolism in the transformations from the training data were 
considered: 
 Bond annotations 
 Atom-atom mappings 
 Maximum common substructure search 
Each of these approaches is discussed below. 
Symyx® Metabolite database bond annotations 
The first option examined was to make direct use of the annotations contained in the 
Symyx® Metabolite database.  The CTfile formats provide support for bond annotations 
detailing their ‘reacting centre status’, and this has been used in the construction of the 
Metabolite database.  The available annotations are listed in Table 4.   
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Value Meaning 
0  Unmarked 
1  A centre 
-1  Not a centre 
2  No change 
4  Bond made (if in product)/broken (if in reactant) 
8  Bond order changes 
12 (4+8) Both made/broken and bond order changes 
Table 4: CTfile reaction centre status annotations. 
Unfortunately, the bond annotations were not found to map well to the substrate reaction 
centres.  Figure 37 shows a small selection of transformations from the Metabolite 
database, with the annotated bonds and atoms considered to be reaction centres 
highlighted. 
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(MDLNUMBER: RMTB00000003) 
 
(MDLNUMBER: RMTB00000001) 
 
(MDLNUMBER : RMTB00000023) 
 
(MDLNUMBER: RMTB00039453) 
Figure 37: Symyx® Metabolite database bond annotations; the highlighted bonds are 
all marked ‘bond made/broken’, and the highlighted atoms are those that we would 
consider to be reaction centres. 
It is clear that there is no simple correspondence between the bond annotations in the 
Symyx® Metabolite database and the reaction centre atoms; assigning as reaction centres 
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all those atoms belonging to an annotated bond would lead to a large number of extra 
atoms being labelled as reaction centres.  The possibility that the bond annotations could be 
due to the mechanistic detail of the transformation has been considered, but given the 
likely mechanism of the hydrolysis (shown in Figure 38) taking place in the first 
transformation, this is unlikely to be the case. 
  
Figure 38: Left, substrate of the hydrolysis shown in Figure 37 with annotated bonds 
from the Metabolite database highlighted, and right, with the mechanistically 
important bonds highlighted.  The bond annotations do not correspond to the 
mechanistically important bonds. 
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Symyx® Metabolite database atom-atom mappings 
In addition to the ‘reacting centre status’ annotations of the bonds, transformations from 
the Symyx® Metabolite database are annotated with atom-atom mappings, indicating 
correspondence between atoms in the substrate and metabolite structures.  Each atom that 
is conserved between the substrate and metabolite molecules is assigned a unique number, 
and annotated with that number in each of the structures.  SPORCalc made use of these 
annotations in its determination of reaction centres. 
 
 
 
Figure 39: Examples of atom-atom mapping annotations from the Symyx® Metabolite 
database.  The MCS is highlighted in bold, and the Metabolite database supplied atom 
mapping numbers are displayed. (Top – MDLNUMBER:  RMTB00000022; Bottom – 
MDLNUMBER: RMTB00015481)  
In many cases the atom-atom mapping annotations provided by the Metabolite database do 
give a good indication as to the atoms conserved between the substrate and metabolite 
compounds, and hence the locations of the reaction centres.  However a number of 
problems were identified. 
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Missed annotations 
Examination of the atom-atom mapping numbers in the Symyx® Metabolite database 
showed that they could not be used on their own to identify sites of metabolism.  Some 
transformations are not annotated with any atom-atom mapping information, and in many 
cases some conserved atoms are missed out from the mapping.  This is illustrated by the 
sulfuration shown in Figure 40, below. 
 
Figure 40: Atom-atom mapping numbers from the Symyx® Metabolite database 
(MDLNUMBER: RMTB00046671).  The oxygen atom marked with an asterisk is not 
assigned a mapping in the database despite being conserved between the substrate 
and product. 
Although the documentation for the Symyx® Metabolite database states that “atom-atom 
maps are usually assigned based on the apparent change in the transformation, rather than 
the actual transformation mechanism” (259), we have considered the possibility that the 
oxygen at which the reaction takes place (indicated with an asterisk in the figure) could have 
been excluded from the atom-atom mappings for mechanistic reasons.  However, the 
mechanism through which sulfotransferases act (260) would conserve the atom over the 
course of the transformation, as shown in Figure 41.  This suggests that the indicated atom 
is omitted from the mapping in error. 
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Figure 41: The proposed mechanism for sulfuration (260): Sulfuration takes place in 
the active site of a sulfotransferase enzyme, with cleavage of the sulphate group from 
3’-phosphoadenosine 5’-phosphosulfate (PAPS) proceeding via an SN2-like mechanism, 
stabilized by surrounding charged and polar residues.  The substrate, metabolite and 
sulfonate group are shown in bold, with the conserved substrate substructure 
highlighted in red.  The substrate’s hydroxyl oxygen is retained in the metabolite’s 
structure. 
 The omission of mappings for atoms found at centres of addition such as this is not 
occasional, but rather seems to have been a systematic choice by the database’s curators.  
The result of this is that the mapping numbers alone cannot be used to identify the 
conserved structure between a substrate and metabolite. 
Mapping errors 
While the majority of the atom-atom mappings provided in the Symyx® Metabolite 
database do appear to be accurate, aside from the missed mappings, there are a number of 
instances where they are incorrect, leading to strange apparent conserved structures.  One 
such case is shown in Figure 42(a) below.  The annotated atom-atom mapping numbers, and 
the conserved structure they imply, clearly do not correspond to the structure that is in 
actual fact conserved between the substrate and metabolite.  Interestingly, in a similar 
transformation from the same metabolic scheme, shown in Figure 42(b), the annotations 
have been correctly assigned, although the exclusion of the oxygen adjacent to atom 4 from 
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the mapped structure, suggests that the mappings in this case could have been assigned on 
the basis of mechanism, rather than just the apparent change in the transformation, in spite 
of what is indicated in the database’s documentation (259). 
(a) 
 
(MDLNUMBER: RMTB00011859) 
(b) 
 
(MDLNUMBER: RMTB00005370) 
Figure 42: (a) An example transformation from the Symyx® Metabolite database, 
where the atom-atom mappings are incorrect; (b) A related transformation where the 
atom-atom mappings have been correctly assigned. 
Maximum common substructure search 
Well over two decades ago it was suggested that the changes occurring in the course of 
chemical reactions could be identified through determination of the maximum common 
subgraph of the reactant and product (261) molecules, and this formed the basis of the 
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approach taken by SPORCalc.  The authors of SPORCalc were aware of the problem of 
incomplete mapping annotations, and, as described earlier, performed a series of maximum 
common substructure (MCS) searches with increasingly strict matching criteria until a result 
was found in which the mappings of all annotated atoms were in agreement with the 
mappings specified by the annotations.  If no such mapping can be found then SPORCalc 
defaults to using the mappings produced by an MCS search with an intermediate strictness 
of matching criteria. 
Since the annotated mappings are incomplete, an approach taking the Symyx® Metabolite 
database’s atom-atom mapping annotations as a starting point for the maximum common 
substructure search, and ‘growing’ the MCS from that structure was considered.  However, 
due to the identification of errors in the mappings such as that described above, it was 
decided not to pursue that method. 
Instead, a scheme based on the MCS between the substrate and metabolite has been 
adopted.  The difficulty in handling the data from the Symyx® Metabolite database is that 
each record contains only a single reactant and a single product – the main substrate and 
primary metabolite formed by the transformation.  Additionally, some transformations 
represent the overall result of a number of elementary reaction steps, posing additional 
challenges.  Rather than taking SPORCalc’s approach of trying MCS generated using various 
configurations, until a match with the Metabolite database’s annotations is found, 
MetaPrint2D identifies the ‘best’ conserved structure that it can, and only in the case of 
multiple equally good structures uses the Metabolite database’s mappings to choose 
between them. 
Exactly what is the best conserved substructure between a substrate and metabolite is not 
always easy to define.  Figure 43, below, shows three possible MCS for a transformation 
from the Metabolite database, each of which is the outcome of an MCS search performed 
according to a different configuration of the search algorithm.  If the search is performed 
with the requirement that bond orders must be conserved between the substrate and 
metabolite, then the MCS shown in (a) is found.  If this requirement is relaxed, then the 
result shown in (b) is detected – with 9 atoms and 8 bonds conserved, compared to the 7 of 
each for the result of the first search.  A third possibility, found if disconnected results are 
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permitted, is shown in (c); this also contains 9 conserved atoms and 8 conserved bonds, and 
unlike that shown in (b) the bond orders are conserved. 
 
(a) 
 
 
(b) 
 
 
(c) 
 
Figure 43: The output of maximum common substructure searches with various 
settings: (a) bond orders conserved; (b) bond orders not conserved; (c) bond orders 
conserved, disconnected structures permitted. (MDLNUMBER: RMTB00016651) 
It is clear from this example that a MCS does not necessarily reflect the atoms and bonds 
conserved over the course of a reaction.  It is important to note that mappings of bonds 
cannot be restricted on the basis of their order, as these often change over the course of a 
reaction.  In order to determine the most appropriate ‘reaction conserved substructure’, 
MetaPrint2D relies on a set of heuristics to generate constraints on the permitted atom 
mappings, and then performs a search for the best maximum common substructure within 
the bounds of those constraints. 
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‘Simple’ transformations 
In many cases either a simple addition such as hydroxylation or acetylation, or a simple 
elimination such as deacetylation or dealkylation, has occurred.  In these instances there 
have either been additions or eliminations of atoms and bonds (other than hydrogen 
atoms), but not both.  Examples of such transformations are illustrated in Figure 44.  
Whether a transformation potentially represents a simple addition or elimination can easily 
be ascertained by comparing the numbers of atoms in the reactant and product structures.  
If the product contains more atoms than the reactant then an addition may have taken 
place, and this can be determined by checking whether the reactant structure is completely 
contained within the product structure.  Alternatively, if the reactant contains more atoms 
than the product then an elimination reaction may have taken place, in which case the 
product will be a substructure of the reactant.  Testing whether one structure is completely 
contained within another – the so called ‘subgraph isomorphism problem’ is much quicker 
and simpler than maximum common subgraph-isomorphism, so this test is carried out at 
the start of the analysis of each transformation. 
 
(a) 
(MDLNUMBER: RMTB00001293) 
 
(b) 
(MDLNUMBER: RMTB00001671) 
Figure 44: Examples of ‘simple’ transformations, where either the entire substrate or 
product structure is conserved.  The added or eliminated portion of the structure is 
shown in red, and the conserved structure highlighted in bold. (a) Addition: 
acetylation (b) Elimination: dealkylation. 
This test also identifies cases in which the Symyx® Metabolite database describes the result 
as ‘optical resolution’, where no transformation has occurred; rather a single enantiomeric 
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form is selected.  Since MetaPrint2D currently disregards stereochemical information, these 
transformations are discarded. 
Constrained MCS search 
If there is no ‘simple’ mapping between the substrate and metabolite structures then 
MetaPrint2D performs a maximum common substructure search in order to determine the 
conserved substructure.  However, in order to determine the most relevant MCS a series of 
heuristics imposing constraints on the permitted atom mappings have been developed. 
These constraints are based around the principle of ring conservation – that if there are 
equivalent ring systems or single rings in both the substrate and metabolite structures then 
it is likely that they are conserved over the course of the transformation.  MetaPrint2D first 
checks whether the Murcko framework (262), or scaffold, of either molecule is conserved, 
and then checks for any conserved ring systems (sets of simple rings sharing one or more 
atoms or bonds) and finally any remaining simple rings. 
1. Scaffold constraints 
Murcko frameworks consist of the set of ring atoms and bonds in a molecule, together with 
the atoms and bonds contained in linkers between rings.  The first constraints on the MCS 
mappings that MetaPrint2D attempts to generate are based on the detection and 
conservation of this scaffold. 
In order to do this the scaffold structures of both the substrate and metabolite molecule are 
identified, and a regular substructure search performed to determine whether one is 
completely contained within the other – i.e. whether a scaffold is conserved between the 
substrate and metabolite.  If this is the case then the constraint that the conserved scaffold 
atoms must map to their equivalent atoms in the other compound is imposed. 
If a conserved scaffold is identified then no further search for constraints is performed, since 
all of the ring atoms and bonds from the structure with the smaller scaffold will have had 
their potential mappings constrained. 
An example illustrating the generation of scaffold-based atom mapping constraints is shown 
in Figure 45, below. 
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Substrate Metabolite 
  
Isolate scaffolds – i.e. all rings and linkers 
  
Identify conserved scaffold 
  
Generate mapping constraints, and apply to entire molecule 
Atom numbering indicates mapping constraints.  Bold bonds indicate scaffold structure; this must be 
included in maximum common substructure generated. 
 
 
Figure 45: The generation of scaffold atom mapping constraints for MCS search 
illustrated for the metabolism of Ancitabine (MDLNUMBER: RMTB00036597).  The 
scaffolds, or Murcko frameworks, of the substrate and metabolite structures are 
identified, and it is determined whether the smaller scaffold is completely contained 
within the larger.  If this is the case then atom mappings between the two structures 
are generated.  In this example each scaffold atom has a unique mapping to an atom 
in the other structure, but often groups or classes of equivalent atoms are detected. 
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2. Ring constraints 
If the scaffold structure is not completely conserved, then a search for conserved ring 
systems and finally for conserved simple rings is carried out.  Ring systems consist of either 
lone rings, or of sets of single rings having one or more atoms or bonds in common, 
resulting in bridged, fused or spiro systems.  The ring systems in both the substrate and 
metabolite structures are detected, and any ring systems common to both molecules 
identified.  If there are ring systems common to both structures then atom mapping 
constraints are generated for the atoms in these systems.  In the case that a structure 
contains more than one identical ring system, mapping constraints are only generated if the 
other structure contains the same number of occurrences of a matching ring system. 
Finally, after any conserved ring systems are identified, conserved structures between any 
rings that remain unmapped are explored. 
An example illustrating the process is shown below in Figure 46. 
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Substrate Metabolite 
 
 
Identify ring systems 
  
Find conserved ring systems 
  
Find conserved rings within remaining ring systems 
  
Generate atom-atom mapping constraints for molecules 
 
 
Figure 46: Generation of ring system constraints (MDLNUMBER: RMTB00000482). 
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MCS search algorithm 
Once conserved scaffolds, ring systems and rings have been identified and constraints on 
permitted atom-atom mappings generated, a final heuristic is applied: any atoms that are 
not contained in any of the conserved structures may only map to another atom that is not 
contained in a conserved structure.  A maximum common substructure search is then 
performed within the bounds of these constraints. 
Maximum common substructure searching is an example of the ‘maximum common 
subgraph isomorphism’ problem, a computational task which is described as NP-complete 
(263), meaning that there is no efficient algorithm guaranteed to find the best solution.  
Between two structures having m and n atoms, respectively, there are  𝑚𝑛+1𝑛 potential 
MCS solutions (264).  However the performance of algorithms can be vastly increased in 
most cases through the application of appropriate heuristics; in the case of the searches 
performed by MetaPrint2D, both heuristics within the search algorithm itself, and 
additionally the constraints on the allowed atom-atom mappings that are generated. 
Many algorithms for the determination of maximum common substructures have been 
proposed (265).  MetaPrint2D relies on a modified version of the Recursive backtracking 
algorithm, developed by Krissinel and Henrick (264) to carry out its maximum common 
substructure searches.  This algorithm is itself an enhancement of the well known Ulmann 
algorithm (266).  The alternative approach would be to employ an algorithm based on 
maximal clique detection (267,268). 
Each iteration of the recursive backtracking algorithm picks an unmapped atom from the 
query structure and identifies the set of atoms in the target structure to which it may be 
mapped without violating the constraints imposed by the previously mapped atoms.  Each 
candidate mapping is picked in turn, with the search continuing until no more query atoms 
are available, in which case the algorithm backtracks to its previous state, and picks the next 
candidate mapping.  The time required to perform the MCS search depends on the number 
of recursive calls made.  Krissinel and Henrick have developed a strategy for efficiently 
pruning the search space, eliminating time consuming exploration of undesirable branches 
that cannot lead to a good solution to the search, at the expense of a small additional 
overhead per iteration. 
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At each iteration the algorithm checks whether the current search direction is worth 
continuing, or whether it should backtrack and pick a different path to search, by testing 
whether the number of nodes which could be mapped (the sum of the number of nodes 
currently mapped and the number of unmapped nodes with permitted mappings remaining) 
is at least as high as the number of nodes in the best result found so far.  When picking the 
next node, the node with the fewest potential mappings is selected, narrowing the search 
space as rapidly as possible.  Finally, when each mapping is made, the potential mappings of 
all remaining unmapped nodes are refined on the basis that nodes neighbouring the last 
mapped node in the query structure must neighbour the target structure node to which it 
was mapped, and similarly, nodes not neighbouring the query structure node may not map 
to a neighbour of the mapped node in the target structure. 
The recursive backtracking algorithm utilised by MetaPrint2D is slightly modified from 
Krissinel and Henrick’s published algorithm.  The option to specify constraints on the 
permitted atom and bond mappings has been added, as has an option to ensure that only 
connected results are generated, by ensuring that at each step in the search the current 
structure can only be extended into neighbouring atoms. 
Filtering suggested maximum common substructures 
Often there are several potential MCSs, with different mappings between reactant and 
product atoms.  If this is found to be the case then Occam’s razor is applied, and it is 
assumed that the simplest explanation – i.e. the MCS with the fewest reaction centres and 
fewest added, removed or changed bonds – is the best. 
The following examples illustrate how the problem is addressed. 
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1. Minimize the number of reaction centres 
 
Ignoring the symmetry of the N-
methyl groups, this 
transformation has two possible 
MCS mappings, conserving the 
same number of atoms and 
bonds. 
 
Identifying the mapping that 
minimizes the number of reaction 
centres discriminates between 
them (atoms and bonds forming 
the MCS are shown in bold). 
 
 
The MCS between the substrate 
and metabolite in this N-
demethylation is a single carbon 
atom.  The carbon atom in the 
metabolite could potentially map 
to any carbon in the substrate 
structure.  Minimising the number 
of reaction centres correctly 
identifies the mapping to one of 
the N-methyl substrate carbon 
atoms. 
Figure 47: Illustration of the selection of ‘best’ MCS, by minimizing the number of 
reaction centres. 
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2. Pick the MCS with the greatest number of unchanged bonds 
 
(a) 
 
 
(b) 
 
Figure 48: Alternative mappings for an amide hydrolysis; both have the same number 
of reaction centres; (b) is preferred since the carbonyl oxygen’s bond order is 
conserved. 
The performance of the reaction centre identification has been evaluated through manual 
inspection of 300 randomly selected transformations from the Symyx® Metabolite database.  
The results of this evaluation are presented on page 120, in Chapter 4. 
Classifying reaction centres 
Once the structure common to the reactant and product has been identified, reaction 
centres are detected and classified.  In order to maintain compatibility with SPORCalc the 
same classification scheme is used.  Reaction centres are identified through examination of 
bonds changed between the reactant and product structures.  Bonds found in the reactant 
molecule but not in the product are listed, as are bonds in the product molecule but not in 
the reactant.  In addition, bonds whose order is changed between the reactant and product 
are identified. 
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Atoms are marked as reaction centres and assigned to one or more of the same reaction 
classes used by SPORCalc.  This classification is performed on the basis of the atom and 
bond changes, and in the case of additions, also on the group added: 
 Phase I addition – defined as the addition of a single oxygen atom, which covers 
hydroxylation, oxidation and epoxidation 
 Phase II addition – defined as the addition of any other group 
 Elimination 
 Bond breaking 
 Bond formation 
 Bond order change 
 Substitution – defined as both an addition and an elimination centred on the same 
atom 
Filters can be applied during the model construction process enabling generation of models 
for any combination of these reaction types.  In order to facilitate comparison with 
SPORCalc, and other site of metabolism prediction tools, in the course of this work models 
have been restricted to the prediction of Phase I additions and eliminations. 
3.4.2 Multi-component structures 
There are a small number of transformations for which the Symyx® Metabolite database 
reports more than one component in either the substrate or metabolite structures.  In all 
cases the additional component is due to the presence of a counter-ion, such as the acetate 
anion in Figure 49, below. 
 
Figure 49: Example of a transformation in which the substrate structure contains an 
acetate counter-ion (MDLNUMBER: RMTB00042423). 
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In most cases the presence of the counter-ion is reported in either the substrate or 
metabolite, not both.  For such transformations only the largest component is analysed, and 
any counter-ions are discarded 
3.4.3 Aromaticity detection 
When determining whether a region of a molecule has undergone a metabolic 
transformation it is important that different aromatic resonance forms are taken into 
consideration; the representation of aromaticity and other delocalised systems is a 
challenge for chemical information systems.  In cases such as that illustrated in Figure 50, it 
can appear that bonds have changed order over the course of a transformation, when in 
actual fact the substrate and metabolite structures are different resonance forms of the 
same aromatic system.  
 
Figure 50: The bonds in the aromatic ring highlighted in red appear to change order 
between the substrate and metabolite structures.  These, however, do not represent 
reaction centres: the two structures are equivalent resonance forms of the delocalised 
π-system. (MDLNUMBER: RMTB00007698) 
In other cases, however, a transformation really has occurred: 
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Figure 51: In this case the change in order of the aromatic bond highlighted is due to a 
metabolic transformation, and is not the result of an alternative resonance structure. 
(MDLNUMBER: RMTB00004389) 
In Figure 51 both of the five-membered rings containing the highlighted bond can be 
considered aromatic by chemical information systems using Huckel’s 4n+2 electron rule.  
However, the change in bond order is not simply down to a change of resonance structure.  
This can be recognised in two ways: firstly, the change in bond order is not a concerted 
change of an alternating single/double bond system, and secondly a hydrogen atom has 
been added to the nitrogen atom, increasing its number of substituent atoms. 
3.4.4 Fingerprint generation 
MetaPrint2D utilises the same type of circular atom environment fingerprints as SPORCalc 
(see Page 68) to represent the chemical environment occupied by atoms.  These atom-
centred fingerprints consist of lists of the atom types encountered at successive topological 
distances from a central atom.  MetaPrint2D first assigns SYBYL® atom types (251), listed in 
Table 5 below, to each atom in a structure.  Fingerprints are then generated for each atom 
in turn, by means of a depth limited breadth-first search (BFS) encompassing the central 
atom and all atoms up to five bonds distant.  At each depth within the search, a list of the 
atom types encountered at that depth, together with their frequency of occurrence, is 
recorded.  Atoms are only recorded the first time they are encountered by the BFS, 
regardless of any cycles in the structure.  These atom type lists form the basis of the 
fingerprints used in MetaPrint2Ds. 
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Fingerprint:  C.ar  ;  2x C.ar  , C.sp2  ;  2x C.ar  , O.sp2 , O.sp3  
Figure 52: Atom environment fingerprint generation.  Neighbouring atoms are visited 
via breadth-first search, and the number of occurrences of each atom type at each 
topological distance is recorded. 
Atom 
type 
Description 
Atom 
type 
Description 
C.3 sp3 hybridized carbon N.3 sp3 hybridized nitrogen 
C.2 sp2 hybridized carbon N.2 sp2 hybridized nitrogen 
C.1 sp hybridized carbon N.1 sp hybridized nitrogen 
C.ar aromatic carbon N.ar aromatic nitrogen 
C.cat carbocation (C+) N.am amide nitrogen 
O.3 sp3 hybridized oxygen N.pl3 planar 3-coordinate nitrogen 
O.2 sp2 hybridized oxygen N.4 positively charged sp3 nitrogen 
O.co2 carboxylate/phosphate oxygen Li lithium 
S.3 sp3 hybridized sulphur Na sodium 
S.2 sp2 hybridized sulphur K potassium 
S.O sulphoxide sulphur Ca calcium 
S.O2 sulphone sulphur Al aluminium 
P.3 sp3 hybridized phosphorus Si silicon 
F fluorine H hydrogen 
Cl chlorine Du dummy atom 
Br bromine LP lone pair 
I iodine   
Table 5: The SYBYL® atom types used by SPORCalc and MetaPrint2D. 
C.ar
C.ar
C.ar
C.sp2
C.ar
C.ar
O.sp3
O.sp2
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3.4.5 Fast fingerprint searching 
As with SPORCalc, the model generation process for MetaPrint2D can be carried out 
beforehand, and the data saved, so the efficiency of this step does not affect the experience 
of users when making a query.  However, the speed of the searching of this data contained 
in the model is vital in determining the user’s experience.  Ideally predictions should be fast 
enough to be made in ‘real-time’ as far as a user is concerned, enabling immediate 
visualisation of the effects of alterations to a structure. 
SPORCalc’s database simply listed the environment of each atom in the Symyx® Metabolite 
database in a set of data files; one file contained the atom environments of all the reaction 
centres in the database, and other files contained the full list of atom environments, 
separated by the type of their central atom.  Predictions were made by iterating through all 
these files, comparing each atom environment fingerprint to the fingerprints of the atoms in 
the query structure, and keeping count of the number of reaction centre and substrate hits. 
To hold all this data, SPORCalc’s data files were very large – in the region of 600MB for each 
model.  Storing and searching this quantity of data led to SPORCalc taking several minutes 
per molecule to generate predictions.  A number of alternative approaches to storing and 
searching the model have been investigated, with the aim of increasing the speed of 
prediction. 
The 2008.1 release of the Symyx® Metabolite database contains 1352387 atoms, occupying 
166766 distinct environments.  Storing a list of atom environments, each with pre-
computed reaction centre and substrate occurrence counts, rather than recording each 
atom individually leads to a reduction in both file size and computation time of almost 90%. 
Input/Output operations (reading from/writing to a disk) are very time-consuming in 
comparison to equivalent operations on data stored in Random Access Memory (RAM).  
Calculations can be performed much more rapidly if MetaPrint2D’s dataset can be held 
entirely in RAM, rather than being read from disk on every use.  Each fingerprint consists of 
six levels of 33 bins, each of which contains a value from a small range (typically 0-5).  
Storing each bin of the fingerprint in a single byte of memory, a fingerprint would take up 
198 bytes.  This means that the fingerprints for the 165951 distinct environments found in 
the 2008.1 release of the database would require around 31MB of memory.  Additional 
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memory is needed for the storage of occurrence counts, and overheads associated with the 
data structures, but that will not expand the memory requirements to the point where this 
quantity of data cannot easily be stored in the memory of modern computer systems, which 
typically have gigabytes of RAM available. 
Since MetaPrint2D is intended to be used as a library, potentially integrated into larger 
systems, it is still desirable to minimize the storage requirements as much as possible as 
MetaPrint2D may not have access to the computer system’s entire resources.  Additionally, 
under its default settings the Java virtual machine only has access to a small proportion of 
the host computer’s resources.  Users may wish to work with models generated with various 
constraints (e.g. Human/Rat...), so it is beneficial to be able to hold several models in 
memory at the same time. 
Memory usage has been further reduced through exploitation of the hierarchical structure 
of the fingerprints.  At each level, the fingerprint contains a count of the number of 
occurrences of each atom type at that distance from the atom on which the fingerprint is 
centred.  These single-level sub-fingerprints are often identical to a single-level of many 
other full six-level fingerprints.  For example, all fingerprints centred on an aromatic carbon 
will have an identical first level (containing a single C.ar typed atom), and many will have an 
identical second level (containing two C.ar typed atoms, and nothing else).  This structure 
can be exploited in two ways.  Firstly, if the fingerprints are sorted on the basis of the 
hierarchy of single-levels fingerprints, only the sub-fingerprints for the levels differing from 
the previous fingerprint need be stored.  Alternatively the memory requirements of the 
model can be reduced through caching these single-level sub-fingerprints in memory, and 
having the six-level fingerprints share instances of them. 
These approaches are illustrated in Figure 53. 
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(a) 
 
 
 
(b) 
 
Figure 53: Illustration of the memory savings of the schemes described above.  Each 
row of cells (e.g. ABCD) illustrates a full fingerprint, formed from a number of sub-
fingerprints.  The sub-fingerprints represented by cells in a dark colour must be stored 
in full, while those greyed out can reference a copy of the data stored elsewhere, 
thereby saving memory. (a) Hierarchical difference: if the fingerprints are sorted 
according to their hierarchy, only the differences from the previous fingerprint need 
be stored.  (b) Single-level caching: alternatively, a single copy of each sub-fingerprint 
can be kept in a pool, with all the relevant fingerprints referencing that copy. 
The memory savings afforded by these optimizations are shown in Table 6, below. 
Storage Method Memory Usage / MB 
No optimization 77.05 
Hierarchical difference 44.51 
Single-level caching 27.02 
Table 6: The memory requirements for storage of a MetaPrint2D model constructed 
from all the data in the 2008.1 Symyx® Metabolite database.  No optimization: full 
fingerprints held in memory; Hierarchical difference: hierarchical structure of 
fingerprints exploited; Single-level caching: single-level sub-fingerprints cached, and 
shared between full six-level fingerprints.  (Memory usage recorded on a Dell Inspiron 
6400 laptop with Intel Core 2 T5300 @ 1.73GHz; 3.24GB RAM) 
Indexing 
In order to further reduce the time required to search the atom environment data it is 
indexed as it is loaded into memory.  This means that when a search is performed, rather 
than having to iterate through the entire dataset, the relevant portions can be rapidly 
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retrieved and the number of more computationally demanding similarity calculations 
performed kept to a minimum. 
In the standard parameterizations of SPORCalc the similarity searches were carried out with 
the constraint that the first one, two or three levels must exactly match the query 
fingerprint.  This clearly lends the data to being indexed on the first three fingerprint levels.  
In order to facilitate flexibility in searches, constrained to any level of exact matches, each of 
the first three levels of fingerprint is indexed separately.  The alternative would be to index 
level 1, level 1+2, level 1+2+3 – which would require much more memory, for only a small 
extra gain in performance. 
Each index takes the form of a hash map (269).  This is a data structure mapping identifiers 
(keys) to associated values in an efficient manner.  The indexes in MetaPrint2D use single-
level sub-fingerprints as keys, and the set of all fingerprints having that pattern at the 
indexed level as the corresponding value.  When a search is performed, the sets of data 
having the required fingerprint at each level are looked up, and the conjunction of all such 
data (i.e. those data points with the correct sub-fingerprint at every level) is returned.  Set 
operations are very fast, and in this instance their speed is further increased by considering 
the index search results in order of increasing size, which minimises the number of 
calculations to be carried out. 
A hash map consists of a simple sequence of buckets, each of which can hold one or more 
data items (key/value pairs).  A hash function is employed to calculate the index of the 
bucket in which a data item should be stored, from the item’s key.  When fetching a data 
item from the hash map only a single bucket has to be inspected, rather than searching all 
the data, allowing for very fast retrieval.  Hash maps can offer “constant time performance” 
(269) – meaning that the retrieval time is independent of the number of items stored in the 
hash map, as opposed to storing data in a simple list where search time scales rapidly with 
the quantity of data.  Once a certain capacity has been reached the number of buckets is 
increased, and the data items redistributed between them.  MetaPrint2D makes use of the 
standard implementation of a hash map data structure provided by the Java language 
(java.util.HashMap). 
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Figure 54: Illustration of the indexing of fingerprints by a hash map.  The boxes 
represent three level fingerprints, with each letter representing a single-level sub-
fingerprint.  The fingerprints are stored in a hash map, indexed by their second level.  
Each fingerprint is mapped to a bucket based on its second level sub-fingerprint and a 
hash function.  All of the fingerprints having a sub-fingerprint in common are stored in 
a set in the corresponding bucket. 
The performance of a hash map is dependent on the quality of the hash function used.  The 
hash function should be quick to calculate, and distribute the data items uniformly between 
the buckets, with few collisions (generating the same value for items with different keys).  
The hash function used by MetaPrint2D is based on the hash function for strings described 
in the Java language specification (270): 
𝑕𝑎𝑠𝑕 𝑐𝑜𝑑𝑒 =  𝑐𝑖 × 31
𝑖  
In both cases a hash function is required for a similar data structure; a string consists of a 
sequence of characters (represented by their numeric ASCII/UNICODE values) and a 
MetaPrint2D fingerprint consists of a sequence of bin values.  Through trial and error it was 
determined that in order to minimise hashing collisions, optimal parameters for the 
exponential term in the hash functions for MetaPrint2D fingerprints and sub-fingerprints are 
63 and 15, respectively. 
Since the fingerprints in MetaPrint2D are immutable (un-changeable) the output of the hash 
function for a particular fingerprint will never change.  This means that performance can be 
further increased by calculating the hash of a fingerprint a single time, and caching the value 
with the fingerprint. 
Index Bucket
1 N(DNQ)
2 B(ABC,FBZ); J(PJT)
3
4 Q(XQT)
5
ABC
XQK
FBZ
DNQ
PJT
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Data file size and loading times 
A number of optimizations to the data file were investigated, in order to decrease its size 
and speed-up loading.  As mentioned above, rather than storing the fingerprint for each 
atom of the Symyx® Metabolite database, the total occurrence counts for each distinct 
atom environment are stored. 
Within each atom environment fingerprint, the majority of the atom types at each single-
level have a count of zero, so, rather than storing the value of every bin in the full 
fingerprint a sparse fingerprint representation is employed, where only the indexes of the 
non-zero bins, together with their values, are stored.  The hierarchical nature of the 
fingerprints is also exploited.  The inner-layers of the fingerprints are much less variable 
than the outer layers, so rather than storing each fingerprint in full, when writing the data 
file the fingerprints are sorted in an ascending order, and only the single-level sub-
fingerprints that differ from those of the previous fingerprint are stored, in a similar manner 
to that described on page 110. 
SPORCalc stored fingerprints in an ASCII text format: a space delimited string of numbers.  In 
order to store the fingerprints as numerical values in memory, as required by the similarity 
calculations, this string must be split into a list of numbers, and then the text 
representations of the numbers converted to their numeric equivalents.  This computation 
can be reduced, decreasing the data’s loading time, by storing the data in binary format, so 
the byte values can be read directly from the files, removing the need for conversion. 
As shown in Table 7, together these optimizations have reduced the size of the data files for 
a model from over half a gigabyte to just over three megabytes, or well under one 
megabyte if GZip compression is applied to the file, and loading times have reduced from 
around two and a half minutes to well under one second, on commodity hardware (Dell 
Inspiron 6400 laptop Intel Core 2 T5300 @ 1.73GHz; 3.24GB RAM). 
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File format File size/MB t1/s t2/s t3/s t4/s t5/s tav/s 
6lvfp files 558.9 149.08 146.86 146.55 147.59 145.20 147.03 
Text file 63.8 17.09 16.49 16.47 16.75 16.56 16.67 
Bin file 32.7 4.70 4.13 4.31 4.42 4.28 4.37 
Sparse diff file 3.35 0.84 0.68 0.63 0.61 0.61 0.67 
Compressed file 0.839 0.92 0.74 0.68 0.67 0.68 0.73 
Table 7: File sizes and load times (recorded on a Dell Inspiron 6400 laptop Intel Core 2 
T5300 @ 1.73GHz; 3.24GB RAM). 6lvfp files = six level fingerprint files – full list of 
atom fingerprints as used by SPORCalc; text file = atom environment and occurrence 
counts stored in ASCII format; bin file = atom environment and occurrence counts 
stored in binary format; sparse diff file = binary file with sparse fingerprints exploiting 
hierarchical structure; compressed file = sparse diff file compressed using GZip 
compression.  The data are for models generated from the 2008.1 Symyx® Metabolite 
database, containing 1,352,387 atoms occupying 166,766 distinct environments.  
Timings have been recorded on five independent runs, each of which is reported, 
together with their mean. 
3.5 Software availability 
The core of MetaPrint2D’s calculation engine has been designed as a self-contained library, 
providing a straightforward Application Programming Interface (API).  This enables a variety 
of different user-interfaces to be developed, and makes it straightforward for MetaPrint2D 
to be embedded into larger applications. 
Three interfaces to the MetaPrint2D library, designed to facilitate a range of use cases, have 
currently been produced: a website, a command-line utility and a plug-in for the Bioclipse 
rich client platform.  These are now described, and their relative merits and disadvantages, 
along with potential future applications are discussed. 
3.5.1 Web site 
The first interface provided is a website, hosted at the Unilever Centre for Molecular Science 
Informatics in the Cambridge University Chemical Laboratories (http://www-
metaprint2d.ch.cam.ac.uk/).  This interface is the most straightforward to use, requiring no 
set-up or configuration, just access to a graphical web browser which comes preconfigured 
on almost all modern computers.  Users can input molecules using SMILES, or sketch a 
structure using the JME editor (271), and results are clearly presented in a form a chemist 
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will immediately recognise.  Predicted sites of metabolism are highlighted using a traffic-
light system.  Full details of the results are accessible by moving the cursor over an atom.  
Any regions of the molecule that are not well covered by the database are highlighted in 
grey, giving the chemist insight into the reliability of the model’s predictions (this will be 
discussed further in the next chapter). 
 
Figure 55: Results of a query carried out through the MetaPrint2D website. 
Installing and maintaining the MetaPrint2D software on a central server, rather than 
requiring users to set-up and maintain the code on their own machines, makes it simple to 
keep the application up-to-date and means that users can be sure they are accessing the 
most recent version of the software and data files.  There are, however, downsides to the 
server-client model.  The software is only accessible when users are connected to the 
internet, and the server provides a single point of failure, vulnerable to heavy usage or 
malicious attacks, though this can be mediated through techniques such as queuing 
computationally expensive tasks, and limiting the frequency with which users can make 
requests.  If demand were to grow, then flexible cloud-like compute resources, such as the 
Amazon Elastic Compute Cloud (EC2) (272) could be used to increase service availability at 
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times of high demand, without having to maintain the infrastructure of a server pool with a 
large amount of redundant capacity. 
There can also be issues regarding security of intellectual property (IP) rights when working 
with remote services.  Users may be wary of submitting confidential molecules across the 
internet; indeed many companies have absolute bans on doing so, though this position is 
becoming less prevalent with the growth in usage of Electronic Laboratory Notebook (ELN) 
systems, with the greater IP protection they afford (273). 
The web-based version of MetaPrint2D can also be packaged up with a small web-server, 
producing a stand-alone version, ideal for demonstration purposes.  This removes the need 
for a connection to the internet, and running the service locally also means that there can 
are no concerns concerning the transmission of confidential data across public networks.  
The web-based version of MetaPrint2D cannot, however, currently be distributed due to 
license restrictions prohibiting the distribution of the JME editor, which is currently used for 
structure input. 
The current web interface could readily be adapted to provide a SOAP or RESTful 
‘webservice’ interface facilitating integration with workflow tools and other remote 
applications. 
3.5.2 Command-line Utility 
A command-line based interface for MetaPrint2D has also been developed and released.  
This interface can take as its input a single SMILES string, a file containing a list of SMILES, or 
an SDF file containing one or more molecules, and generates site of metabolism predictions 
for each molecule, and optionally images displaying the likely sites of metabolism of the 
compounds, similar to those produced by the website (shown in Figure 55, above).  The 
command-line MetaPrint2D application carries out computations locally on the user’s 
computer, so does not require internet access to run, and removes the IP considerations 
surrounding the transmission of potentially sensitive data to remote services.  Use of the 
command line tool does however require some degree of technical expertise, and as such is 
more appropriate for the power-user wishing to batch-process a large number of 
compounds, or integrate MetaPrint2D’s site of metabolism predictions into a script or 
workflow. 
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The command-line application’s batch processing mode is able to fully leverage the speed of 
the MetaPrint2D calculation library, enabling high-throughput virtual screening of large 
compound collections. 
3.5.3 Bioclipse plug-in 
The third interface to MetaPrint2D currently available is a plug-in for the Bioclipse, created 
in collaboration with the developers of Bioclipse*.  Bioclipse (274) is an open source chemo- 
and bioinformatics platform, built on the Eclipse (275) rich client platform. 
The integration with Bioclipse provides the most powerful interface to the MetaPrint2D 
library.  Chemists are able to draw molecular structures into the editor, in a manner 
common to many other applications, and visualise how predicted sites of metabolism 
change as they modify the structure, in real time – the screenshot below shows that 
Bioclipse was able to capture the molecular structure from the editor, assign the required 
atom types, generate site of metabolism predictions with the MetaPrint2D library, and 
render the results of those predictions in the editor, all in 172 milliseconds.  Bioclipse is also 
able to run MetaPrint2D over large files of structures, predicting sites of metabolism for 
each structure, and displaying the output in a scrollable table, and due to its speed, this is a 
fairly trivial task. 
                                                     
* The MetaPrint2D plug-in for Bioclipse was written by Ola Spjuth of Uppsala University, one of the 
developers of Bioclipse, with assistance from the author of MetaPrint2D.  The plug-in provides an 
interface between Bioclipse’s internal data-structures and user interface, and the MetaPrint2D 
library. 
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Figure 56: MetaPrint2D running in Bioclipse. 
As with MetaPrint2D’s command-line application, Bioclipse removes the considerations 
regarding intellectual property rights that are associated with use of the MetaPrint2D 
website, since all calculations are carried out locally on the user’s computer, and no 
information is transmitted across the Internet.  The downside of the application is, however, 
that a significant effort may be required for initial set-up and configuration – the Bioclipse 
application must be installed and configured, and the MetaPrint2D plug-in then added.  In a 
corporate environment where use of computer systems is often governed by strict security 
policies, approval may be required before Bioclipse can be installed, and the system 
administrator’s assistance may be required for installation.  Users will also need to take time 
to familiarise themselves with the more complex interface than that presented by the 
website. 
3.5.4 Other possible applications 
The design of MetaPrint2D, placing the core calculation engine into a library independent of 
any user interface, means that many applications and interfaces beyond those described 
here can be developed.  The work undertaken in collaboration with the Bioclipse project has 
shown how MetaPrint2D can be integrated with other applications.  Similar work could be 
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carried out with chemical editors and electronic laboratory notebook systems, in order to 
make MetaPrint2D’s predictions more readily available to chemists. 
The potential to use MetaPrint2D for high-throughput virtual screening or as a component 
in a workflow has already been mentioned in connection with the command-line 
application.  This could also be achieved through direct integration of the MetaPrint2D 
library with a workflow engine, possibly leading to the development of a molecular 
descriptor based on the likelihoods of sites in a molecule being metabolised.  Anecdotal 
evidence from users of SPORCalc within AstraZeneca suggests that compounds with three or 
more highly likely sites of metabolism (scoring ‘red’ in the web interface’s traffic-light 
system) are highly metabolically labile, and potentially toxic.  Observations such as this 
could lead to MetaPrint2D’s integration with some sort of structural alerts or warning 
system. 
3.5.5 Licensing 
The MetaPrint2D library has been released as an Open Source project, hosted on the 
SourceForge community site (http://sourceforge.net/projects/metaprint2d/).  The code is 
published under the GNU Affero General Public License (AGPL).  This ensures that the 
MetaPrint2D software will be made as widely available as possible, and permits any 
individuals and organisations to freely use and modify the code to suit their needs, with the 
proviso that anyone wishing to ‘convey’ (distribute, or make available to others through a 
web service) copies of MetaPrint2D, or any derivative works, must also make available the 
source code containing their modifications under the terms of the AGPL.  This will ensure 
that future development of the MetaPrint2D library will benefit the whole community. 
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4. Evaluation and optimization of MetaPrint2D 
This chapter describes the evaluation and optimization that have been performed on 
MetaPrint2D.  The result of the assessment of MetaPrint2D’s reaction centre identification 
algorithms is reported.  A number of data pre-processing steps are proposed and their 
effects investigated, and the reliability of MetaPrint2D’s predictions analysed.  MetaPrint2D 
models generated from data on specific cytochrome P450 isoforms are also discussed, as is 
the quality of the available test data, and the results of MetaPrint2D’s evaluation have been 
compared to that reported for other site of metabolism prediction tools. 
4.1 Reaction centre identification 
In order to evaluate the reaction centre detection the results of an analysis of 300 randomly 
sampled transformations from the 2008.1 release of the Symyx® Metabolite database were 
manually inspected.  In order to do this a ‘debug’ application (shown in Figure 57) was 
created.  This displays the substrate and metabolite structures in two adjacent panels.  The 
MCS atoms and bonds are displayed in a solid colour, and the remainder of the structure is 
shown ‘greyed out’.  Atoms identified as reaction centres are also highlighted. 
 
Figure 57: Metabolite analyser debug viewer used to evaluate reaction centre 
identification.  The conserved structure and identified reaction centres are 
highlighted. 
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For eight of the selected transformations it was not possible to carry out any analysis as the 
metabolite structure was not specified in the Metabolite database.  Of the remaining 292 
transformations examined only two (0.7%) caused problems, with the conserved structure 
correctly identified in all the other cases.  The problem transformations are shown in Figure 
58. 
In the case of transformation RMTB00003542, we believe it is likely that the detected MCS is 
correct; however no confirmation of this is available from the Symyx® Metabolite database, 
since this entry does not contain any mapping annotations.  In the case of transformation 
RMTB00043645, however, the detected MCS is in error; the transformation is a 
demethylation, and the true MCS is shown in (b). 
This error results from the structure of the Metabolite database: each transformation 
record contains only a single substrate and metabolite molecule.  In the case of a reaction 
producing several products, there are can be a number of records in the database, one 
recording for each product, though many reactions only record the largest/major 
metabolite formed.  For the majority of demethylation reactions in the Metabolite database 
the fate of the methyl group is not reported. 
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MDLNUMBER: RMTB00003542 
 
MDLNUMBER: RMTB00043645 
(a) 
 
(b) 
 
Figure 58: Problem transformations identified during the evaluation of the reaction 
centre identification algorithm.  These are discussed in the paragraph above. 
4.2 Pre-processing of Symyx® Metabolite data 
Models for the SPORCalc metabolic site predictor were constructed using every 
transformation in the Symyx® Metabolite database.  During the development of 
MetaPrint2D a number of possible data pre-processing steps were identified, some or all of 
which were thought to potentially improve the quality of the models generated.  In order to 
determine whether any of the pre-processing steps should be used, models were trained 
applying each of these techniques and their performance evaluated and compared. 
4.2.1 Multi-step transformations 
Related transformations in the Symyx® Metabolite database are organised into ‘schemes’ 
organised around a parent compound, as illustrated in Figure 59.  
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Figure 59: Metabolic scheme MTB2, from the Symyx® Metabolite database, 2008.1.  
The database contains 17 transformation records in this scheme – 12 corresponding to 
the transformations shown by arrows above, and a further five representing the 
overall transformation from the parent compound to each of the second generation 
metabolites 2A-2E. 
The database contains a separate entry for each transformation in the scheme, e.g. P→1A 
(representing the transformation from the parent compound P to the first generation 
metabolite 1A), P→1J, 1A→2A, and also an additional entry for each final product not 
formed in a single step from the parent compound e.g. P→2A, P→2B.  When analysing the 
records representing the overall transformation of a multi-step reaction path, the changes 
can be so great that it becomes difficult to determine the conserved structure between the 
parent compound and the final metabolite, and hence determine the sites of metabolism.  
This is particularly true of longer pathways; the Metabolite database contains reaction 
schemes with pathways up to 13 steps deep. 
124 
 
Figure 60: The overall transformation resulting from a seven step metabolic pathway 
(MDLNUMBER: RMTB00005520).  It is not immediately obvious how the metabolite 
structure maps to that of the parent compound, or which atoms are sites of 
metabolism.  Manual inspection of the individual steps of the pathway has identified 
the conserved substructure, and this is highlighted in red. 
Inclusion of multi-step records in the construction of MetaPrint2D models could cause two 
further problems.  As illustrated by the multi-step transformation shown in Figure 61, atom 
environments found to be sites of metabolism in the overall transformation may not 
correspond to sites of metabolism in any of the individual steps making up the pathway.  
Additionally, inclusion of the extra transformations leads to double (or higher) counting of 
some reaction centre and substrate atom environments, distorting the model. 
 
Figure 61: Analysis of this overall transformation (MDLNUMBER: RMTB00052516) 
suggests the presence of sites of metabolism (highlighted red) at both ends of the 
parent compound.  However, inspection of the individual steps in the reaction scheme 
shows that hydrolysis of the reactive epoxide always occurs before the hydroxylation 
of the phenyl ring. 
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4.2.2 Per-transformation versus per-molecule 
There is a second means by which the generation of MetaPrint2D models from the 
transformations in the Symyx® Metabolite database can lead to double (and higher) 
counting of the atom environments and reaction centres in certain compounds.  This is 
through the repetition of substrate compounds for different transformations.  
Considering the seven first generation metabolites of the parent compound ‘P’ in the 
reaction scheme shown previously (Figure 59, page 123), those atoms never occurring at a 
reaction centre will be recorded as such seven times – once for each transformation.  The 
atom at the reaction centre for the transformation to ‘1K’ will be recorded once as occurring 
at a site of metabolism and six times as not occurring at a site of metabolism.  The atoms 
involved in the remaining 1-step transformations will each be recorded as occurring at a site 
of metabolism twice, and as not occurring at a site of metabolism five times.  If the 
multistep transformations directly between ‘P’ and ‘2A-E’ are included, as just discussed, 
then the picture becomes even more complicated.  This is illustrated in Figure 62. 
 
Figure 62: The sites of metabolism (highlighted red) from all the transformations of a 
compound (MDLNUMBER: MMTB00000002).  The letters adjacent to sites of 
metabolism indicate the products resulting from metabolism at that site. 
4.2.3 Symmetry 
A further consideration is the metabolism of molecules exhibiting symmetry.  In instances 
where a site of metabolism exists in a symmetrical region of a molecule, as illustrated in 
Figure 63, the occurrence counts for the environment of the atom at the site of metabolism 
are updated twice, once as occurring at a reaction centre, and once as not.  In fact, the 
metabolic transformations are equally likely to occur at the equivalent atoms. 
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Figure 63: An example of a compound (MDLNUMBER: MMTB00000002) with sites of 
metabolism (highlighted in red) occurring in a symmetrical region of a molecule.  The 
atoms marked with an asterisk are not recorded as sites of metabolism, despite being 
chemically identical to those from transformations on the opposite side of the ring. 
4.2.4 Duplicate transformations 
Since the metabolism of different parent compounds can produce a common metabolite, 
which may be metabolised further, and the Symyx® Metabolite database is organised into 
schemes structured around a parent compound, some transformations appear in the 
Metabolite database multiple times.  This raises the question of whether recording all 
reports of such transformation biases the model, and whether such transformations should 
be identified and only recorded a single time. 
It was considered that this repeated counting of some atom environments could distort the 
results, though it is possible that this duplication could actually improve the results, by 
increasing the weighting of regularly occurring environments. 
4.3 Evaluating metabolic site predictions 
4.3.1 Current approaches to evaluation 
A number of recent studies have included evaluations of the ability of various software tools 
to predict sites of metabolism on molecules e.g. (218,235,234,276).  Two main approaches 
to assessing performance have been followed: a qualitative analysis via the visual inspection 
of a tool’s output compared to the known sites of metabolism of a molecule and a 
quantitative analysis.  The quantitative analysis reports the percentage of molecules for 
which the highest ranked predicted site of metabolism is an experimentally observed site, 
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and the percentage of molecules for which at least one of the top three ranked sites is an 
experimentally observed site of metabolism. 
In the evaluation of MetaPrint2D the percentage occurrence of experimentally observed 
sites of metabolism in the top one and top three ranked hits has been calculated, in order to 
enable some degree of comparison to previous studies; however these commonly used test 
metrics contain some intrinsic flaws.  The expected values of the test metrics are dependent 
on both the sizes of the molecules under investigation, and the number of sites of 
metabolism each possesses.  This leads to a bias towards higher test scores for studies on 
smaller molecules or molecules with a greater number of sites of metabolism. 
Figure 64(a) shows a box plot of the distribution of sizes of substrate molecules in the 
Metabolite database, and the wide variation in size of metabolised compounds is clearly 
visible.  Considering a molecule with ten atoms, metabolised at a single site; ranking the 
atoms at random there is a 10% chance of metabolism occurring at the highest ranked site, 
and a 30% chance of it occurring at one of the top three ranked sites.  In comparison, for a 
molecule with 20 atoms, also metabolised at a single site, the chances of metabolism 
occurring in the top one or top three randomly ranked site are 5% and 15%, respectively – 
half that of the molecule with ten atoms. 
The number of sites at which metabolism has been reported to occur can also vary widely 
between molecules, as illustrated by the compounds in Figure 64(b).  In benzopyrene 
metabolic transformations have been reported to occur at 60% of the non-hydrogen sites in 
the molecule, while for 5-chloro-2-mercaptobenzothiazole metabolism has only been 
reported at a single site – meaning there would be only a 9% chance of selecting the correct 
site at random. 
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(a) 
 
(b) 
 
 
Benzopyrene 
20 atoms 
12 reported sites of metabolism 
5-Chloro-2-mercaptobenzothiazole 
11 atoms 
1 reported site of metabolism 
Figure 64: (a) Box plot showing the distribution of sizes (heavy atom count – i.e. the 
number of non-hydrogen atoms in the molecule) of the substrate molecule on version 
2008.1 of the Symyx® Metabolite database.  Outliers, as calculated using the 
boxplot.stats method from the statistical package R (108), with default 
parameters, are not shown.  (b) Both the size of molecules and the number of sites at 
which they are metabolised (highlighted in red) can vary widely. 
4.3.2 Area under the ROC curve-based performance measure 
In order to overcome these biases, an alternative method of evaluating the performance of 
metabolic site prediction tools was proposed.  This approach, based on the receiver 
operating characteristic (ROC) curve (277), is independent of both the size of molecules and 
their numbers of metabolic sites. 
0 10 20 30 40 50 60
heavy atom count
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Receiver operating characteristic (ROC) curves 
Receiver operating characteristic curves provide a technique for visualising a classifier’s 
performance, depicting the trade-off between hit rates, and rates of false positives.  ROC 
curves were first developed during the Second World War for the analysis of radar signals, 
where it was important to determine whether a signal was from an enemy plane, or due to 
noise, and have long been used in signal detection theory.  In recent years ROC curves have 
been applied in a wide range of fields such as medical diagnostics and machine learning. 
A ROC curve consists of a plot of the True Positive Rate versus the False Positive Rate as the 
threshold at which the classifier discriminates between positives and negatives is varied. 
 
Figure 65: Example ROC curves for three different cases.  The curve in orange is that 
for a classifier that performs perfectly, and that in blue for one that is completely 
random.  In red is the more usual outcome – predictions that are better than random, 
but not perfect. 
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There are two major advantages of using ROC curves over common measures of classifier 
performance, such as accuracy, sensitivity, specificity, precision and recall.  Firstly, through 
use of the relative scores produced by the classifier, ROC curves can measure the ability of 
the classifier to distinguish between positive and negative instances without having to be 
calibrated to produce good probability estimates, and secondly, they are insensitive to the 
relative number of positive and negative instances. 
The area under the ROC curve (AUC) is a commonly used summary statistic, used to 
represent the 2-dimensional curve in a single number, and enable simple comparisons 
between classifiers.  The AUC varies from 0.0 to 1.0, with 1.0 indicating that the classifier 
discriminates between positive and negative instances perfectly, 0.5 indicating that the 
performance is equivalent to randomly assigning classes, and a value of less than 0.5 
indicating that the classifier is generating negative classifications (so multiplying by -1 gives 
a classification).  The AUC has been shown to be equal to the probability that a randomly 
selected positive instance will be ranked higher than a randomly selected negative instance, 
which is the equivalent to the nonparametric Wilcoxon rank test (278,279). 
Evaluating site of metabolism prediction using ROC curves 
Prediction of the sites of metabolism in a molecule can be treated as a binary classification 
problem: each atomic position in a molecule either is or is not a site of metabolism.  Each 
individual molecule from a test set presents an independent classification problem, and the 
ability of the prediction tool to discriminate between its sites of metabolism and atomic 
sites that are not metabolised can be assessed. 
If an AUC value is determined for each molecule in the test set (giving a measure of the 
performance of the method under evaluation when identifying the sites of metabolism in 
that molecule) then the overall performance of the tool can then be evaluated by examining 
the distribution of AUC values generated using standard statistical techniques such as 
averages and variance (278). 
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4.3.3 Generation of test data 
Selection of test data 
In order to carry out an unbiased evaluation of a prediction tool it is important that the 
evaluation is carried out using data not used in the development of the method.  This is 
often achieved through techniques such as cross-validation.  Since access to a series of 
annual releases of the Symyx® Metabolite database was available while this work was being 
carried out, an obvious alternative to cross-validation presented itself: training MetaPrint2D 
using data from one release of the Metabolite database, and testing using the data added to 
subsequent releases.  This has the added advantage of simulating a likely usage scenario, 
whereby MetaPrint2D is trained using all available data and then used by chemists to 
investigate the new compounds they are working with.  This evaluation scheme also 
facilitates investigation of the robustness of MetaPrint2D to updates of the Metabolite 
database. 
Many compounds within a single metabolic scheme exhibit only relatively minor variation.  
In order to ensure that the test data contained a diverse selection of compounds, and was 
not biased by clusters of very similar compounds, the selection of test compounds was 
restricted to new parent molecules.  This means that new molecules present either in later 
generations of new metabolic schemes, or newly identified metabolites in previously known 
schemes are excluded from the evaluation. 
The number of compounds in each test set is shown in Table 8.  
Release Novel parent compounds Containing A/E 
2006.1 601 498 
2007.1 546 461 
2008.1 509 408 
Table 8: The number of novel parent compounds identified in each release of the 
Metabolite database, and the number of those which contain phase I additions and/or 
eliminations (labelled ‘Containing A/E’ in the table above). 
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Processing of test data 
In order to identify all the sites of metabolism of a test molecule, all of the single step 
transformations in which it appears as the substrate were identified, and their reaction 
centres mapped onto a single copy of the molecule.  Symmetrical points in the molecule 
were also identified, and reaction centres mapped between equivalent atom positions, 
producing a complete set of reaction centres for the compound.  This process is illustrated 
for the metabolic sites of Flavanone in Figure 66. 
(a) 
 
 
 
  
(b) 
 
(c) 
 
Figure 66: (a) Four of the metabolic transformations of Flavanone (280), with the 
reaction centres marked on the parent compound; (b) Flavanone with reaction centres 
from all four transformations merged; and (c) with symmetry mappings applied. 
4.4 Evaluation of MetaPrint2D and the effects of data pre-
processing options 
In order to evaluate the performance of MetaPrint2D, and the effects of the various pre-
processing options proposed, a number of MetaPrint2D models have been generated and 
their performance evaluated.  Models have been generated from the data contained in each 
of the 2005.1, 2006.1 and 2007.1 releases of the Symyx® Metabolite database.  The 
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predictions by each model have been evaluated against the transformations of novel parent 
compounds from subsequent releases of the Metabolite database.  This process has been 
repeated for each of the pre-processing options discussed above. 
Details of the models generated and the evaluation metrics calculated are given in Table 9 
and Table 10, and the results of this evaluation are presented below. 
 
Model Description 
all Model constructed using all transformations 
nomulti Multi-step transformation records were excluded 
nodup Duplicate transformations were excluded 
sym Symmetry mappings were applied 
merge All transformations for each compound were merged 
hasrc Molecules with no phase I reaction centres were excluded 
Table 9: The MetaPrint2D models constructed. 
 
Name Description 
Top 1 % of molecules for which highest rank atom is a site of metabolism 
Top 3 % of molecules for which at least one of the three highest ranked 
atoms is a site of metabolism 
Mean AUC Mean area under the ROC curve 
Median AUC Median area under the ROC curve 
Table 10: The evaluation metrics calculated. 
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4.4.1 Results 
Results are presented to three significant figures in order to illustrate the small degree of 
variation.  The significance, or otherwise, of this variation is discussed on page 135. 
Training data: 2005.1 
Model 
Top 1 Top 3 Mean AUC Median AUC 
2006 2007 2008 2006 2007 2008 2006 2007 2008 2006 2007 2008 
all 60.2% 59.7% 58.8% 76.1% 77.0% 75.5% 0.766 0.780 0.792 0.903 0.895 0.882 
nomulti 61.0% 60.3% 60.3% 76.5% 77.9% 75.7% 0.770 0.785 0.794 0.920 0.889 0.892 
nodup 60.6% 59.7% 59.8% 76.5% 77.7% 75.7% 0.767 0.781 0.792 0.917 0.903 0.880 
sym 60.0% 58.4% 59.3% 75.5% 75.5% 76.0% 0.764 0.779 0.791 0.899 0.885 0.887 
merge 57.0% 57.5% 59.3% 75.3% 77.9% 76.5% 0.764 0.784 0.791 0.891 0.901 0.893 
hasrc 59.4% 61.2% 59.8% 76.3% 77.2% 74.3% 0.767 0.781 0.787 0.918 0.895 0.875 
Table 11: These models were trained using data from the 2005.1 release of the 
Metabolite database, and evaluated using novel parent compounds from the 2006.1, 
2007.1 and 2008.1 releases. 
Training data: 2006.1 
Model 
Top 1 Top 3 Mean AUC Median AUC 
2007 2008 2007 2008 2007 2008 2007 2008 
all 59.0% 59.6% 78.1% 77.0% 0.781 0.799 0.896 0.889 
nomulti 59.9% 59.6% 77.4% 76.0% 0.785 0.802 0.889 0.891 
nodup 59.2% 60.0% 78.3% 77.0% 0.781 0.800 0.901 0.897 
sym 58.1% 59.3% 75.5% 76.5% 0.779 0.799 0.885 0.893 
merge 58.8% 59.8% 77.7% 76.0% 0.784 0.799 0.904 0.897 
hasrc 60.7% 59.8% 77.7% 76.0% 0.781 0.794 0.900 0.881 
Table 12: These models were trained using data from the 2006.1 release of the 
Metabolite database, and evaluated using novel parent compounds from the 2007.1 
and 2008.1 releases. 
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Training data: 2007.1 
Model 
 Top 1 Top 3 
Mean 
AUC 
Median 
AUC 
 2008 2008 2008 2008 
all  59.6% 77.2% 0.804 0.900 
nomulti  59.3% 76.`5% 0.805 0.902 
nodup  60.3% 77.2% 0.803 0.900 
sym  59.6% 76.7% 0.803 0.900 
merge  60.0% 75.7% 0.803 0.913 
hasrc  60.5% 76.2% 0.799 0.892 
Table 13: These models were trained using data from the 2007.1 release of the 
Metabolite database, and evaluated using novel parent compounds from the 2008.1 
release. 
4.5 Analysis of MetaPrint2D’s performance 
The performance of MetaPrint2D’s predictions changes very little with the pre-processing 
options discussed.  Wilcoxon signed rank tests (281,282) have been carried out to determine 
whether there is any significant variation between the distributions of AUC scores generated 
from models constructed using all available data, and those constructed with each of the 
pre-processing options.  Wilcoxon’s signed rank test is used in place of the paired Student's 
t-test since the distribution of AUC scores is not normally distributed, as can clearly be seen 
in Figure 67 on page 137.  The results of these tests are presented in Table 14 below.  The 
only pre-processing option to consistently improve the performance of the model (p-values 
much lower than 0.05) is the exclusion of multi-step transformations from the training data, 
and this only produces a very small improvement in the AUC (~0.01). 
There is also little variation between predictions using models generated from different 
releases of the Metabolite database; the quality of MetaPrint2D’s predictions on test data 
from the 2008.1 Metabolite database shows little variation between models trained using 
the 2005.1, 2006.1 or 2007.1 releases of the database. 
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training testing nomulti nodup sym merge hasrc 
2005 
2006 
2.25E-08 0.00274 0.187 0.204 0.470 
Δ =0.011 Δ =0.0083    
2007 
1.37E-07 0.741 0.0620 0.236 0.553 
Δ =0.011     
2008 
0.00463 0.371 0.192 0.827 0.0069 
Δ =0.0079    Δ =-0.0081 
2006 
2007 
1.69E-06 0.392 0.00138 0.282 0.545 
Δ =0.0099  Δ =0.0068   
2008 
0.00030 0.0872 0.352 0.967 0.0910 
Δ =0.0093     
2007 2008 
0.00325 0.446 0.0178 0.831 0.00579 
Δ =0.0079  Δ =0.0064  Δ =0.0080 
Table 14:  p-values for Wilcoxon signed rank tests comparing the distributions of AUC 
scores generated from models constructed using all data, and models constructed 
using each of the pre-processing options.  Variations between distributions that are 
significant at the 95% confidence level (p-value < 0.05) are highlighted in bold, and the 
shift in the distribution’s median (Δ) given. 
4.5.1 Distribution of MetaPrint2D’s performance scores 
The distribution of area under the ROC curve (AUC) scores for the novel compounds from 
the 2006.1 database tested on a model constructed using the 2005.1 database, are shown in 
Figure 67 below.  This is representative of the distributions of the other combinations of 
data/models.  Examination of the distribution of AUC scores shows that in the majority of 
cases predictions are very accurate, with AUC scores in the range 0.95-1.00, however there 
is a long tail to the distribution, with MetaPrint2D performing much worse than random 
(AUC < 0.5) in a small number of instances.   
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Figure 67: Histogram showing the distribution of AUC values generated using a model 
build on all compounds from Metabolite database 2005.1, and test compounds from 
2006.1.  The distribution is highly skewed towards higher values, indicating very good 
predictions were made for the majority of test compounds. 
The molecules with the very lowest AUC scores have been identified and a selection of these 
is shown below.  On examination of the molecules’ transformations, a trend is apparent: the 
sites of metabolism occur at atoms occupying novel environments (atom environments not 
represented in the training data), so are assigned a normalized occurrence ratio of zero, but 
there are other environments within the molecule that have been found to occur at reaction 
centres in the training data, so receive a non-zero normalized occurrence ratio. 
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MDLNUMBER: MMTB00051019; AUC = 0.0625 
 
Searching the training data for the atom environment at the reaction centre in this transformation 
did not produce any hits, indicating that the environment is completely novel to the model 
MDLNUMBER: MMTB00052513; AUC = 0.125 
 
Searching the training data for the reaction centre fragment did not produce any hits; the phenyl 
ring, however, is found in many records in the Symyx(R) Metabolite database, and is observed to 
undergo a variety of transformations. 
MDLNUMBER: MMTB00050992; AUC = 0.1538 
 
Searching the training data for the reaction centre fragment produced only three hits, none of which 
underwent a metabolic transformation centred anywhere within this region of the compound. 
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MDLNUMBER: MMTB00044960; AUC = 0.167 
 
Searching the training data for any molecules containing selenium produced 51 hits, none of which 
occupied a remotely similar atom environment. 
MDLNUMBER: MMTB00050971; AUTOC = 0.167 
 
Searching the training data for other molecules containing the reaction centre fragment revealed 
only a single hit, which undergoes a completely different transformation, centred on an atom in a 
different atom environment: 
 
Figure 68: Examples of molecules for which MetaPrint2D’s predictions had the lowest 
AUC scores. 
4.5.2 Novel atom environments 
Given that the molecules for which MetaPrint2D generated the worst predictions all had 
some atoms occupying novel atom environments the relationship between the proportion 
of novel atom environments in a molecule, and the reliability of MetaPrint2D’s site of 
metabolism predictions has been investigated. 
In order to generate as detailed an analysis as possible, all 1367 novel parent compounds 
from the 2006.1, 2007.1 and 2008.1 Symyx® Metabolite databases have been collated, and 
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their sites of metabolism predicted using a MetaPrint2D model trained on the 2005.1 
release of the Metabolite database.  For each molecule the proportion of the atoms that 
occupy novel atom environments has been recorded.  The area under the ROC curve (AUC) 
statistics calculated for the test molecules have been binned according to the proportion of 
novel atom environments in the molecule.  The results of this are shown in Figure 69, below. 
Analysis of Figure 69, below, shows that the sites of metabolism of molecules in which no 
atoms occupy novel atom environments are predicted well.  The quality of predictions 
clearly decreases as the proportion of atoms with a novel environment increases.  When all 
atoms in a molecule are in novel atom environments performance of the classifier is 
essentially random (AUC=0.5).  This is to be expected, since atoms in a novel environment 
will all be assigned the same normalised occurrence ratio (nOR=0.0). 
The greatest uncertainty in the quality of prediction is found when between a third and a 
half of the molecule’s atoms are occupying novel atom environments.  This is again due to 
the novel environments being assigned a normalised occurrence ratio of 0.0.  In instances 
where the novel environment is not found at a reaction centre accurate predictions for that 
molecule are still possible.  When the novel environment is found at a reaction centre, 
however, the low score assigned means that the accuracy of prediction for that molecule 
will be very low, since the majority of the other atoms in the molecule will have a higher 
(than zero) normalised occurrence ratio, even when the likelihood of their being a site of 
metabolism is very low. 
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Figure 69: Graph showing the variation in performance of MetaPrint2D with the 
proportion of atoms in query structures occupying novel environments.  Predictions 
on 1367 novel parent molecules from the 2006.1, 2007.1 and 2008.1 releases of the 
Metabolite databases were made using a model trained on data from the 2005.1 
release.  AUC statistics and the proportion of novel atoms in the query compound 
were calculated for each molecule (novel atoms = 0.0 means that no atoms in the 
compound are in novel atom environments, while novel atoms = 1.0 indicated that all 
atoms in the compound occupy novel atom environments).  The data was binned 
according to the novel atom proportion, split at boundaries 0.05, 0.15, 0.25...0.85, 
0.95.  For each bin the mean, median, first and third quartile (Q1 and Q3 in the figure 
above) values are plotted, and locally weighted scatter plot smoothing (LOESS) lines 
have been fitted using the loess.smooth function from the statistical package R 
(108), with default parameters. 
Ideally, atom environments that have been observed in the training data and found to occur 
only very rarely, or never, at reaction centres should receive lower scores than atom 
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environments for which no information is available.  To facilitate this MetaPrint2D was been 
modified so that novel atom environments are assigned the mean normalised occurrence 
ratio of all the non-novel atoms from a sample set of test data (nOR=0.159), and the above 
analysis repeated.  The result of this change is shown in Figure 70, below. 
As a result of this modification the position of the 75-percentile line (Q3) barely changed, 
however the mean, median and 25-percentile (Q1) AUC all increased, indicating that this 
modification has resulted in fewer badly predicted molecules. 
 
Figure 70: Graph showing the variation in performance of MetaPrint2D with the 
proportion of atoms in query structures occupying novel environments.  Dotted lines 
taken from Figure 69, above, generated when novel atom environments are assigned 
a normalised occurrence ratio of 0.0; solid lines have been generated in the same 
manner, but with novel atom environments assigned the mean normalised occurrence 
ratio of the data set: 0.159. 
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The distribution showing how the performance of MetaPrint2D varies with the degree to 
which a molecule fits the descriptor space described by MetaPrint2D’s model can be used to 
estimate the reliability of a prediction generated by MetaPrint2D.  Figure 71, below, shows 
the distribution of novel atoms in the molecules from the test data.  Almost all of the atom 
environments in the majority of compounds are well characterised by the model. 
 
Figure 71: The distribution of proportions of novel atoms among test molecules. 
4.6 Speed of predictions 
The speed of MetaPrint2D has been assessed, through predictions of the sites of 
metabolism of 232 common drug molecules (mean heavy atom count: 20.9 atoms).  The 
total time taken to perform the calculations (including loading the model and assigning 
SYBYL® atom types) averaged 6.81 seconds over five runs, which is equivalent to less than 
30ms per molecule. 
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Run times 
Mean time 
(seconds) 
Mean time 
per molecule 
(milliseconds) t1/s t2/s t3/s t4/s t5/s 
6.81 6.86 6.80 6.81 6.79 6.81 29.37 
Figure 72: Time taken for MetaPrint2D to generate site of metabolism predictions for 
232 common drug molecules (recorded on a Dell Inspiron 6400 laptop Intel Core 2 
T5300 @ 1.73GHz; 3.24GB RAM).  Timings recorded on five independent runs, and 
averaged. 
4.7 Parameterization of MetaPrint2D 
SPORCalc provided the following pre-configured parameterizations, together with the 
option to set a custom parameterization: 
Setting 
Similarity 
threshold 
Exact 
levels 
Level weightings 
1 2 3 4 5 6 
Loose 1.0 2 - - 1.0 0.75 0.50 0.25 
Default 0.5 3 - - - 0.75 0.50 0.25 
Strict 0.1 4 - - - - 0.5 0.25 
Figure 73: The pre-configured parameterization of SPORCalc. 
The initial evaluations of MetaPrint2D were performed using this parameterization, and the 
effects of varying the parameterisation have subsequently been explored.  Early 
investigations found that there were very few atom environments being discarded due to 
their exceeding the similarity threshold; the major source of variation between 
parameterizations lies in the number of number of levels to which exact fingerprint matches 
are required. 
Figure 74 shows how the distribution of AUC scores changes as the number of fingerprint 
levels to exactly match is varied. 
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Figure 74: Box plots showing the changes in distribution of AUC scores for 
MetaPrint2D predictions as the number of fingerprint levels to match exactly is varied.  
Outliers, as calculated using the boxplot.stats method from the statistical package 
R (108), with default parameters, are not shown. 
In general the best results (highest AUC scores) are found when the first two or three 
fingerprint levels are exactly matched.  Exact matching to three levels produces slightly 
more very well predicted molecules than exact matching to two levels (the 4th quartile is 
higher), but also has more badly predicted molecules (the 1st quartile extends lower). 
The kernel density plots in Figure 75 show the AUC distributions in more detail. 
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Figure 75: Kernel density plots showing the changes in distribution of AUC scores for 
MetaPrint2D predictions as the number of fingerprint levels to match exactly is varied. 
When a high number of levels of exact matching are required (n=5 and n=6) the distribution 
is predominantly bimodal, with peaks around AUC=0.5 and 1.0.  The peak at AUC=1.0 is due 
to molecules well represented by the model; due to the specific nature of searches carried 
out using these settings, very good results are generated for such molecules.  However, for 
many of the atom environments in the test data such a search requiring exact matches to so 
many fingerprint levels returns little or no data, and the classifier is unable to discriminate 
between such atoms.  This leads to an AUC of around 0.5.  There is also a third, smaller, 
peak in the AUC=0.6–0.7 region of the distribution.  This is due to atoms occupying 
environments that sometimes occur at sites of metabolism; typically this arises from regions 
of a molecule which remain unaltered during some steps of a metabolic scheme, while 
containing a centre of metabolism in other steps. 
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As the number of levels that must be matched exactly is reduced the number of molecules 
for which MetaPrint2D makes good predictions increases, and reaches a maximum when 
two or three levels of exact match are required. 
4.8 Isoform specific models 
While there are a large number of cytochrome P450 isoforms, only a relatively small number 
account for the majority of known CYP450 catalysed xenobiotic transformations.  A small 
proportion of the transformations in the Symyx® Metabolite database have annotations 
indicating which, if any, cytochrome P450 isoforms catalyse the transformation.  The 2008.1 
release of the database contains 29602 metabolic transformations observed to occur in 
humans.  Of these only 3839 (13.0%) are annotated with a specific cytochrome P450 
isoform.  The reported CYP450 substrates are shared between over 150 isoforms and their 
variants.  However, for the majority of CYP450 isoforms only a few substrates are reported.  
In the 2008.1 Metabolite database only eleven isoforms have one hundred or more 
reported substrates.  These are listed in Table 15, below. 
Isoform Substrate count 
CYP3A4 1019 
CYP1A2 607 
CYP2D6 559 
CYP2C9 470 
CYP2E1 412 
CYP2C19 401 
CYP2B6 314 
CYP1A1 295 
CYP2A6 287 
CYP2C8 265 
CYP3A5 201 
Table 15: The eleven CYP450 isoforms with more than one hundred substrates 
reported in the 2008.1 release of the Symyx® Metabolite database. 
Separate MetaPrint2D models have been constructed for each of these isoforms, and their 
performance assessed.  Due to the much smaller numbers of substrate molecules available 
than for the models described earlier, a different assessment strategy was adopted.  
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Cytochrome P450 3A4, which has the largest number of reported substrates, has around 
one hundred new substrates reported with each database release; however, the numbers of 
the other cytochromes P450 are smaller.  This means that the previous approach of 
constructing models using all the data available in a particular release of the Symyx® 
Metabolite database and assessing the performance of that model using data added in a 
subsequent release of the database would leave very small quantities of data available for 
testing. 
Instead, the models have been generated and evaluated using Monte Carlo cross-validation 
(283).  For each CYP450 isoform 20 modelling runs were performed.  In each run 80% of the 
isoform’s substrates were randomly selected to be used to construct the model, the 
performance of which was tested using the remaining 20% of the substrates.  The same 
statistics as used previously – percentage correct in top one and top three hits, and the 
mean and median areas under the ROC curve – were generated for each set of test data, 
and the values averaged over the 20 runs. 
Cytochrome 
P450 Isoform 
Number of 
Substrates 
% Top 1 % Top 3 
Mean 
AUC 
Median 
AUC 
% Novel 
CYP3A4 1019 56.0 (3.3) 71.5 (3.2) 0.816 (0.016) 0.904 (0.020) 16.4 
CYP1A2 607 56.8 (4.8) 75.1 (3.5) 0.795 (0.024) 0.859 (0.033) 22.9 
CYP2D6 559 64.5 (4.0) 78.8 (2.9) 0.836 (0.018) 0.938 (0.019) 22.8 
CYP2C9 470 59.4 (4.7) 74.2 (4.5) 0.802 (0.026) 0.899 (0.038) 23.5 
CYP2E1 412 57.5 (5.3) 78.0 (3.4) 0.772 (0.028) 0.840 (0.045) 27.5 
CYP2C19 401 59.1 (4.5) 74.8 (4.4) 0.813 (0.028) 0.906 (0.043) 24.5 
CYP2B6 314 59.5 (7.1) 73.9 (6.6) 0.790 (0.034) 0.869 (0.066) 27.5 
CYP1A1 295 49.2 (6.3) 66.9 (5.9) 0.764 (0.022) 0.805 (0.041) 26.3 
CYP2A6 287 54.7 (6.9) 70.4 (5.3) 0.758 (0.028) 0.820 (0.050) 30.8 
CYP2C8 265 52.7 (6.4) 68.8 (5.6) 0.772 (0.030) 0.854 (0.041) 29.2 
CYP3A5 201 49.1 (8.2) 67.1 (7.3) 0.778 (0.036) 0.815 (0.080) 25.9 
Table 16: Performance of cytochrome P450 Isoform specific models.  The results are 
the mean of 20 Monte Carlo cross-validation runs, with standard deviations of each 
value given in parentheses. 
The performance of these models (presented in Table 16) shows little variation from that of 
the global models reported earlier.  The small standard deviations of the performance 
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scores, indicates that the results showed little variation between cross-validation runs.  As a 
result of the considerably smaller data sets a much greater number of atom environments 
have little or no data in the training set.  In the earlier models only 3.5% of atoms in test 
compounds occupied novel atom environments, but for the isoform specific models 16-30% 
of the atoms occupy environments with little or no data. 
In order to explore the specificity of the isoform specific models the models generated for 
each CYP450 isoform have been used to predict the sites of metabolism of the substrates of 
each of the other isoforms. Table 17 contains the mean area under the ROC curve results for 
each of these experiments.  The isoforms are listed in order of decreasing data quantity.  
Initial inspection appears to show a trend in the performance of each test set decreasing 
with the model size.  This is confirmed by statistical testing; Pearson’s correlation tests on 
the performance of each test set against the natural logarithm of the number of substrates 
used to generate the models give correlation coefficients in the range 0.750 – 0.898, 
indicating a positive correlation between the two, at the 95% confidence level, for all 
isoforms.  This correlation is clearly visible in Figure 76, below. 
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CYP3A4 0.816 0.882 0.900 0.906 0.859 0.910 0.925 0.874 0.914 0.918 0.962 
CYP1A2 0.783 0.795 0.871 0.867 0.847 0.870 0.898 0.899 0.897 0.898 0.810 
CYP2D6 0.767 0.820 0.836 0.866 0.821 0.867 0.860 0.808 0.854 0.852 0.789 
CYP2C9 0.779 0.807 0.872 0.802 0.822 0.887 0.846 0.791 0.843 0.894 0.793 
CYP2E1 0.734 0.807 0.829 0.813 0.772 0.810 0.865 0.822 0.882 0.841 0.742 
CYP2C19 0.753 0.792 0.854 0.846 0.790 0.813 0.823 0.760 0.831 0.871 0.764 
CYP2B6 0.741 0.800 0.810 0.799 0.813 0.820 0.790 0.806 0.853 0.845 0.785 
CYP1A1 0.704 0.783 0.780 0.755 0.761 0.750 0.800 0.764 0.791 0.789 0.778 
CYP2A6 0.737 0.804 0.814 0.808 0.832 0.820 0.850 0.821 0.758 0.850 0.762 
CYP2C8 0.726 0.778 0.800 0.811 0.771 0.831 0.820 0.778 0.815 0.772 0.761 
CYP3A5 0.695 0.684 0.701 0.680 0.670 0.694 0.718 0.731 0.704 0.733 0.778 
Table 17: The mean AUC performance of models trained on substrates metabolised by one CYP450 isoform on predicting sites of 
metabolism of substrates of other isoforms.  The diagonal cells, highlighted, show the cross-validated performance of each model, from 
Table 16. 
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Figure 76: Performance predicting sites of metabolism of CYP2B6 substrates by 
models trained on the substrates of other isoforms plotted against the natural 
logarithm of the numbers of substrates used to build the model.  The data has a 
correlation coefficient of 0.817.  Analysis of substrates of other CYP450 isoforms 
shows a similar correlation. 
These results show that MetaPrint2D models trained using the substrates of one CYP450 
isoform can predict the sites of metabolism of substrates of other isoforms as well as, or in 
some cases better than, other substrates of the isoform on which the model was developed.  
This shows that there is a fairly small variation in the specificity of the different CYP450 
isoforms, and the effects of this variation are small enough to be masked by the uncertainty 
in the model.  Given how small a quantity of data is available for each CYP450 isoform, and 
that the various isoforms catalyse the same types of reactions, differing mainly in the size 
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and shape of their binding pocket and hence which compounds they are able to metabolise, 
it is not too surprising that the inclusion of additional data improves the discrimination 
between potential sites of metabolism, even if it is from molecules metabolised by a 
different isoform. 
4.9 Comparison with other tools 
Table 18 shows the reported performances of several site of metabolism predictions 
methods. 
Isoform  SPORCalc MetaSite MetaGlide QMBO Scientist 
CYP2C9 
 
 
55% / 81% a 
49% / 87% b 
70% / 91% a 
53% / 60% b 
83%, 84% c 
33% / 67% a 
42% / 79% b 
58% / 84% a 
53% / 82% b 
49% / 81% a 
70% / 88% b 
CYP3A4 
 
 
55% / 81% a 
49% / 87% b 
61% / 87% a 
49% / 74% b 
90%, 86% c 
41% / 72% d 
21% / 40% e 
39% / 65% a 
45% / 71% b 
58% / 84% a 
51% / 87% b 
49% / 81% a 
70% / 88% b 
CYP2D6   62%, 85% c    
Table 18: Performance of selected site of metabolism prediction methods reported in 
other studies.  SPORCalc is the in-house version running at AstraZeneca.  MetaSite is a 
commercial offering.  MetaGlide makes predictions based on docking using Glide.  
QMBO is a quantum mechanical method based on hydrogen abstraction energy.  
Finally the predictions of a biotransformation scientist were included in one study.  
Sources of data:  (a) Afzelius et al. (218) public data set, % top 1 and top 3 hits contain 
site of metabolism; (b) Afzelius et al. (218) in-house data set, predictions are centred 
on functional groups rather than atoms, % top 1 and top 3 hits contain site of 
metabolism; (c) Cruciani et al. (276) % correct prediction in top 2 hits from two in-
house data sets reported; (d) Zhou et al. (234) % top 1 and top 3 hits with reactivity 
on; (e) Zhou et al.  (234) % top 1 and top 3 hits with reactivity off. 
The results of MetaPrint2D’s evaluation, reported above, are similar to these results.  Direct 
comparison is difficult since it is apparent that the reported performance of a method varies 
considerably with the dataset used for the evaluation. 
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4.10  Accuracy of the test data 
The reliability of the analysis of site of metabolism predictions described here depends on 
the assumption that all of the sites of metabolism for a molecule are reported.  This is also 
an issue with regards to the quality of the models constructed.  Analysis of the relationship 
between the proportion of sites in a molecule at which metabolism is found to occur, and 
the year in which metabolic studies on the compound were first reported (Figure 77) shows 
a weak but clear trend towards a smaller proportion of more recently reported molecules 
being found to be sites of metabolism.  This suggests that the metabolic profiles of more 
recently studied compounds may not yet be fully characterised, though it could be the case 
that there has been a tendency for those substrates undergoing a greater variety of 
metabolic transformations to have been identified earlier. 
 
Figure 77: There is a weak but clear trend for more recently studied molecules to have 
a lower proportion of their structure reported to be sites of metabolism. 
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This trend has a Pearson’s product-moment correlation coefficient of -0.543, which 
hypothesis testing (H0: ρ = 0, p = 0.003) indicates is statistically significant. 
Figure 78 shows a plot of the mean number of sites of metabolism identified in a molecule 
against the number of heavy (non-hydrogen) atoms it contains.  At the extremes of high and 
low heavy atom counts there is considerable variation in the mean number of sites of 
metabolism, which can be accounted for by the low number of compounds of those sizes.  
For the molecule sizes with a considerable amount of data available (the data from around 
10-40 heavy atoms) there is very little variation in the mean number of sites of metabolism 
per molecule, in spite of an almost quadrupling in molecule size. 
 
Figure 78: Red: The mean number of sites of metabolism of molecules of each size.  
Blue (scale not shown): Regression line indicating the number of molecules of each 
size.  The number of sites of metabolism identified remains fairly constant, 
irrespective of the size of the molecule; for molecule with more than around 40 heavy 
atoms there is too little data to draw any conclusions. 
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This suggests that the sites of metabolism of larger compounds could be under-reported.  It 
seems likely that the majority of studies are reporting only the two most major metabolites 
detected; it is possible that once two metabolites have been identified investigation of a 
compound ceases. 
4.11 Conclusions 
Chapters 3 and 4 have reported the development and evaluation of MetaPrint2D – a new 
tool for the prediction of sites of xenobiotic metabolism.  MetaPrint2D has been made 
freely available as an Open Source library, meaning anyone can develop applications making 
use of it, and future improvements should feed back into the project.  Three interfaces to 
the MetaPrint2D library have been provided, suiting a variety of use cases; MetaPrint2D is 
accessible through a website run from the Chemistry Department at the University of 
Cambridge, through integration with the Bioclipse platform, and as a simple command-line 
application. 
The data-mining approach to site of metabolism prediction used by MetaPrint2D allows 
predictions to be made on tens of structures per second, on a regular desktop PC.  This is 
much faster than other comparable tools, and means that for the first time chemists using a 
tool such as Bioclipse will be able to investigate how the likely sites of metabolism of a 
molecule change as they make modifications to its structure in real time.  MetaPrint2D’s 
speed will also enable the inclusion of site of metabolism predictions in high-throughput 
virtual screening programmes. 
MetaPrint2D has undergone one of the most extensive evaluations reported for any site of 
metabolism prediction tools, with predictions tested on around 1200 substrates.  In the 
course of this evaluation a novel ROC curve-based method for evaluating the performance 
of site of metabolism predictions has been proposed, which overcomes the biases inherent 
to the evaluation metrics currently used. 
The evaluation of MetaPrint2D demonstrated the stability of the model to updates of the 
training data.  It has also demonstrated how the model’s applicability to a query compound 
can be straightforwardly estimated from the proportion of sites within the molecule for 
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which little or no data is available from the training database, and that this can be used to 
assign a degree of confidence to the model’s predictions. 
There are some limitations to MetaPrint2D’s current approach to site of metabolism 
prediction: stereochemistry is ignored, as are 3-dimensional effects.  Despite this, 
MetaPrint2D’s performance has been found to be comparable to that reported for other 
tools.  Finally, MetaPrint2D only predicts the relative likelihood of metabolism occurring at 
each site within a molecule, ignoring rates and yields. 
The next chapter discusses the extension of MetaPrint2D in order to predict specific types of 
metabolic transformation, and the structures of potential metabolites. 
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5. Extension of MetaPrint2D to the prediction of 
transformation types and the generation of 
metabolites 
As discussed in Chapter 2, current methods for predicting the metabolites formed through 
xenobiotic metabolism are rule based, often only provide a coarse-grained discrimination 
between the different products’ likelihood of formation, and are prone to over-prediction of 
the number of metabolites.  This chapter reports an extension of the data-mining approach 
to site of metabolism used by MetaPrint2D.  Introduction of a list of reaction type 
definitions enabled identification of the transformations that each predicted site of 
metabolism is likely to undergo, and the metabolites generated. 
5.1 Introduction 
MetaPrint2D and its predecessor SPORCalc predict sites of xenobiotic metabolism, but make 
no prediction of the metabolites likely to be formed.  MetaPrint2D-React is an extension of 
MetaPrint2D which includes predictions of the types of transformation that occur, and 
generates the structures of the metabolites formed.  Like the other approaches to 
metabolite prediction described in Chapter 2, a set of reaction patterns are used to define 
the possible transformations, but MetaPrint2D-React provides much finer grained 
differentiation between the likelihoods of various metabolites being formed than the other 
rule-based tools. 
As discussed previously, tools for the prediction of metabolites, such as Meteor (239), use a 
set of rules to define ‘biophores’ (descriptions of functional groups and other molecular 
properties) that are used to determine where in a molecule metabolic transformations may 
take place.  In order to predict the metabolites of a compound, its structure is searched for 
the presence of each biophore, identifying all the sites in the structure where each 
transformation could occur.  When different biophores indicate that several competing 
transformations could occur, relative reasoning rules can be used to assert one 
transformation’s precedence over another.  Each biophore has associated with it a 
likelihood score; this may be one of a small number of categories such as very likely, likely, 
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unlikely or may be a more finely grained score such as the empirical probabilities assigned to 
each rule by Sygma (242). 
MetaPrint2D-React extends the data model used by MetaPrint2D in order to include sub-
models for each class of reaction.  In addition to recording the reaction centre and substrate 
occurrence counts, each atom environment fingerprint in MetaPrint2D-React also records 
occurrence counts for each type of transformation that has been observed to occur in the 
training data at an atom occupying that environment.  Since this has been achieved through 
extension of the data structures described in Chapter 3, it adds very little overhead to the 
search performance. 
In order predict the metabolism of a compound MetaPrint2D-React performs a search of 
the model’s data for similar atom environments to each atom in the query structure in 
exactly the same manner as MetaPrint2D does.  However, in addition to calculating the 
overall occurrence ratio for each atom in the structure, a separate occurrence ratio for each 
type of transformation reported in the training data is calculated.  Structures of predicted 
metabolites are then generated through application of the reaction rules associated with 
each predicted transformation type. 
This approach enables much finer grained differentiation between the relative likelihoods of 
predicted metabolites than any of the methods described in Chapter 2 since the occurrence 
ratio of each metabolite is based on a data mining search of the environments occupied by 
atoms in the molecule, rather than a match against one of a list of pre-defined 
transformation patterns, or biophores. 
There are also a number of other benefits.  Since pattern matching is not used to determine 
the sites at which transformations occur, a much smaller and simpler set of 
biotransformations can be defined, making maintenance of the rule base much simpler.  For 
instance, rather than requiring many different rules for hydroxylation, defining precisely 
which substructures at which hydroxylation may occur, together with a separate likelihood 
for each rule, MetaPrint2D-React needs only a single definition of hydroxylation: the 
addition of an -OH group, and can determine the appropriate locations at which to apply the 
transformation, and the likelihood of it taking place, through a statistical analysis of the data 
in the Symyx® Metabolite database. 
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In addition, MetaPrint2D-React’s metabolite prediction has the potential to be much faster 
than a purely rule-based approach.  Substructure searches are a relatively computationally 
expensive procedure; in the case of a method relying on a list of several hundred 
biotransformation rules, the query structure must be searched for occurrences of the 
substrate pattern of each of the hundreds of rules.  MetaPrint2D-React can determine the 
sites in a molecule at which each type of transformation can occur using the fast fingerprint 
search described previously.  The most time consuming part of the MetaPrint2D search is 
the lookup of similar atom environments and the addition of occurrence counts for specific 
transformation types makes little difference to the calculation time. 
Some methods, such as Meteor, base their estimate of a metabolite’s likelihood of 
formation on an assessment of the structure of the metabolite formed.  This means that 
even if the user only wishes to examine a subset of the predicted metabolites, say the 10 
most likely, all of the metabolite structures must be generated and assessed.  By generating 
likelihoods of formation from the results of atom environment fingerprint searching, 
MetaPrint2D-React allows small subsets of the metabolites to be rapidly selected for further 
analysis. 
5.2 Identifying transformations 
5.2.1 Metabolite database annotations 
The 87,446 biotransformations recorded in the 2008.1 release of the Symyx® Metabolite 
database encompass a wide range of types of reaction.  68,900 of the records have reaction 
class annotations, assigning one or more of 286 reaction class labels such as Hydroxylation 
and Hydrolysis to the transformation.  Of these reaction class labels, 115 are assigned to 
twenty or fewer biotransformations and only 95 are assigned to more than one hundred 
transformations.  The most common reaction class labels are listed in Table 19. 
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C-Hydroxylation 8386 N-Oxidation 811 Oxidative Dealkylation 277 
Hydrolysis 7658 N-Deacylation 768 Glycination 254 
C-Oxidation 6033 Covalent Binding 757 S-Alkylation 230 
Aromatic 
Hydroxylation 
4063 Isomerization 751 N-Acetylcysteination 227 
Aliphatic 
Hydroxylation 
3855 O-Conjugation 746 Condensation 221 
O-Glucuronidation 3666 Tautomerization 724 Cleavage 214 
N-Dealkylation 3537 O-Methylation 678 Deglycosidation 208 
Reduction 3108 N-Acylation 670 Epimerization 203 
Ring Opening 2515 N-Reduction 632 Dealkylation 201 
Oxidation 2232 Dehydration 604 O-Deacetylation 196 
O-Dealkylation 1702 Decarboxylation 604 Dehydroxylation 189 
N-Demethylation 1673 Phosphorylation 587 N-Deacetylation 185 
Hydrogenation 1579 Ring Closure 573 Desulfuration 178 
Conjugation 1464 Chain Shortening 550 O-Phosphorylation 173 
Glutathionation 1322 Rearrangement 533 Lipid Binding 161 
O-Sulfation 1315 O-Alkylation 531 C-Dealkylation 157 
Dehydrogenation 1254 Deamination 519 Dimerization 155 
Epoxidation 1232 O-Deacylation 478 Dephosphorylation 154 
Dehalogenation 1187 Nucleophilic Addition 467 Chain Elongation 152 
Aromatization 1166 Cyclization 459 O-Dephosphorylation 152 
O-Demethylation 1156 Elimination 442 N-Methylation 152 
Dearomatization 1072 Esterification 405 Inversion 150 
S-Oxidation 1033 
Oxidative 
N-Dealkylation 
376 Radical Formation 147 
Protein Binding 1027 N-Glucuronidation 337 Lactonization 147 
Optical Resolution 1013 Hydration 333 Glycosidation 144 
N-Acetylation 1013 
Nucleophilic 
Substitution 
306 O-Deglycosidation 140 
DNA Binding 1010 Sulfation 290 Sulfuration 135 
Glucuronidation 1005 S-Methylation 289 Amidation 133 
Oxidative Deamination 875 S-Dealkylation 286 
Oxidative 
Desulfuration 
132 
Hydroxylation 856 N-Hydroxylation 285 N-Alkylation 118 
Table 19: The 90 most common reaction class labels from the 2008.1 release of the 
Symyx® Metabolite database, together with their occurrence counts. 
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Initially the use of these database annotations as the basis for determining the types of 
reaction to have occurred was considered, however this approach was not found to be 
feasible.  Unfortunately the reaction type annotations in the Symyx® Metabolite database 
are inconsistent, and often incomplete.  For instance, hydroxylation reactions occurring at a 
carbon atom are variously labelled with one or more of Hydroxylation, C-hydroxylation, 
Aromatic Hydroxylation and Aliphatic Hydroxylation.  The hydroxylation transformations 
shown in Figure 79, illustrate this variability. 
(a) 
 
Aromatic Hydroxylation 
C-Hydroxylation 
 
(b) 
Aromatic Hydroxylation 
(c) 
 
C-Hydroxylation 
 
(d) 
 
C-Hydroxylation 
Hydroxylation 
 
(e) 
 
Aliphatic Hydroxylation 
C-Hydroxylation 
Hydroxylation 
(f) 
 
Aliphatic hydroxylation 
Figure 79: Examples of hydroxylation transformations from the Symyx® Metabolite 
database with their annotated reaction classes. 
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Transformations (b)-(e) from Figure 79 are all from the same reaction scheme, and even 
here there is little consistency in the annotations, while for transformation (f) no 
hydroxylation is immediately obvious.  This single record in the database represents the 
combined result of a series of elementary reactions (shown in Figure 80), and the 
annotations describe the reactions occurring in the separate steps, rather than the overall 
transformation. 
 
Figure 80: The series of elementary reactions making up the transformation shown in 
Figure 79(f).  The record is annotated Aliphatic Hydroxylation, N-Acetylation, N-
Deacylation and Ring Closure. 
There is little consistency, however.  In some similar cases where records represent the 
result of more than one elementary reaction the classes of some steps are omitted from the 
annotations, and in other cases the records are only annotated with the apparent reaction 
shown by the overall transformation.  Alternatively, a record may represent the product of 
several transformations in different regions of the molecule, but only one of these is 
annotated. 
The annotations also vary between database releases.  The transformation shown in Figure 
81 is described as an Epoxidation and Hydrolysis in the 2007.1 release of the database, but 
in the 2008.1 release is additionally annotated as Aliphatic Hydroxylation, C-Hydroxylation 
and Hydrogenation.  The Hydroxylation annotations can be accounted for as the result of 
the overall process, but the last annotation does not appear to be related to the reaction 
scheme. 
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Figure 81: This transformation (MDLNUMBER: RMTB00078230) is annotated 
Epoxidation and Hydrolysis in the 2007.1 release of the Metabolite database.  In the 
2008.1 release it is additionally annotated Aliphatic Hydroxylation, C-Hydroxylation 
and Hydrogenation. 
Other annotations are simply incorrect: 
 
Figure 82: This transformation (MDLNUMBER: RMTB00010291) is annotated as an N-
deglucosidation in the 2008.1 release of the Symyx® Metabolite database, but the 
transformation it represents is a hydroxylation. 
A further challenge in working with the reaction class annotations from the Symyx® 
Metabolite database arises from the fact that each record in the database only represents a 
single product of the transformation.  Reactions that generate more than one product are 
recorded in a series of records, one for each product.  In these cases the assigned reaction 
classes can vary, depending on which product is under consideration.  The reaction shown in 
Figure 83(a) is recorded as two separate transformations, originating from the same 
substrate, one leading to each of the product compounds.  Transformation (b) is described 
as an ‘Oxidative Deamination’ and an ‘Oxidative N-Dealkylation’, while transformation (c) is 
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described as a ‘C-Oxidation’ and an ‘N-Dealkylation’ – despite both records being separate 
views onto the same metabolic transformation. 
(a) 
 
 
(b) 
 
Oxidative Deamination 
Oxidative N-dealkylation 
(MDLNUMBER: RMTB00065456) 
(c) 
 
C-Oxidation 
N-Dealkylation 
(MDLNUMBER: RMTB00000032) 
Figure 83: The Symyx® Metabolite database reports the overall reaction (a) in two 
separate records (b) and (c), one for each of the products.  The reaction class 
annotations differ between these records, depending on which product is under 
consideration. 
5.2.2 SMARTS patterns 
Since the reaction class annotations in the Symyx® Metabolite database were unsuitable for 
use in assigning transformation types to sites of metabolism, a method for classifying the 
transformations using reaction SMARTS (55) patterns was developed.  SMARTS is a language 
for describing molecular patterns, based on the widely used SMILES representation of 
molecular structure.  Reaction SMARTS is an extension of the SMARTS language enabling 
description of reactions.  Reaction SMARTS describe structures required to be present in 
reactant and product molecules, and can specify mappings between atoms in these 
structures.  An example reaction SMARTS is described in Figure 84, below. 
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[OH:1]>>[O:1]C(=O)C 
Figure 84: Reaction SMARTS pattern representing an esterification reaction.  The 
reactant (to the left of the ‘>>’) must contain an -OH group, and this maps to an 
oxygen in the product with an acetyl group added. 
MetaPrint2D-React identifies reaction centres through a constrained maximum common 
substructure search, in exactly the same way as described in Chapter 3 for MetaPrint2D.  
MetaPrint2D assigned broad classifications (phase I addition, phase II addition, elimination, 
bond breaking, bond formed, bond order changed) to the reaction centre atoms.  
MetaPrint2D-React instead uses a list of reaction SMARTS patterns to classify the 
transformations on the basis of the structural changes between the substrate and 
metabolite compounds. 
In order to determine which reaction types should be included in MetaPrint2D-React the 
most common reaction classes in the Symyx® Metabolite database were identified, along 
with common types of transformations reported in the literature.  Reaction SMARTS 
patterns were then written to describe these transformations.  MetaPrint2D-React stores 
these reaction type definitions in a configuration file, making it straightforward to make 
changes to the reaction types that are supported by the software. 
Since the fingerprinting/data-mining approach of MetaPrint2D is used to determine the 
sites in a molecule where transformations should be applied, very general reaction rules can 
be used.  Rather than the highly specific rules such as ‘4-Hydroxylation of 1,3-Disubstituted 
Benzenes’ required by tools like Meteor, only a single rule for hydroxylation (using a 
wildcard to represent the atom to which the –OH group is added) is necessary.  The same is 
true for many other types of reaction.  If users wish to discriminate between transformation 
types at a more fine-grained level than these generic rules permit, for example between 
aliphatic C-hydroxylations, aromatic C-hydroxylations and N-hydroxylations, then this can 
easily be achieved with the addition of extra rules – appropriate reaction SMARTS patterns 
can be added to the reaction type definitions and the training data reprocessed to generate 
a new model. 
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(a) 
 
(MDLNUMBER: RMTB00046712) 
(b) 
(MDLNUMBER: RMTB00015229) 
Figure 85: Both the N-glucosidation shown in (a) and the O-glucosidation shown in (b) 
can be described using the same reaction SMARTS pattern by representing the atom 
to which the glucose is conjugated by a wildcard which can match any chemical 
element. 
The reaction types defined in MetaPrint2D-React mostly correspond to reaction classes in 
the Symyx® Metabolite database.  Some of the Metabolite database’s reaction classes are 
very broad, and have been assigned to a number of quite different reactions.  The 
annotation ‘Hydrolysis’, for instance, can describe an ester, amide or epoxide hydrolysis 
reaction.  MetaPrint2D-React has separate reaction SMARTS patterns to handle these 
various cases. 
The Symyx® Metabolite database also contains a number of quite generic reaction classes, 
such as acylation.  In such cases MetaPrint2D-React can define several reaction patterns 
covering both specific commonly occurring cases and broader generic reaction types.  In the 
case of acylation (illustrated in Figure 86), MetaPrint2D-React contains two rules; the first 
covering the specific case of acetylation, the most common type of acylation, and a broader 
rule to catch the remainder of cases.  Similarly in the case of dealkylation reactions 
MetaPrint2D-React defines two rules: one covering the most common case – 
demethylation, and a broader rule for the generic case. 
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[*:1]>>[*:1]C(=O)[CH3] 
Acetylation 
 
[*:1]>>[*:1]C(=O)* 
Acylation 
Figure 86: MetaPrint2D–React includes generic reaction type rules such as acylation, 
and also more specific rules to cover the most common instances, such as acetylation. 
In other cases multiple rules may be required in order to represent variants of a group that 
is added: 
(a) 
 
(MDLNUMBER: RMTB00012784) 
(b) 
 
(MDLNUMBER: RMTB00038161) 
Figure 87: Separate reaction SMARTS patterns are required to describe the 
glycosidation reactions shown in (a), and with and additional phosphate group in (b). 
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Finally, in order to avoid enumerating the large number of possible substitution reactions, 
MetaPrint2D-React has the capability to recognise substitutions as the combination of an 
addition pattern and an elimination pattern. 
The browser tool used to evaluate the reaction centre identification algorithms used by 
MetaPrint2D (described on page 120) has been adapted to assist with the evaluation and 
refinement of the reaction type rules.  The browser enables each record from the Symyx® 
Metabolite database to be inspected, highlighting the regions of the molecule undergoing a 
transformation.  The reaction classes detected by the rules are listed and the atoms at 
which the reaction occurred highlighted.  Any regions undergoing transformation that are 
not described by a transformation rule are also highlighted.  The initial reaction type rules 
were refined through manual inspection of records sampled at random from the Symyx® 
Metabolite database using this browser.  Common types of transformation that were not 
adequately described by the initial rule set were identified and the rules adapted 
accordingly. 
The reaction type rules developed through this process characterize 81.2% of reaction 
centre atoms identified in the 2008.1 release of the Symyx® Metabolite database.  Examples 
of the reaction SMARTS patterns describing the most common reaction types, together with 
cases of the transformations they represent, are presented below. 
 
 1
6
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5.2.3 Reaction type definitions 
Description Frequency Example Transformations SMARTS Patterns 
Hydroxylation 12732 
 
MDLNUMBER: RMTB00000015 
[*:1]>>[*:1]-[OH] 
Dealkylation 6996 
 
MDLNUMBER: RMTB00000099 
[*:1]-C>>[*:1] 
Glucuronidation 5741 
 
MDLNUMBER: RMTB00015763 
[*:1]>>[*:1]C1C(O)C(O)C(O)C(C(=O)O)O1 
Demethylation 3560 
 
MDLNUMBER: RMTB00000024 
[*:1]-[CH3]>>[*:1] 
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Description Frequency Example Transformations SMARTS Patterns 
Reduction (double to single 
bond) 
3466 
 
MDLNUMBER: RMTB00017724 
[*:1]=[*:2]>>[*:1]-[*:2] 
Oxidation (+=O) 2905 
 
 
MDLNUMBER: RMTB00001469 
 [*:1]>>[*:1]=O 
Amide hydrolysis 2707 
 
MDLNUMBER: RMTB00074205 
[N:1]-[C$(*=O):2]>> [*:1].[OH]-[*:2] 
[N:1]-[C$(*=O):2]>> [OH]-[*:2] 
[N:1]-[C$(*=O):2]>> [*:1] 
Conjugation 2400 
 
MDLNUMBER: RMTB00066487 
[*:1]>>[*:1]-[#0] 
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Description Frequency Example Transformations SMARTS Patterns 
Oxidation (single to double 
bond) 
2218 
 
MDLNUMBER: RMTB00000313 
[*:1]-!:[*:2]>>[*:1]=!:[*:2] 
Sulfation 1988 
 
MDLNUMBER: RMTB00046671 
[*:1]>> [*:1]-S(=O)(=O)-O 
Ester hydrolysis 1971 
 
MDLNUMBER: RMTB00000001 
[C:1](=[O:2])-[O:3]-[*:4] 
    >>[C:1](=[O:2])-[OH].[OH:3]-[*:4] 
[C:1](=[O:2])-O-* 
    >>[C:1](=[O:2])-[OH] 
C(=O)-[O:1]-[*:2]>>[OH:1]-[*:2] 
Methylation 1154 
 
MDLNUMBER:  RMTB00000079 
[*:1]>>[*:1]-[CH3] 
Dehalogenation 1115 
 
MDLNUMBER: RMTB00000221 
[*:1]-[I,Br,Cl,F]>>[*:1] 
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Description Frequency Example Transformations SMARTS Patterns 
Dehydroxylation 1088 
 
MDLNUMBER: RMTB00070716 
[*:1]-[O;H,-]>>[*:1] 
Epoxidation 1035 
 
MDLNUMBER: RMTB00000022 
[*:1]=[*:2]>>[*:1](-O1)-[*:2]-1 
Oxidation (=O,-OH) 1004 
 
MDLNUMBER: RMTB00000113 
[*:1]>>[*:1](=O)-[OH] 
Acetylation 935 
 
MDLNUMBER: RMTB00011676 
[*:1]>>[*:1]-C(=O)-[CH3] 
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Description Frequency Example Transformations SMARTS Patterns 
Phosphorylation 821 
 
MDLNUMBER: RMTB00003618 
[*:1]>>[*:1]-P(=O)(-O)-O 
Tautomerization 720 
 
MDLNUMBER:  RMTB00086505 
[*:1]=[*:2]-[*:3]>>[*:1]-[*:2]=[*:3] 
Epoxide hydrolysis 701 
 
MDLNUMBER: RMTB00059271 
[r:1]1-[r:1]-[Or:2]-1>>[*:1](-[OH])-[*:1]-[OH:2] 
Hydroxidation 681 
 
MDLNUMBER: RMTB00006966 
[*:1]>>[*:1]-[O-] 
Oxidative deamination (=O) 678 
 
MDLNUMBER: RMTB00060711 
[*:1]-N>>[*:1]=O 
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5.3 Predicting transformations 
MetaPrint2D-React predictions are based on a circular atom environment fingerprint 
similarity search, performed analogously to that used by MetaPrint2D for site of metabolism 
predictions.  In order to enable prediction of the types of transformation that can occur at 
each site, every fingerprint is associated with a count of how many times each reaction type 
has been observed at an atom occupying that environment in the training data.  When 
predictions are made, each atom in the query compound has a score (normalized 
occurrence ratio) generated for each type of reaction, in addition to the overall score for the 
likelihood of metabolism occurring at that site.  The overall score is equal to the sum of the 
scores for each reaction type at that site. 
The fingerprint search determines the possible reactions at each site in the molecule, and 
these predictions are refined through checks that the reactant pattern for each reaction 
type matches the sites at which they are predicted to occur.  For many reaction types, such 
as hydroxylation, this is a trivial process that can be omitted since the reactant pattern is 
simply the wildcard ‘any atom’, but for others, particularly those transformations involving 
several atoms in their pattern, this is an important step.  In the case of reaction types with 
several atoms in their reactant pattern, such as hydrolysis or epoxidation, it is possible that 
the reaction is predicted to occur at some of the required atoms but not others: 
 
[$(C=O):1][O:2]>>[$(C=O):1][OH].[O:2] 
Figure 88: Hydrolysis has been predicted to occur at the highlighted position, but not 
at the adjacent carbonyl carbon, required by the reaction pattern.  Since there is not a 
full match of the reaction pattern to atoms at which hydrolysis is predicted, the partial 
prediction is discarded. 
The atoms’ overall scores are analogous to the normalized occurrence ratios calculated by 
MetaPrint2D when making site of metabolism predictions.  The values differ from the site of 
metabolism scores computed by MetaPrint2D however, as MetaPrint2D-React captures a 
different subset of the reaction centres.  The site of metabolism prediction models used by 
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MetaPrint2D were trained using reaction centres classified as either phase I addition, or 
elimination.  MetaPrint2D-React makes predictions on a greater range of additions, 
including phase II conjugations, but only includes the subset of elimination reactions 
specifically described by reaction SMARTS patterns. 
5.4 Generating product structures 
In order to generate the structures of metabolites the reaction SMARTS patterns are treated 
as SMIRKS (55) transformation patterns.  SMIRKS is a language for defining transformations, 
derived from SMILES and SMARTS. 
In order to apply a SMIRKS transformation to a structure the reactant component of the 
SMIRKS pattern is matched against the sites of the query structure predicted to undergo the 
transformation.  The SMIRKS pattern is analysed in order to determine the atoms conserved 
between the reactant and product patterns (using mapping IDs incorporated in the SMIRKS 
pattern), and the added, deleted and altered atoms and bonds are identified.  The 
metabolite structure is then generated through duplication of the query structure and 
application of the changes from the transformation pattern. 
5.5 User interface 
Like the site of metabolism prediction code, MetaPrint2D-React has been designed as a 
library, enabling different user interfaces to be developed independently of the prediction 
engine, and facilitating the embedding of the tool in larger applications.  Currently only one 
user interface is available: a website, hosted at the Unilever Centre for Molecular Science 
Informatics in the Cambridge University Chemical Laboratories (http://www-
metaprint2d.ch.cam.ac.uk/metaprint2d-react). 
Query molecules can either be input using the SMILES format, or sketched using the JME 
editor.  The output initially appears in a very similar form to that of the MetaPrint2D 
website: a structure diagram with atoms highlighted using a traffic-light system indicating 
the relative likelihood of metabolic transformations being centred on that site.  Moving the 
cursor over an atom, however, reveals the list of reaction types predicted to occur at that 
site, with their relative scores, as shown in Figure 89. 
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Figure 89: MetaPrint2D-React predictions for a compound.  The relative likelihood of 
metabolism occurring at different sites in the structure is shown, and moving the 
cursor over an atom reveals more details, including the types of reaction predicted to 
occur at that site. 
Clicking on one of the predicted reaction types generates the structure of the metabolite 
resulting from that transformation: 
 
Figure 90: Clicking on one of the predicted reaction types generates the structure of 
the metabolite resulting from that transformation. 
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It is also possible to apply a filter to the results, presenting only the sites predicted for one 
particular class of reaction: 
 
Figure 91: The reaction type filter can be used to limit predictions to one class of 
reaction; here it is being used to show the relative likelihood of hydroxylation 
occurring at different sites in a molecule. 
5.6 Evaluation 
Two evaluations of MetaPrint2D-React have been performed.  The first evaluated the 
identification of sites of metabolism by MetaPrint2D-React and the second evaluated the 
predictions of specific reaction types. 
The evaluation of site of metabolism predictions using MetaPrint2D-React was performed in 
the same manner as the assessment of MetaPrint2D, described in Chapter 4.  The 2006.1 
release of the Symyx® Metabolite database was used to train the MetaPrint2D-React model 
and the quality of predictions was evaluated using novel data from the 2008.1 release.  The 
reaction schemes added to the Metabolite database between the 2006.1 and 2008.1 
releases were identified, and one test compound was randomly selected from each scheme.  
The results of this evaluation are presented in Table 20, below. 
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Molecule Count % Top 1 % Top 3 
Mean 
AUC 
Median 
AUC 
922 58.9% 78.7% 0.812 0.918 
Table 20: Results of the evaluation of site of metabolism predictions made using 
MetaPrint2D-React. 
During this exercise the ability of MetaPrint2D-React to predict types of transformation was 
also assessed.  At each reaction centre in the test compounds the types of transformation 
that MetaPrint2D-React predicted were compared to the transformation types reported at 
that site.  Of the 2889 transformations reported to occur in the training data, 2257 (78.1%) 
were predicted by MetaPrint2D-React. 
A separate assessment has been performed for each reaction type predicted by 
MetaPrint2D-React.  Due to the variation in the number of times that transformation types 
are reported in the Metabolite database, training and test data were selected through 
Monte Carlo cross-validation (283), in a similar manner to the approach used for the training 
and evaluation of cytochrome P450 isotope specific models described previously in Chapter 
4. 
For each reaction type, 20% of the molecules from the 2008.1 release of the Symyx® 
Metabolite database identified as undergoing that reaction were randomly selected to form 
a test set, and the remainder of the data, excluding molecules occurring in the same 
metabolic scheme as any of the test compounds, used to generated a MetaPrint2D-React 
model.  This model’s predictions for the molecules in the test set were assessed using the 
same metrics as described previously – the percentage of molecules having a site of 
metabolism among the top one or three predicted sites of metabolism, and the mean and 
median area under the ROC curve (AUC) statistics.  The selection of test and training data, 
model construction and evaluation of predictions were repeated ten times for each reaction 
type, and the results averaged.  These are reported in Table 21, below. 
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Reaction Type Molecule Count % Top 1 % Top 3 
Mean 
AUC 
Median 
AUC 
Hydroxylation 5726 47.20% 69.30% 0.804 0.891 
Dealkylation 4975 71.80% 87.50% 0.895 0.994 
Glucuronidation 4110 73.80% 88.10% 0.927 1.000 
Demethylation 2340 86.60% 95.10% 0.928 1.000 
Oxidation (=O) 2036 55.80% 72.20% 0.826 0.978 
Amide hydrolysis 1817 79.70% 90.30% 0.934 1.000 
Conjugation to unknown structure 1777 55.80% 78.20% 0.857 0.985 
Reduction (double to single bond) 1571 76.20% 87.80% 0.887 0.992 
Ester hydrolysis 1495 91.50% 97.40% 0.963 1.000 
Oxidation (single to double bond) 1450 72.80% 85.70% 0.851 0.966 
Sulfation 1395 73.40% 87.60% 0.927 1.000 
Dehydroxylation 694 75.30% 90.60% 0.859 0.974 
Acetylation 672 79.30% 85.40% 0.892 1.000 
Methylation 670 61.30% 80.00% 0.841 0.990 
Oxidation (=O,-OH) 607 54.80% 75.10% 0.829 0.947 
Epoxidation 582 62.90% 77.00% 0.812 0.915 
Dehalogenation 570 74.40% 90.60% 0.798 0.852 
Oxidative deamination (=O) 552 81.50% 87.50% 0.877 1.000 
Hydroxidation 539 60.60% 72.30% 0.839 0.995 
Phosphorylation 467 81.30% 85.40% 0.920 1.000 
Epoxide hydrolysis 431 94.50% 96.40% 0.941 1.000 
Glutathionation (+SX) 430 38.60% 62.90% 0.724 0.763 
Oxidative deamination (=O,-OH) 335 75.00% 85.00% 0.874 0.993 
Dehydration 334 79.80% 88.30% 0.818 0.846 
Tautomerization 320 65.00% 80.20% 0.806 0.890 
Hydroxylation/ 
Tautomerization(=O) 
296 59.40% 74.30% 0.771 0.831 
Dephosphorylation 270 74.50% 89.20% 0.929 0.993 
Oxidative deamination (-OH) 268 57.40% 69.90% 0.754 0.761 
Epoxide opening (+X) 267 80.90% 89.80% 0.886 1.000 
Epoxidation/Hydrolysis 266 50.00% 75.50% 0.784 0.819 
Reduction (=O) 250 72.00% 80.90% 0.804 0.906 
Aromatization 220 57.70% 72.30% 0.795 0.864 
Oxidative Elimination 220 73.10% 86.00% 0.791 0.831 
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Reaction Type Molecule Count % Top 1 % Top 3 
Mean 
AUC 
Median 
AUC 
Acylation 196 45.10% 65.20% 0.738 0.808 
Hydration 173 51.30% 61.60% 0.720 0.711 
Glycination 171 79.40% 87.20% 0.866 0.995 
Reduction (=O,-O) 170 90.00% 94.50% 0.925 1.000 
Methoxylation 156 39.00% 60.80% 0.778 0.873 
Dealkylation (x2) 153 54.90% 70.60% 0.768 0.813 
Elimination 152 61.40% 75.90% 0.820 0.895 
Alkylation 147 50.70% 70.20% 0.747 0.820 
Epoxide Hydrolysis/Aromatization 144 88.40% 91.70% 0.929 1.000 
Glutathionation (=) 144 53.00% 71.50% 0.725 0.737 
Elimination (XX) 140 61.30% 76.30% 0.755 0.755 
Conjugation (substituting OH) 133 62.00% 76.50% 0.790 0.882 
Acetylcysteination 131 42.50% 61.40% 0.710 0.723 
N-dealkylation 111 42.30% 55.50% 0.697 0.666 
Dealkylation (3) 111 83.60% 96.00% 0.930 1.000 
Desulfuration 105 77.50% 90.00% 0.818 0.907 
Glutathionation (O>SX) 102 58.70% 78.30% 0.770 0.829 
Glucosidation (+X) 97 42.50% 64.00% 0.778 0.916 
CoA Binding 90 73.00% 85.00% 0.911 1.000 
Dealkylation (2) 89 51.30% 60.60% 0.763 0.828 
Oxidation(=O=O) 87 54.00% 70.70% 0.763 0.857 
Cysteamination 80 38.80% 54.90% 0.685 0.629 
Demethylation (x2) 76 79.90% 90.00% 0.863 0.976 
N-Dearylation 70 53.50% 58.90% 0.777 0.855 
Denitration 65 91.50% 96.50% 0.892 0.938 
Amination 64 26.70% 61.30% 0.708 0.685 
Protein Binding 62 41.90% 63.30% 0.752 0.783 
Conjugation (+SX) 62 53.00% 62.70% 0.740 0.755 
Glutamation 61 21.70% 32.40% 0.731 0.788 
Esterification 58 65.50% 84.20% 0.872 0.989 
Azo_cleavage 57 83.80% 92.50% 0.924 0.994 
Ring_opening 57 26.30% 45.30% 0.655 0.635 
Elimination (XH) 55 71.90% 80.30% 0.834 0.918 
Chlorination 54 54.10% 71.20% 0.809 0.898 
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Reaction Type Molecule Count % Top 1 % Top 3 
Mean 
AUC 
Median 
AUC 
Dehydrohalogenation 51 88.60% 92.80% 0.831 0.894 
Conjugation (=) 48 45.10% 64.20% 0.695 0.724 
Sulfuration 46 19.20% 44.70% 0.566 0.496 
Methiolation 46 30.80% 38.10% 0.609 0.539 
Epoxide Hydrolysis/Dehydration 38 76.90% 80.00% 0.886 0.962 
DNA Binding 37 70.90% 81.00% 0.824 0.945 
Cyanidation 35 32.90% 62.90% 0.708 0.693 
Formylation 34 46.70% 52.00% 0.714 0.751 
Nitrosation 33 52.00% 65.30% 0.714 0.711 
Deamination (NH2) 29 58.00% 69.00% 0.648 0.584 
Disulphide Reduction 28 30.00% 66.00% 0.788 0.803 
Epoxide opening (3) 27 64.00% 72.00% 0.813 0.884 
Glycosidation (+XP) 27 55.20% 83.80% 0.840 0.903 
Aromatization/ Elimination 26 36.50% 69.50% 0.663 0.668 
Sulfonation 25 58.50% 62.50% 0.769 0.825 
Glycosidation (+X) 19 48.30% 80.00% 0.811 0.869 
Oxidation/Dehalogenation 15 76.70% 76.70% 0.737 0.765 
Hydroxylation/ 
Tautomerization(=O=O) 
14 30.00% 60.00% 0.706 0.706 
Thioester hydrolysis 13 85.00% 100.00% 0.962 0.962 
Condensation 12 40.00% 55.00% 0.649 0.649 
Oxidation (=O,-[O-]) 11 75.00% 85.00% 0.713 0.713 
Epoxide dehydration 9 50.00% 50.00% 0.743 0.743 
N2-elimination 9 80.00% 100.00% 0.900 0.900 
Fluorination 8 30.00% 60.00% 0.641 0.641 
Glucosidation (+OX) 8 0.00% 0.00% 0.444 0.444 
Bromination 7 50.00% 70.00% 0.810 0.810 
Peroxidation 6 10.00% 10.00% 0.475 0.475 
Deamination (NHNH2) 6 0.00% 70.00% 0.676 0.676 
Rearrangement 6 90.00% 100.00% 0.931 0.931 
Dealkynylation 4 80.00% 100.00% 0.702 0.702 
Table 21: MetaPrint2D-React’s performance in predicting each type of reaction. 
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For the majority of reaction types MetaPrint2D-React’s predictions are as accurate as, or 
better than, the site of metabolism predictions generated by MetaPrint2D.  The best 
performing reaction types are those that can only occur at a specific substructure, such as 
ester hydrolysis, as opposed to transformations such hydroxylation which using a wild-card 
match can potentially be applied to any chemically relevant site. 
The least accurately predicted transformations are all amongst those with the lowest 
numbers of occurrences, and those occurrences are in several different atom environments.  
This means that when the data is split into training and test sets in the course of cross-
validation runs many of the atom environments occupied by reaction centre atoms in the 
test set do not appear in the training data. 
The reaction types with the least occurrences have been removed from MetaPrint2D-React. 
5.7 Conclusions 
There are some limitations to the methods used by MetaPrint2D-React.  Reaction types 
must be expressed as SMARTS patterns.  This means that transformations must be defined 
in terms of exact substructures – SMARTS patterns cannot represent a query such as ‘a 
chain of 3-5 carbon atoms’.  SMARTS patterns cannot represent the formation of radicals, 
though extensions to address this issue have been proposed (253).  These restrictions make 
it unfeasible for MetaPrint2D-React to capture certain types of reaction, such as 
dimerization and ring contractions, since to do so would require enumerating every possible 
structure.  This is not a major limitation of the approach since such reactions occur quite 
infrequently. 
A related limitation is in the handling of reactions involving transformations at different sites 
in a molecule, linked by a conjugated system.  Examples of these are shown in Figure 92.  
Such transformations can occur with a varying number of bonds separating the main 
reaction sites, and again cannot currently be handled by MetaPrint2D-React unless all 
possible arrangements are enumerated. 
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Figure 92:  In order to represent reactions consisting of transformations at different 
sites in a molecule connected by a conjugated system using SMARTS patterns separate 
SMARTS are required for different lengths of conjugation. 
There are several cases in which MetaPrint2D-React requires a number of separate reaction 
type definitions in order to describe closely related reaction types.  An example where this 
arises is acylation – there is currently a specific rule for acetylation (the acetyl group is most 
common acyl group to be added) and a generic rule that captures the remaining cases of 
acylation.  A similar situation occurs with alkylation where there is a specific rule describing 
methylation, and a generic rule describing other alkylation reactions.  It may be useful, and 
improve the quality of predictions, if it were possible to establish hierarchies of reaction 
types.  This would mean that methylation reactions could count towards the occurrences of 
alkylations, and the overall likelihood of alkylation could be predicted more accurately, 
while still enabling the likelihood of specific types of alkylation to be calculated.  Similarly, in 
the case of oxidative deamination there are three different rules covering the hydroxyl, 
aldehyde and carboxy metabolites. 
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6. Retrospective prediction of recently 
published metabolic schemes 
This chapter reports further work carried out to evaluate the performance of MetaPrint2D-
React.  Fifteen studies reporting the metabolic disposition of a novel xenobiotic compound 
were identified from the January to October 2008 issues of the journal Drug Metabolism 
and Disposition.  Site of metabolism and type of transformation predictions for the parent 
compounds in each of these studies were generated by MetaPrint2D-React.  These are 
compared to the compounds’ reported metabolic dispositions below. 
The metabolic studies used in this evaluation were selected on the basis of two criteria.  
Firstly, that the parent compounds in the studies were not included in the data used to train 
the MetaPrint2D-React model, and secondly that the paper reporting the study included a 
clear summary of the proposed metabolites of the parent compound. 
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6.1  [14C]Brasofensine (284) 
6.1.1 Reported metabolites 
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6.1.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React correctly identified the two possible demethylation reactions as the 
most likely transformations for the query molecule.  The stereoisomerism was not predicted 
since this type of transformation is not included in MetaPrint2D-React’s models since the 
descriptors currently used by MetaPrint2D-React do not include any information on 
stereochemistry.  In addition to the reported transformations, MetaPrint2D-React predicted 
(with a low normalised occurrence ratio) two possible sites of hydroxylation.  Overall, all 
four sites of metabolism (for transformations supported by MetaPrint2D-React) were 
identified. 
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6.2 14C-Brivaracetam (285) 
6.2.1 Reported metabolites 
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6.2.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React’s model does not contain very much data on several of the atom 
environments occupied by atoms in this molecule, but correctly predicted the amide 
hydrolysis, hydroxylation and oxidation reactions.  Hydrolysis of the cyclic amide and 
alkylation were also predicted, though not reported.  Given that 5% of the metabolites 
identified in the study were not characterised, it is possible that these transformations could 
be occurring.  All four sites of metabolism were identified. 
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6.3 Bicifadine (286) 
6.3.1 Reported metabolites 
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6.3.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React correctly predicted hydroxylation of the 5-membered ring, and one of 
the sites of oxidation.  Hydroxylation of the methyl group was also correctly predicted.  
Sulfation of the nitrogen atom was not predicted, though hydroxylation, which is likely to be 
the first step of this process, was predicted.  Three of the four reported sites of metabolism 
were identified. 
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6.4 N-(2-Hydroxyethyl)-3,5-dinitrobenzamide 2-mustard 
prodrug (287) 
6.4.1 Reported metabolites 
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6.4.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React correctly predicted reduction of the nitro groups, and the 
glucuronidation reaction was also identified, but with a low likelihood ratio.  The reported 
acetylation was not predicted, and neither was the N-dealkylation.  In the latter case this 
was due to the nitrogen atom occupying a novel atom environment.  In all, only three of the 
reported sites of metabolism were identified. 
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6.5 Dabigatran (288) 
6.5.1 Reported metabolites 
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6.5.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React correctly predicted the amide hydrolysis and glucuronidation, and gave 
a likely location for the reported hydroxylation of the pyridine ring.  The model contained 
little information on a number of atom environments found in the molecule, and possibly as 
a result of this failed to predict the amine hydrolysis or oxidation.  The model also failed to 
predict the N-dealkylation, and suggested an additional hydroxylation that has not been 
reported to be observed.  Overall, half of the reported sites of metabolism were identified. 
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6.6 Ligustilide (289) 
6.6.1 Reported metabolites 
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6.6.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React performed poorly on this molecule, only one of the predicted 
hydroxylation reactions was correctly located, and all the other reported transformations 
missed.  This is not surprising given that almost half of the atoms in the structure are 
occupying novel atom environments, so lie outside of the model’s domain of applicability. 
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6.7 Lithocholic acid (290) 
6.7.1 Reported metabolites 
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6.7.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React correctly predicted the oxidation transformation but failed to predict 
the hydroxylation reaction, and the stereoisomerism is beyond the scope of the model.  The 
model also predicted a number of additional transformations which have not been 
reported. 
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6.8 Pactimibe (291) 
6.8.1 Reported metabolites 
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6.8.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React correctly predicted the glucuronidation reaction, and suggested that 
other types of conjugation could occur.  The hydroxylation was also correctly predicted, 
though a number of additional potential sites of hydroxylation that have not been reported 
were suggested.  Neither the reduction or dealkylation reactions were predicted; in both 
cases there are atoms occupying novel environments in the vicinity of the metabolic sites. 
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6.9 Seliciclib (292) 
6.9.1 Reported metabolites 
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6.9.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React predicted half of the reported metabolic transformations of this 
compound.  The hydroxylation, dealkylation and one of the sites of oxidation were 
identified; however the alkylation, hydrolysis and second site of oxidation were not.  Several 
transformations that have not been reported were also suggested. 
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6.10 Aryl-propionamide derived selective androgen receptor 
modulator (293) 
6.10.1 Reported metabolites 
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6.10.2 MetaPrint2D-React predicted transformations 
 
 
Quite a large number of metabolites have been reported for this compound.  MetaPrint2D-
React suggested locations for both of the reported aromatic hydroxylation reactions, and 
the glucuronidation, and predicted reduction of the nitro group.  The model failed to predict 
the dephenylation reaction or the sulfonation, but did predict a number of transformations 
that have not been reported: dehalogenations, amide hydrolysis and an additional site of 
hydroxylation.  In the case of both the dephenylation and sulfonation transformations it is 
likely that the first step in these processes would be a hydroxylation reaction and these 
were predicted at the appropriate sites. 
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6.11 Colchicine (294) 
6.11.1 Reported metabolites 
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6.11.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React successfully predicted demethylation of three of the four methoxy 
groups, but failed to predict formation of the glutathione conjugate, though this was 
reported to be the result of a multi-step process.  No predictions were possible for a large 
region of this compound due to the number of atoms occupying novel environments. 
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6.12 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-
yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (295) 
6.12.1 Reported metabolites 
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6.12.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React performed quite poorly on this compound.  Of the three reported sites 
of hydroxylation of the quinoline ring, only two were identified and they were predicted to 
be generated in tandem, through epoxide formation and hydrolysis, while they are reported 
to occur independently of each other.  The site of hydroxylation in the ring system at the 
opposite end of the compound was incorrectly predicted, and the deamination reaction was 
not predicted at all – due to the atoms occupying novel environments.  The final reported 
hydroxylation reaction was not identified either, though oxidative deamination was 
predicted to occur at that site, the first step of which would likely involve the addition of a 
hydroxyl group. 
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6.13 Lasofoxifene (296) 
6.13.1 Reported metabolites 
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6.13.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React correctly predicted the reported glucuronidation and sulfation 
transformations, and suggests locations for the reported hydroxylation reactions.  The 
model failed to predict the reported oxidation reaction, and predicted an N-
dealkylation/oxidative deamination that has not been observed. 
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6.14 Chenodeoxycholic acid (297) 
6.14.1 Reported metabolites 
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6.14.2 MetaPrint2D-React predicted transformations 
 
 
MetaPrint2D-React correctly predicted both of the hydroxyl oxidation reactions, and also 
suggests that glucuronidation and sulfation reactions could occur at these positions.  The 
hydroxylation reactions were not identified; MetaPrint2D-React predicted hydroxylation at 
all of the vacant positions in the steroid ring system with a very low likelihood ratio, and 
made very little differentiation between the positions.  MetaPrint2D-React also predicted 
that glucuronidation and other types of conjugation are likely to occur in the chain region of 
the molecule.  The study focused on the contribution of cytochromes P450, so, like the 
glucuronidation and sulfation reactions mentioned earlier, these metabolites would not 
have been identified. 
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6.15 Torcetrapib (298) 
6.15.1 Reported metabolites 
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6.15.2 MetaPrint2D-React predicted transformations 
  
 
This was another compound containing a considerable number of atoms occupying 
environments novel to MetaPrint2D-React’s model, and this has impacted heavily on the 
quality of the metabolite predictions, with none of the reported transformations correctly 
identified. 
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6.16 Conclusions 
Overall, the quality of MetaPrint2D-React’s predictions on these compounds was a little 
disappointing.  In some cases both sites of metabolism and the types of transformations 
occurring at those sites were well predicted, but for many of the compounds a large number 
of reported transformations were missed.  In large part this was due to the relatively high 
proportion of atoms occupying novel atom environments.  Since MetaPrint2D-React is 
based on a data mining method, if there is no relevant or suitable data available then 
reliable predictions cannot be expected. 
In the evaluations of MetaPrint2D and MetaPrint2D-React reported earlier, only around 
3.5% of the evaluation compounds’ atoms occupied novel atom environments, while for this 
test set the proportion was over 15%, indicating that these compounds fit less well into the 
model’s domain of applicability.  This is reflected in the proportion of transformations that 
were correctly predicted; 78% of the transformations found in the sample of the Symyx® 
Metabolite database used to evaluate MetaPrint2D-React where correctly identified, while 
in the case of this data only 53% of the reported transformations were predicted, although 
in a some instances a reaction that is likely to form the first step of the reported 
transformation was predicted.  In both cases it was checked that none of the test 
compounds had been used in the training of the model, in order to ensure a fair evaluation. 
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7. Conclusions and further work 
This thesis has reported the development and evaluation of MetaPrint2D and MetaPrint2D-
React.  MetaPrint2D is the result of a re-development of the Substrate Product Occurrence 
Ratio Calculator (SPORCalc) statistical knowledge-based method for site of metabolism 
prediction and MetaPrint2D-React is an extension of this approach enabling the prediction 
of the types of reaction likely to occur at each site and the metabolites formed. 
MetaPrint2D and MetaPrint2D-React have been released as freely available open source 
software.  MetaPrint2D is accessible through a number of different user interfaces – a web 
site, a command line application and through the Bioclipse rich client application.  The 
variety of interfaces to MetaPrint2D has been made possible through the abstraction of 
MetaPrint2D’s ‘calculation engine’ into a library, separate from the user interface.  This 
library provides an application programming interface (API) that other applications can use 
in order to integrate MetaPrint2D.  MetaPrint2D-React is also available as a library, but 
there is currently only a single user interface available – a web site. 
Extensive evaluations of MetaPrint2D and MetaPrint2D-React have been performed, in the 
course of which a new metric for assessing the performance of site of metabolism 
predictions has been proposed.  This receiver operating characteristic (ROC) curve based 
procedure overcomes the various biases inherent to the most commonly used metrics for 
site of metabolism predictions – the percentage of molecules for which a true site of 
metabolism is found within the top one or top three predicted sites. 
MetaPrint2D’s predictions have been shown to be comparable in accuracy to those of other 
recent site of metabolism prediction tools, but with the advantage of being very fast to 
compute.  MetaPrint2D can generate site of metabolism predictions for drug-like molecules 
in just tens of milliseconds, making it possible for the first time for a chemist to explore the 
effects of structural modifications on a compound’s metabolism in a highly responsive 
interactive manner. 
Having its basis in a data mining method, MetaPrint2D can only generate reliable prediction 
on compounds for which relevant data was included in the model’s construction.  This has 
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been illustrated both during the evaluation of MetaPrint2D, and during the prediction of 
recently reported metabolites described in the previous chapter.  The accuracy of 
MetaPrint2D depends on how well a query compound fits the model, and it has been shown 
that this can be estimated from the proportion of atoms in a molecule occupying novel 
atom environments – environments that occur only rarely in, or are completely absent from, 
the training data used to develop the model.  In cases where a compound does not occupy a 
region of chemical space characterised by MetaPrint2D an alternative method of prediction 
would need to be used. 
A major factor affecting the performance of MetaPrint2D and MetaPrint2D-React it the 
quality of the data from the Symyx® Metabolite database used to train the models.  As was 
discussed in Chapter 5, there are two problems with this data: the inconsistency with which 
transformations are reported, and that multiple products of a reaction are recorded in 
separate transformation records. 
The Symyx® Metabolite database collates observed metabolic transformations as reported 
in the literature.  Little normalization of the data appears to take place in the preparation of 
the database, so the manner in which a transformation is reported can vary depending on 
the source publication.  Some metabolic schemes report only those metabolites that were 
characterised experimentally, but others report ‘putative metabolites’ – intermediates 
postulated to have been formed during the course of reactions between positively 
characterised compounds.  The experimental methods used can determine whether 
intermediate metabolites are observed.  This means that in some cases multiple reactions, 
either connected or occurring in different regions of the molecule, are reported as a single 
step process, while in other cases the same overall transformation is reported as a series of 
separate reactions. 
It may be possible to improve the quality of MetaPrint2D’s models through the application 
of normalization procedures, pre-processing the training data.  Ideally such a process should 
be able to identify common inconsistencies and generate a standardized version of the 
transformations, possibly generating missing intermediates and separating reactions 
occurring in independent regions of a compound. 
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A further limitation of both MetaPrint2D and MetaPrint2D-React is that neither makes any 
estimate of the likelihood of a compound undergoing metabolic transformation, predicting 
only the relative likelihood of transformations centred on each site in the compound if the 
compound is metabolised.  This makes it difficult to use MetaPrint2D-React to construct 
trees of potential metabolites.  There are a number of ways in which this could be resolved, 
such as through the use of simple rules, such as ‘no further reactions occur after a phase II 
transformation’, or integration with a logP calculator together with a rule to terminate the 
tree once a certain hydrophilicity has been reached.  Alternatively it may be possible to 
construct a QSAR model to predict whether a compound will undergo further metabolism 
by comparing the parent and intermediate compounds in metabolic schemes (from the 
Symyx® Metabolite database) to those at the end of metabolic scheme. 
An interesting extension of MetaPrint2D-React would be the application of the statistical 
data mining methods used in this work to reverse metabolism prediction.  In 
biotransformation research it is often necessary to determine the parent compound of a 
metabolite that has been identified.  There are currently no tools designed to make these 
types of prediction.  The only in silico options currently available are to predict the 
metabolites of all possible parent compounds and look to see whether the metabolite 
appears among the predictions, or to search for similar metabolites in collections of known 
transformations, such as the Symyx® Metabolite database.  It should be possible to adapt 
the reaction analysis and data mining tools in MetaPrint2D-React to consider reverse 
transformations – from metabolite to substrate, and in this way make predictions from 
metabolite structures such as whether a hydroxyl group is the result of a hydroxylation, 
ester hydrolysis, epoxide opening or hydration reaction. 
All of the work reported in this thesis was performed using data from the Symyx® 
Metabolite database – both for the production of models, and their evaluation.  There are, 
however, a number of other sources of data that could be investigated.  Many organisations 
such as pharmaceutical companies have large collections of proprietary data – the results of 
unpublished experiments carried out within the organisation.  MetaPrint2D models could be 
constructed using this data alone, or by combining it with data from the Metabolite 
database.  Incorporating an organisation’s bespoke data into the model building process 
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should lead to the generation of models that are more relevant to the regions of chemical 
space on which the organisation is focussing its attention. 
These tools could also be used to model other sources of transformations, in a similar 
manner to the work on predicting microbial catabolism using the University of Minnesota 
Biocatalysis/Biodegradation Database (UM-BBD) (246,247), discussed in chapter 2. 
It may also be possible to adapt the reaction analysis tools of MetaPrint2D-React to other 
uses.  For example, it could be possible to produce a tool for predicting potential side-
reactions during organic syntheses through a similar type of reaction analysis and modelling 
to that described here, performed on reaction schemes reported in synthetic chemistry 
journals and theses. 
As already discussed, during the course of this work it has been shown that the reliability of 
predictions is dependent on the amount of data on which the prediction is based.  Currently 
users can access this information in the form of the raw values behind the calculated 
occurrence ratio, and SPORCalc’s ‘traffic-light’ visualization has been extended to highlight 
regions of the molecule occupying novel environments – having fingerprints with little or no 
related data on which to base a prediction. 
More information could be presented to the user.  Care must be taken not to make the 
display of results too complicated, but it may be possible to provide some indication of the 
quantity of data behind each atom’s occurrence ratio, and hence the confidence in 
predictions at that site, through varying the shade or the size of the coloured highlights of 
the atoms.  Alternatively, finer discrimination between predicted sites of metabolism could 
be indicated through use of varying shades of highlighting. 
 
In conclusion, two new tools for making predictions of xenobiotic metabolism have been 
developed and made freely available.  Xenobiotic metabolism is of great importance to the 
safety and efficacy both of pharmaceutical compounds and within the wider chemical 
industry.  It is hoped that MetaPrint2D and MetaPrint2D-React will help to make it easier to 
identify and address potential metabolic liabilities. 
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